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ABSTRACT 
The design of DNA directed nitrogen mustards has led to the 
development of compounds with increased specificity for DNA and enhanced 
cytotoxicity compared to similar untargeted mustards. By linking an 
intercalating anthraquinone chromophore to a nitrogen mustard function it was 
anticipated that such compounds would also have the potential to irreversibly 
inhibit the topoisomerase II (topo II) enzyme. Fourteen anthraquinones 
containing various hydroxyethylaminoalkylamino side chains 
(hydroxyethylaminoanthraquinones) were synthesised, and ten were reacted 
further to give a series of mono, 5,8-dihydro or 5,8-dihydroxy nitrogen mustard 
anthraquinones (chloroethylaminoanthraquinones) substituted with alkylating 
side chains at the 1 or 1,4 position of the chromophore. The ability of 
hydroxyethylaminoanthraquinones to associate with DNA and to stabilize the 
helix to thermal denaturation was investigated. The increasing order of drug-
helix stability was found to be I-monosubstituted anthraquinone < 1,4-
disubstituted-5,8-dihydroanthraquinone < 1,4-disubstituted-5,8-
dihydroxyanthraquinone. In contrast, in the same DNA denaturation assay the 
chloroethylaminoanthraquinones showed apparent weak affinity for DNA, the 
exception being unsymmetrically substituted ZP281 which stabilised the helix 
by 1 DoC. Four chloroethylaminoanthraquinones ZP281, ZP282, ZP285 and 
ZP289 were selected for DNA covalent binding studies. These revealed that the 
compounds were excellent DNA inter-strand cross linking agents that prevented 
strand separation at concentrations of InM. Furthermore, when compared to the 
non-targeted mustard mechlorethamine, the chloroethylaminoanthraquinones 
demonstrated an altered pattern of guanine alkylation which coincided with a 
preference for reaction at guanine sites with a pyrimidine 5' (5'PyG). This 
suggested that the chromophore influences the site of DNA alkylation and 
enhances the selectivity of the drug for DNA. To determine the cellular 
mechanism of the novel anthraquinones, a topo II inhibition study was 
performed in a yeast strain, Saccharomyces cereviciae (Sc. ce), transfected with 
human topo IIa or p, or yeast to po II. Of the seven compounds assayed three 
alkylating anthraquinones, ZP281, ZP285 and ZP289 inhibited yeast cell growth 
and may target both topo IIa and p as a mechanism of cytotoxic action. ZP285 
was the most potent compound requiring only 4.51lM to achieve 50% yeast cell 
kill. In vitro cytotoxicity assays were performed with ovarian carcinoma cell 
lines; A2780, CHI; cisplatin resistant cell lines A2780cisR, CHlcisR, SKOV-
3; doxorubicin resistant cell line 2780AD; and mismatch repair chromosome 
transfer modified cell line Bl. Seven compounds ZP257, ZP265, ZP275 
(hydroxyethylaminoanthraquinones) and ZP281, ZP282, ZP285 and ZP289 
(chloroethylaminoanthraquinones) were extremely potent in both wild type and 
resistant cells giving ICso values below 0.05 ).lM. Furthermore, compound ZP281 
displayed a relative lack of cross resistance in all resistant cell lines tested. The 
data in this thesis therefore indicates that ZP281 is a good candidate for further 
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Chapter 1 INTRODUCTION 
1. 1 CANCER AND ITS TREATMENT 
Cancer is the second major cause of death in the UK. More than a quarter of a 
million people are diagnosed with it each year and based on national incidence rates it is 
estimated that at least 1 in 3 people will develop the disease during their lifetime. 
Survival rates vary enormously and depend on many factors including the type of cancer 
and at which stage it is treated. In the USA, the five year survival rate for women with 
early diagnosed breast cancer is over 80 per cent, whereas in the UK, the five year 
survival rate varies between 40-60% and is dependent on the patient's area of residence 
in addition to the initial stage of diagnosis and subsequent treatment. The probability of 
developing a paricular type of cancer may in some cases be related to an individual's 
country of origin and their diet and lifestyle. This was evident when a survey revealed 
that the cummulative incidence rate (ages 0-74) of breast cancer varied more than six-
fold over the world, and immigrants living in the USA that originated from countries 
with low risk breast cancer had an increased chance of developing the disease (Cancer 
Research Campaign Annual Report,1997) 
Cancer is defined as the uncontrolled proliferation of cells in which the 
physiological factors governing normal cell growth and tissue development become 
ineffective. Death in cancer patients commonly results from metastasis, which occurs 
when cancer cells invade surrounding tissues and the lymphatic system. Cancer cells can 
thus be carried to take residence as secondary tumours distant from the primary tumour. 
The new tumour can continue to grow by stimulating the development of its own 
vasculature (angiogenesis)(reviewed by Vaupel et al., 1989; Brown et al., 1998) and, 
depending on the site of growth, death will eventually occur. 
To treat cancer with maximum effect a combination of surgery, if appropriate, 
with radiotherapy and/or chemotherapy is used. Chemotherapy is usually administered 
over a period of weeks or months and generally comprises of a number of cytotoxic 
drugs with different modes of action and activity in tumours. Because chemotherapeutic 
drugs are also toxic towards nonnal dividing cells, it is important to compare both the 
long and short tenn toxicities of each drug individually in order to balance the clinical 
benefit to the patient against potential side-effects. Often chemotherapy results in severe 
systemic toxicities which can be dose limiting and can produce side effects including 
nausea, vomiting, myelosuppression, reproductive sterility and alopesia. Tumours can 
also acquire resistance to drug therapy. This commonly occurs if repeated small doses of 
drug are given over a long period of time. Therefore, in some cases where it is 
detennined that the patient is able to withstand such treatment, it can be beneficial to 
administer an initial high dose of the drug in order to maximise cell kill. 
Although there are problems associated with chemotherapy, certain tumours 
such as Hodgkins disease, acute lymphoblastic leukaemia in children, and teratoma of 
the testis in adults are curable. However, many cancers are still non-responsive to 
available treatments and can be alleviated only temporarily. Thus there is an 
overwhelming need to develop new drugs that can be targeted more effectively towards 
tumour cells and do not display the toxic side effects associated with most existing 
cancer treatments. 
1. 2 THE TOPOISOMERASE II ENZYME AND ITS ROLE IN 
DRUG ACTION 
1. 2. 1. CELLULAR ROLE AND STRUCTURE 
DNA exists as a highly complex structure packaged tightly within chromosomes 
as loops, knots, supercoils and catenanes. In order for the cell to function correctly, the 
regulation of DNA topology is of critical importance. Eukaryotic topoisomerases are 
enzymes that achieve this by altering the confonnational state of DNA. At least two 
fonns of topoisomerase exist, type I and type II, refered to as topo I and topo II 
respectively. These enzymes are able to relax supercoiled DNA by introducing transient 
single (topo I) or double (topo II) strand breaks into the helix of either different DNA 
molecules or to different regions of the same DNA molecule, and then by passing a 
second intact helix through the strand break (Liu et a/ ., 1980; Gellert, 1981; Liu, 1983; 
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Stemglanz et al., 1989). Topo II is known to be involved with DNA transcription and 
replication (Brill et al., 1987) and its close association with nuclear processes implies 
that it has a number of important cellular functions. For example, it has been identified 
as the major non-histone protein which links the basis of the radial chromatin loops to 
the central axis of mitotic chromosome fiber, and it is involved with chromosome 
condensation and separation of DNA daughter chromatids at the end of replication (Di 
Nardo et al., 1984; Earnshaw et al., 1985; Uemura et al., 1986; Adachi et al., 1991). 
More recently, it is thought to function as part of the DNA repair process (Larson et al., 
1998). The enzyme topo I is predominantly located in the nucleolar region in 
proliferating cells and is associated with genes and regions which are undergoing active 
transcription by RNA polymerase I or IT (Muller et al.,1985; Capranico et al., 1992). 
Topo I is continuously expressed throughout the cell cycle and therefore may he an 
effective target in slow growing tumours that are currently resistant to chemotherapy 
(Heck et al., 1988). Recently a newly identified topo III has been isolated as a single 
copy gene located at chromosome 17p 11.2-12. The function of topo III has has yet be 
fully described, although it was shown to successfully substitute for topo I in yeast cells 
lacking endogenous topo I (Hanai et al .,1996). 
Eukaryotic DNA topo II exists as two isoforms, a and p, with a molecular 
weight of 170kD and 180kD, respectively. Each isoform is coded on separate 
chromosomes and is regulated differently during the cell cycle by enzyme specific 
phosphorylation (Tsai-Pflugfelder et al .,1988, Jenkins et al., 1992, Tan et al., 1992; 
Corbett et al., 1992 and 1993). The a isoenzyme is under strict cell cycle contol. It is 
minimally expressed in Gland in quiescent cells, but goes on to increase exponentially 
through the S phase, eventually reaching maximal expression in late G2 phase (Chow e/ 
al., 1987). In contrast, topo lIP is expressed in low constant concentration throughout 
all phases of the cell cycle (Woessner et al., 1991). Because of these differences in cell 
cycle distribution it is generally considered that each isoenzyme is targeted separately by 
topo IT inhibitors. Topo ITa particularly is suggested to be the major target of inhibitors 
that arrest cells at G2IM phases (Chen et al., 1995; Qui et al., 1996b). Furthermore, 
because both are expressed differentially in proliferating and non-proliferating tissue, 
and are located at different sites within the cell nucleus, for example, topo ITP has been 
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reported to be nucleolar, although this has more recently been disputed (Meyer et al., 
1997), growing evidence suggests that the isoenzymes also perform separate functions 
within the cell (Capranico et ai., 1992a; Zini et ai., 1994). 
Fig. 1. 1 A restricted length of topo II, amino acids 410-1202. The active 
tyrosine is represented as a ball and stick configuration. 
Both of the human topo IIa. and ~ cDNAs have been cloned and their respective 
proteins can be divided into three conserved consensus sequences. Namely, an N-
terminal ATP-ase binding domain, a central breakage reunion domain (which contains 
the reactive tyrosine, amino acid 804) and a C-terminal domain containing a leucine 
zipper motif. The isoenzymes show high nucleotide sequence homology (approximately 
72%) until the C-terminal domain where only approximately 35% sequence homology 
exists (Austin et al., 1993). Crystal structure analysis of yeast topo II shows that it 
consists of two crescent shaped monomers joined together to form a heart shaped dimer 
which surrounds a large hydrophobic central hole. At the DNA cleavage site the 
hydrophobic centre of the enzyme is accessible by the unpaired nucleotides from each 
DNA strand (Fig. 1. 1) (Roca et ai.,1992; Berger et ai., 1996; Roca et ai. , 1996, 
Capranico et ai., 1997). 
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Topo II cleavage sites are not randomly distributed along DNA, but are restricted 
to regions encompassing loosely defined nucleotide sequences of approximately 15 base 
pairs (Spitzner et a/.. 1988). Preferential cleavage has been identified at alternating 
purine-pyrimidine bases, independent of DNA confonnation (Spitzner et a/ .. 1989; Choi 
et a/.,1995). Furthennore, the initial recognition of DNA by topo II is thought not to be 
restricted to sites on both DNA strands as the two subunits may act cooperatively to 
effect cleavage. Hence, only one molecule of drug is required to be associated with the 
DNA-enzyme complex to create a double strand break in DNA (Bigioni et a/., 1994). 
1. 2. 2. THE CATALYTIC CYCLE OF TOPOISOMERASE II 
The catalytic activity of topo II is manifest through a DNA double strand 
passage two gate mechanism for which an ATP modulated molecular clamp has been 
proposed (Roca et a/., 1992). Initially each enzyme monomer binds non-covalently to 
each DNA strand producing a species known as the 'non-cleavable complex'and 
establishing a DNA cleavage/ religation equilibrium. A trans-esterification reaction 
between an enzyme tyrosine group with each strand of DNA produces a pair of 5' end 
covalently linked DNA-protein phospho diester bonds and a DNA break (G-segment) 
four base pairs apart. This is known as the 'cleavable complex' (Liu et al.. 1983). The 
binding of ATP and the presence of a divalent metal ion co-factor creates a 
confonnational change in the enzyme. This induces the protein to capture a second 
DNA strand (T-segment) which enters through one gate (N-gate) in the enzyme, passes 
through the 'G-segment' and finally out of a second gate in the enzyme (C-gate) which 
lies opposite to the site of entrance (Roca et a/ .• 1996). A second trans-esterification to 
release the original bound DNA results in a post-strand passage cleavage/ religation 
equilibrium and is followed by hydrolysis of ATP to regenerate the original 
confonnational state of the enzyme and to trigger enzyme turnover. This mechanism has 
been defined by its ready conversion to a protein-linked DNA strand break on exposure 
to alkali or detergent, both strong protein denaturants (Liu et a/., 1983). 
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Fig. 1. 2 The effect of different types of inhibitor on specific stages of the 
catalytic cycle of to poi some rase II: A) 'DNA binding inhibitors'-
prevent the enzyme from binding to DNA. B) 'Topo II poisons'-
stabilize the cleavable complex and hinder the resealing of 
strand breaks C) 'Enzyme binding inhibitors' - block 
protein conformational transitions. The black oblong/circle 
represent the sites of various drug action. From Capranico et al., 1997. 
Topo II is the cellular target for a wide variety of anti-neoplastic agents. 
Intercalating drugs such as the anthracyclines and anthraquinones (see section 1. 3. 1 
and 1. 3. 2), and also the non-intercalating epipodophyllotoxins e.g etoposide (VP-16) 
and teniposide (VM-26), primarily act by stabilizing the cleavable complex and shifting 
the rate of equilibrium towards its formation (see Fig. 1. 2B» (Nelson et ai., 1984; 
Robinson et al.,1990). Both these type of drug are commonly refered to as 'topo II 
poisons'as they convert the enzyme into a DNA damaging agent by increasing the 
probability of DNA double strand break production which is potentially a lethal event. 
Although double strand breaks are known to initiate cell death, the exact 
mechanism of inhibitor cytotoxicity is yet to be established. Cleavable complex 
stabilising drugs are generally most cytotoxic to cells in the S phase of the cell cycle i.e 
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during DNA synthesis. However, they cause the greatest number of strand breaks in the 
G2 1M phase, where topo II expression is maximal (Chow et al., 1987). Furthermore, 
once an inhibitor is removed from its site of action the DNA strand breaks are reversed 
(Tewey et al., 1984; Hsiang et al., 1989). These observations signify that the drug-topo 
II-DNA ternary complex itself is not cytocidal and that other cellular processes such as 
ongoing DNA replication may be required to develop the cytotoxic effects of these 
agents. Early studies with the topol inhibitor camptothecin demonstrated that lethal 
lesions may be generated if transient DNA breaks are converted to permanent lesions 
when replication forks attempt to traverse the protein-bound blockages in the DNA 
(Hsiang et al., 1988). Direct evidence of this as a mechanism of cytotoxicity arising 
from topo IT inhibition was established in Human Leukaemia CEM cells by (Catapano et 
al., 1997) who showed that replication fork (RF) arrest inhibited chain elongation, and 
in the c-myc oncogene occurred specifically at the site of to po II mediated cleavage (Qui 
et al., 1996a). 
More recently, topo IT inhibitor related DNA-strand breaks have been associated 
with the onset of apoptosis. The addition of etoposide to immature rat thymocytes, 
caused a concentration dependent fragmentation and laddering of DNA, a clear 
indication of the self destruction of the cell and programmed cell death (apoptosis) (Sun 
et al.,1994). Whether or not this was a consequence of replication fork arrest is 
unknown. 
The cytotoxicity of an inhibitor can in most cases be correlated with the 
frequency of DNA strand breaks that it produces (Long et al., 1984). When this 
relationship is compared between individual inhibitors at a known concentration of 
drug, it becomes evident that each DNA break does not result in the same cytocidal 
potency. For example, the anthracycline doxorubicin creates fewer lesions yet is more 
cytotoxic than etoposide (Paoletti et al., 1993). This may be explained by the rate of 
lesion repair following the removal of drug from the target site (Ross et at., 1982) or the 
duration of exposure of tumour cells to the drug induced cleavable complex. (Fox et al., 
1990; Smith et al., 1990). 
Further studies using DNA sequence specific analysis identified that drugs of the 
same class produce a consistent, characteristic cleavage in the presence of topo II. Some 
7 
sites were found to be identical to those created by the enzyme alone, whilst others were 
entirely new. At the most intense sites the base located either 5' or 3' of the DNA break 
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* Denotes base position in relation to DNA break (-1 = 5', + 1 = 3 ') 
was unique to the inhibitor (Table 1. 0). From this evidence it was postulated that 
effective drug interactions are likely to depend on the local DNA sequence (Paoletti et 
al., 1993). This principle was extended to relate the exact location of the complexes in 
the genome with drug potency. The high affinity of m-AMSA for the c-myc oncogene 
promoter region was shown shown to coincide with enhanced topo II-DNA cleavage 
(Pommier et al., 1992). Similarly, in a study of anthracyclines, the most active 
compounds induced prominent cleavage in only a small region of SV 40 DNA 
(Capranico et al., 1990b). 
A lack of drug sensitivity has in some cases been linked to low levels of topo II 
enzyme within certain tumour types. For example, cancers such as chronic lymphocytic 
leukaemia and colon carcinoma are poorly responsive to these agents (Potmesil et 
al.,1988). Attempts have therefore been made to enhance inhibitor cytotoxicity by 
stimulating the topo II content of tumour cells. Recent studies have demonstrated that 
the addition of topotecan, a topol inhibitor, to athymic mice bearing SW 480 human 
colon carcinoma xenografts increased topo IIa. levels and sensitivity to the topo II 
inhibitor etoposide (Utsugi et al., 1997). Others have found that the addition of Tumour 
Necrosis Factor together with either the topol inhibitor camptothecin or topo II 
inhibitors such as doxorubicin produced a dose-dependent synergistic cytotoxicity 
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against murine L929 fibrosarcoma cells. This combination was identified with a rapid 
and transient increase in the respective topoisomerase which resulted in an increased 
number of strand breaks and cytotoxicity (Utsugi et al., 1990). 
1. 3 DEVELOPMENT OF CHEMOTHERAPEUTIC DRUGS 
1.3.1 ANTHRACYCLINES 
Doxorubicin: R = CH20H 
Daunorubicin: R = H 
Fig. 1. 3 The anthracyclines doxorubicin and daunorubicin. 
An important advance in tumour therapy was the discovery and isolation of 
daunorubicin, the first antibiotic of its class to show activity against acute lymphoblastic 
leukaemia in man (Jacquillat et al., 1966). Doxorubicin, (see Fig. 1.3) an analogue of 
daunorubicin, exhibited the same kind of inhibitory effect on tumour growth, but was 
generally more potent and has since become one of the most established and widely 
used drugs in the clinic today. It is effective in the treatment of breast cancer and 
leukaemia, and has a broad spectrum of activity against a number of solid tumours 
(Arcamone et al., 1985). As with most anti-cancer drugs a disadvantage in the use of 
anthracyclines is their toxicity towards non-tumour cells. Prolonged use of doxorubicin 
can lead to the acute dose limiting effect of myelosuppression, and to cumulative dose 
related cardiotoxicity which is manifest through drug related free radical generation 
(Olson et al., 1990). This limits the total dose of drug that can be given to a patient in 
their lifetime and hinders the utility of these agents in single or in combination therapy. 
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Whilst early studies also correlated the cytotoxicity of the anthracyclines with 
the induction of free radical mediated tissue damage in vitro and in vivo (Lown et al., 
1982; Kappus, 1986), further investigation suggested the contrary. Research by Fisher et 
al., (1989 and 1992) demonstrated that the drug mitoxantrone which also includes a 
quinone chromophore did not undergo redox cycling and despite this, was more 
cytotoxic than doxorubicin to MCF7 human breast cancer cells. By analogy, it was 
proposed that free radical production may only playa small role in the cytotoxicity of 
doxorubicin. 
The chemical structure of both doxorubicin and daunomycin comprises of an 
aglycone ring coupled to a daunasamine sugar (see Fig 1. 3) which allows the drug to 
bind to DNA via the reversible process of intercalation (see Fig 1. 4). The mechanism 
A B 
Fig 1. 4 Comparison of a) B-DNA with b) B-DNA following intercalation. 
The drug is represented by the shaded areas of the helix. A model 
proposed by Lerman, 1961. 
of intercalation was first proposed by Lerman in (1961) who hypothesised that the base 
pairs of DNA were co-planar but could be separated by an additional 3.4 angstroms to 
accommodate a planar acridine chromophore. The close contact between 7t-orbitals of 
the drug molecule and the base pairs stabilise the complex by stacking interactions, 
which are essentially van der Waals forces, hydrophobic interactions and charge transfer 
forces. As the drug becomes intercalated in between the base pairs, the DNA begins to 
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forces. As the drug becomes intercalated in between the base pairs, the DNA begins to 
locally unwind and stiffen, bend and elongate which leads to a disruption of the regular 
helix stucture (Reinert et al., 1983). At high drug concentration the consequence of this 
is directly to affect DNA-protein interactions (see section 1. 3.2. 3). 
At the site of intercalation the long axis of the anthracycline chromophore is 
seen to lie almost perpendicular with that of the DNA base pairs. Rings B and C overlap 
with adjacent base pairs, whilst the A ring passes through the intercalation site into the 
minor groove. The daunosamine sugar also lies in the minor groove (Wang et al., 1987). 
Studies have indicated that anthracyclines have an intercalation sequence preference at 
GCA or GeT triplet base pairs and have strong binding affinity with DNA (Pullman, 
1991). Despite this, intercalative binding has proved to be insufficient for antitumour 
activity, instead, the cytotoxicity of anthracyclines is manifest through the stabilisation 
of the DNNTopo II cleavable complex (Tewey et al., 1984a; Capranico et al., 1989) 
(see section 1.2). This was supported by the observation that a doxorubicin derivative 
with a weaker DNA binding chromophore (idarubicin) was more effective at inducing 
topo II related cleavage, implicating the chromophore and not the sugar moiety in topo 
II inhibition (Capranico et al., 1989 and 1990b). 








H R = H: Ametantrone 
R = OH: Mitoxantrone 
Fig. 1. 5 The anthraquinones Mitoxantrone and Ametantrone 
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In an attempt to identify compounds which lacked the toxicities associated with 
doxorubicin but at the same time retained its spectrum of activity, research led to the 
synthesis of two lead compounds: Mitoxantrone, 1,4-Bis{N-[2-[N'-(2-hydroxyethyl)-
amino ] ethyl] amino ]-5,8-dihydroxy-9,1O-anthracenedione and its 5,8-dihydro derivative 
ametantrone (see Fig. 1.5) (Zee-Cheng et al., 1978; Johnson et al., 1979; Murdock et 
al., 1979). Both compounds comprise of a tricyclic aromatic quinone chrompohore 
disubstituted on the 1 and 4 positions with an ethanolamine containing side chain. The 
anthraquinones retain only one feature from the anthracycline structure, that is, a planar 
aromatic chromophore as it is essential for drug intercalation into DNA (Kapuscinski et 
al., 1981, Lown et al., 1985). Since its isolation in 1979 mitoxantrone has proved to be 
effective in the clinic and is currently used in the treatment of breast cancer, lymphoma 
and acute leukaemia (Koeller et al., 1988). In addition to having a broad spectrum of 
activity it also has reduced cardiotoxicity in comparison to doxorubicin (Herman et al., 
1997). 
The first studies of mitoxantrone showed that it inhibited DNA synthesis and 
RNA processing (Johnson et al., 1979; Kapusczinski et al., 1981; Foye et al., 1982; 
Cheng et al., 1983). Its cytotoxicity was found to coincide with the aggregation and 
compaction of chromatin (Kapusczinski et al., 1986) and the creation of protein 
associated DNA single and double strand breaks which correspond with the drug 
stabilisation of both DNA-topo I and II enzyme complexes (see section 1. 3. 2. 3) 
(Tewey et al., 1984b; Crespi et al., 1986). 
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The detection of mitoxantrone metabolites following the analysis of human urine 
samples established that it is capable of undergoing oxidative activation to a number of 
highly electrophilic species. These include the product of intramolecular rearrangement, 
hexahydronaphtho{2,3-f}quinoxaline-7,12-dione (MH2) (see Fig. 1. 6) (Rezka et al., 
1986; Chiccarelli et al., 1986). MH2 can bind DNA covalently and is thought to 
contribute to the non-protein associated DNA single strand breaks created following 
drug treatment (Reska et al., 1989; Panoussis et at., 1995). 
1. 3. 2. 2. STRUCTURE AND BINDING 
Mitoxantrone binds to DNA biphasically, by intercalation and by the weaker 
electrostatic interaction of its basic amino side chains with the anionic phosphate groups 
of the DNA helix (Kapuczinski et at., 1981; Collier et at., 1988; Pohle et at., 1990). 
With the use of computer modelling three intercalative binding modes for mitoxantrone 
have been proposed. In the first mode the drug lies parallel to the long axis of the DNA 
base pairs with one sidechain in each groove, 'straddling'the intercalation site. The 
second model shows the chromophore lying perpendicular to the DNA base pairs with 
both side chains lying in the major groove (Fig. 1.7b) (Islam et al., 1985; Collier et aI., 
1988; Tanious et al., 1992). Recently a third mode was proposed (Mazerski et al., 
1998). This arrangement requires both sidechains of the drug to thread through to the 
minor groove with the chromophore lying perpendicular to the long axis of the DNA. 
Once intercalation has occured, it is suggested that the small width of the minor groove 
slows the rate of drug dissengagement from DNA and promotes longer retention times 
which can be directly related to mitoxantrone's high potency. Despite this evidence, the 
general agreement is that the perpendicular mode is the most favourable binding 
configuration for the 1,4 di-substituted anthraquinones and that it is the 5,8 hydroxyl 
groups of mitoxantrone that slow its dissengagement from the minor groove (Denny et 
al., 1990). 
To further attempt to understand the high affinity of mitoxantrone for DNA 
evidence of its sequence selectivity and base pair preference have been determined. The 
computer modelling of specific DNA nucleotide sequences with mitoxantrone have 
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Maior Groove 
b Minor Groove 
Maior Groove 
Fit: 1. 7 Shows chromophore a) parallel and b) perpendicular intercalation 
into DNA. Figure obtained from Islam et al., 1985. 
reported preferential intercalation at GC sites (Fox et al., 1986; Chen et al., 1986). 
Whilst further work with DNase footprinting studies show preferential binding at 
5'(AlT)CG and 5' (AlT)CA base pairs (Panoussis et al., 1994). In a comparitive DNase 
footprinting study, mitoxantrone but not ametantrone was found to select for the 
5'(AlT)CG triplet sequence suggesting that in this case the chromophore hydroxyl 
groups may influence the site of intercalation (Bailly et al., 1996). Although 
mitoxantrone has demonstrated some preference for GC base pairs, it has been 
suggested that a slow disengagement from GC sites may infact be due to their reduced 
rate of opening compared to AT sites (Malhotra et al., 1980). 
1. 3. 2. 3. TOPO IT INHmITION AND CELLULAR MECHANISMS OF 
ACTION 
The most important mechanism of mitoxantrone cytotoxicity is the inhibition of 
topo IT. At low concentrations mitoxantrone is a potent topo II inhibitor (see section 1. 
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2. 3). Its cytotoxicity corresponds with G2 cell cycle arrest and the long term trapping of 
the topo II cleavable complex (Roberts et al., 1989; Fox et al., 1990; Smith et aI., 1990). 
Conversely, at high drug concentration (> 1 JlM) mitoxantrone loses its cell cycle 
specificity and a dose dependent decrease in DNA strand breaks is observed through 
intercalation mediated distortion of the helix. At this point mitoxantrone becomes an 
enzyme catalytic inhibitor. Topo II is prevented from binding DNA because the 
potential sites of cleavable complex formation are saturated with drug (see Fig.!. 2A) 
(Smith et at., 1990). Confocal spectral imaging of K562 erythroleukaemia cells to 
localise the cellular effects of mitoxantrone established that it binds in monomeric and 
aggregate form to both nuclear and cytoplasmic structures and its persistent drug action 
is goverened by the dissociation of the cytoplasmic aggregates to the nucleus (Feofanov 
et al., 1997, Smith et aI., 1990 and 1992). Furthermore, as a direct effect of high 
mitoxantrone concentration the initiation of apoptosis and cell death has been observed, 
indicating an enhanced mode of cytotoxicity, probably through drug saturation of the 
cellullar target (Feofanov et al., 1997; Bhalla et aI., 1993). 
1. 3. 2. 4. MITOXANTRONE ANALOGUES 
A wide range of anthraquinone analogues have been synthesised and evaluated 
including compounds that have undergone bis-substitution onto the 2 and 6, and 1 and 8 
Fig 1. 8 Modified positions on the anthraquinone chromophore 
and side chains 
positions of the chromophore (Murdock et a/., 1979; Johnson et a/., 1979; Collier et 
al.,1988, Agbanjie et al., 1992). These studies revealed that the ideal requirement for 
potent anti-tumour activity is the substitution of two side chains onto the 1 and 4 
positions and also hydroxyl groups onto the 5 and 8 positions (Rt = OH) of the 
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chromophore. Additionally, each side chain should retain its cationic nature and 
contain an ethylene (C2) alkyl spacer (n = 2) between its two amino groups (see Fig. 1. 
8) (Denny et al., 1990). Although this is exemplified by mitoxantrone which remains 
amongst the most potent within its class of drug, comparitive studies into the effects of 
varying the sidechain length (n ~ 2) and substituents (R2 and R3) of a number of 
anthraquinone derivatives has not revealed a clear correlation between structure and 
biological activity. For example, the sequential addition of a methylene group to 
increase side chain length coincided with a decline in tumour activity, despite the 
increased lipophilicity of the compounds (Johnson et al., 1979; Cheng et al., 1983). 
Increasing the number of hydroxyl ethyl groups on the sidechain from two to four (R2 = 
R3 = -CH2CH20H) weakens the affinity of the drug for DNA and correlates with a 
decline in cytotoxicity through increased drug-water solubility (Murdock et al., 1979). 
In contrast, the synthesis of I, 4- bis{N-[2-N,N'-(dimethylamino)ethyl]amino}-5,8-
dihydroxyanthracene-9,10-dione (AQ4) which contains two tertiary amino sidechain 
substituted with four N-methyl groups (R2 = R3 = CH3) produced a highly lipophilic 
compound which binds to DNA more efficiently than mitoxantrone, evident by its 
higher thermal melting temperature and DNA association constant (Murdock et al., 
1979; Patterson, 1993). Hence, although drug structures can give a good indication of 
anti-tumour activity they cannot always be relied upon to give an optimum 
determination of drug potency. 
1. 3. 2. 5. ASYMMETRIC ANTHRAQUINONES 
In a study to evaluate the influence of sidechains on DNA binding, a number of 
unsymmetrically substituted 5, 8 dihydro anthraquinones were prepared. Krapcho et 
al.,(1986) found that although some showed excellent activity in vitro they were mostly 
inactive in vivo. Subsequent work resulted in the synthesis of I-[N-[2-(N, N'-
dimethylamino )ethyl]amino ]-4-[ N-[2-(N" 'hydroxyethylamino )ethyl] amino ]-5,8-
dihydroxyanthracene-9,IO-dione also known as (AQ6) (see Fig.I. 9). This proved to be 
the most active analogue and was found to be more cytotoxic than mitoxantrone and 
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doxorubicin in both sensitive and resistant human colon carcinoma sub lines (Krapcho et 
ai., 1990). More recently, the cytotoxicity of AQ6 has been identified with S phase cell 
cycle kill and linked to the inhibition of the enzyme topo IT (Smith et ai., 1997). The 
rationale behind the unexpectedly high activity of AQ6 was thought to be because the 
optimal hydrophobic-lipophilic balance had been achieved with this drug structure. It 
was also concluded that identical sidechains are not essential for anti-tumour action as 
the level of activity depends on the nature of the second ann (Stefanska et at., 1990). 
1. 4 NITROGEN MUSTARDS AND ANTI-TUMOUR DRUG 
DEVELOPMENT 
1. 4. 1 THE EARLY ORIGINS OF CANCER THERAPY 
The origin of cancer chemotherapy can be traced back to the First World War 
and to the use of mustard gas (sulphur mustard) in the battlefields. At that time the 
ability of mustard gas to induce specific action on the bone marrow was attributed to its 
production of hydrochloric acid in intracellular regions presumed to be hypersensitive to 
acidity. Once its promising anti-tumoural effect was realised, the difficulty in containing 
sulfur mustard was overcome by the development of a compound with similar chemical 
and biological properties, nitrogen mustard. This compound could be stored as a stable 
hydrochloride salt and could easily be neutralised to produce an active nitrogen mustard 
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free base. As a result, the nitrogen mustards became the first drugs to be used in the 
trials of systemic therapy. In 1946 Gilman and Philips were first to describe the 
alkylation chemistry of the sulphur and nitrogen mustards and to summarise their effect 
on biological systems. Since then, the simplicity of the nitrogen mustard structure and 
its potential for chemical variation has led to the synthesis of hundreds of derivatives 
including cyclophosphamide (Brock et aZ., 1963), melphalan (Bergel et aZ., 1954), and 
chlorambucil (Everett et aZ.,1953), three drugs that continue to playa major role in 
current anti-cancer chemotherapy. 
1.4.2. CLASSIFICATION AND MODE OF ACTION 
Nitrogen mustards are a member of the alkylating, anti-neoplastic agents which 
have an ability to react with biologically important macromolecules through the 
formation of highly electrophilic intermediates. Alkylation can occur by two 
nucleophilic substitution mechanisms: SN 1 or SN2 and is dependent on the nature of the 
substituents attached to the alkylating moiety (reviewed by Niculescu-Duvaz et aZ., 
1991). In the case of mechlorethamine 
CI ;--/CI H3CL -~. H3C-~ _ 
~ Nu 
Nu-
Fig 1. 10 SN2 reaction of mechlorethamine via aziridinium ion formation. 
(also known as nitrogen mustard) the SN2 mechanism predominates and reaction occurs 
via the formation of a positively charged aziridinium ion intermediate (see Fig 1. 10). 
Because the bases of DNA are susceptible to alkylation at physiological pH it was 
believed that the biological effects of alkylating agents result from such reactivities 
(Brookes et aZ., 1960). Specific alkylation sites on DNA were identified by Pullman et 
aZ., (1981) by comparing the molecular electrostatic (MEP) of each DNA base. The 
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most negative site on DNA and hence the most reactive site was found to be at the 
guanine N7 position with less reactive sites at the 0 6 of guanine and N1 and N3 adenine. 
The detection of crosslink formation emerged from the isolation of nitrogen 
mustard linked guanine dimers (Lawley et aI., 1965). Since then, covalent binding to 
DNA has been defined by inter-strand crosslinks (alkylation at two bases each on 
opposite DNA strands), intra-strand crosslinks (alkylation of two bases on the same 
DNA strand) and mono adducts (a single base alkylation). The proportion of each 
adduct formed can vary between agents. For mechlorethamine the majority of the 
adducts appear to be monoalkylations at guanine N7, with inter-strand crosslinks 
between GN 7 -GN 7 accounting for 4-7% of total adduct formation (Kohn et al., 1966). 
Adducts at adenine N3 have also been observed following reaction with 
mechlorethamine and melphalan, although to a lesser extent (Osborne et al., 1993 and 
1995). Studies to identify base pair sites of nitrogen mustard inter-strand crosslink 
formation have demonstrated that complementary 5'GN*C (N*=any base) sequences 
are favoured with 5'GC sites being less prevalent (Rink et al., 1993; Rink et al., 1995b). 
A mechlorethamine 5'GN*C inter-strand crosslink has been shown by computer 
modelling to bend the DNA duplex by 12.4-16.8° per lesion thus altering the structure 
of DNA and in tum potentially modulating its affinity for DNA binding proteins (Rink 
et al., 1995a). 
Generally, the formation of inter-strand cross links is considered to be the most 
effective way to create lethal lesions as intra-strand crosslinks are more likely to 
undergo error free repair (see section 1. 5. 1. 4) (Lawley et al.. 1996). Whilst 
monoadducts are described as being a determinant of mutagenic damage rather than 
cytotoxic effect (Povirk et al., 1994). The importance of bifunctional crosslinking 
agents is their potential to create inter-strand di-adducts with DNA and despite the fact 
that these cross links are less abundant they are generally considered to be the major 
cytotoxic lesion as they may lead to DNA double strand breaks and cell death. 
1. 4. 3. DNA SEQUENCE SPECIFICITY OF NITROGEN MUSTARDS 
Nitrogen mustards are known to have a characteristic nucleotide alkylation 
preference for guanine bases, more particularly, Pullman et al., (1981) found that a 
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guanine situated within a run of three guanines would be expected to be more reactive 
than the other two guanines. This was confirmed by Kohn et al., (1987) who established 
a relationship between molecular electrostatic potential (MEP) and the reaction intensity 
of a number of nitrogen mustards. For example, mustards such as mechlorethamine 
which contain a high positive charge, react intensely at guanine N7 positions. In 
comparison, chlorambucil which also contains a negative charge within its structure 
rendering it electrically neutral reacts to a lesser extent but still at the same sites. Not all 
alkylating agents follow this principle, in some cases the substituent attached to the 
alkylating moiety can introduce distinct sequence preferences for reaction. Uracil 
mustard was seen to prefer 5 'PyGC sites over runs of guanines and mustards attached to 
intercalating chromophores were more selective towards alkylation at particular 
guanines (Mattes et al., 1986a; KOhn et al., 1987; Ponti et al., 1991). 
Agents that modify DNA covalently can block, at specific sites, the progress of 
both DNA and RNA polymerases (Ponti et al., 1991; Gray et al., 1991). The processing 
of these induced blockages by either DNA repair (see section 1. 5. 1. 4) or the activation 
of cell death can determine the outcome of cytotoxicity. In murine leukaemia cells 
exposed to cisplatin (a platinating agent which can inter-strand crosslink DNA), long-
standing arrest in G2 and subsequent cell death coincided with the appearance of DNA 
double strand breaks (Sorensen et al., 1988). Others have postulated that due to their 
sequence selectivity, nitrogen mustards may specifically target GC rich regions of the 
genome. These include the 5' flank control regions of a number of protooncogenes 
(Hartley et al., 1988). Analysis ofalkylated sites within the the 5' flank of the c-Ha-ras 
oncogene showed that these were prefered sites of damage by a number of guanine N7 
specific alkylating agents (Mattes et al.,1988). Furthermore, mechlorethamine was able 
to inhibit the binding of transcription factors such as NFkB and SPI to their GC rich 
consensus sequences but not those that bind to AT rich sequences (D'Inca1ci et a/., 
1993). More recently, studies have indicated that actively transcribing regions/strands of 
DNA are modified preferentially by DNA binding agents because of their increased 
accessibility, however this may be dependent on the nature of the lesions and their 
location in the genome (Larminat et al., 1993; Wasserman et al., 1994a; and 1994b). 
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Nitrogen mustards are used in the treatment of many cancers such as Hodgkins 
disease, breast cancer and ovarian cancer (reviewed by Black et al., 1990 and 1990a). 
Their short half-life and high reactivity results in a rapid removal from the site of 
administration and the non-specific targeting of rapidly growing tissues. Overall, only a 
low concentration of drug reaches its target and is often found secreted within the liver 
and kidneys. Consequently, nitrogen mustards are particularly subject to dose related 
toxicity (Connors et al., 1986). As many have been classified as potential mutagens and 
potential human carcinogens, it is important to establish a balance between therapeutic 
efficacy (cell killing) and unwanted side-effects (mutation induction). 
1. 4. 4. DNA TARGETED ALKYLATING AGENTS 
1. 4. 4. 1. ACRIDINE LINKED MUSTARDS 
Cl 2HCI 
Fie 1. 11 2-methoxy-6-chloro-9-[N-3-(N' -ethyl-eN"~ -2-chloroethyl)-
amino )propyl]aminoacridine dihydrochloride 
Bifunctional alkylating agents are highly reactive compounds with low 
specificity for DNA. One way to overcome this lack of selectivity is to attatch a DNA 
affinic chromophore to the alkylating moiety. Although initial studies proved successful, 
over the years relatively few groups have focused on the development of DNA targeted 
nitrogen mustards. 
In 1959, Peck et al synthesised a number of monofunctional alkylating agents 
attached to various heterocyclic chromophores. One particular mustard, 2-methoxy-6-
chloro-9-[ N-3 -(N-ethyl-N" -2-chloroethylamino )propyl] aminoacridinedihydrochloride 
(see Fig. 1. 11) showed good activity by prolonging the survival rate of mice bearing 
ascites tumours. Furthermore, it also exhibited mutagenic capability in Drosophila. As 
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the corresponding bis mustards also displayed highly improved cytotoxicity the 
heterocyclic nucleus and 2-chloroethyl groups were identified as being of critical 
importance. A further fifty mono and bifunctional derivatives with varying sidechain 
length and acridine chromophore were synthesised and tested. From this research it was 
concluded that a DNA affinic chromophore could influence the activity of a nitrogen 
mustard group by directing it towards and intercalating into DNA (Peck et al., 1961, 
Preston et al., 1964). Further studies by the same group confirmed that a tricyclic or 
tetracyclic aromatic chromophore was required for high antitumour activity and as a 
result a mechanism was proposed suggesting that initial intercalation was followed by 
the alkylation of DNA bases by the chloroethyl group (see Fig 1.12) (Creech et aI., 
1972). 
More recently, Ferguson et al., (1989) synthesised a number of mono and 
bifunctional aniline mustards attached to a 9-aminoacridine chromophore by a linker 
chain of varying length. By also varying the substituent attached immediately to the 
aniline ring, the reactivity of the aromatic mustard with DNA could be altered. When 
the cytotoxicity of these compounds was determined in DNA repair proficient and 
deficient strains the compounds were found to be considerably more potent in the repair 
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Fig 1. 12 Quinacrine intercalated in between DNA base pairs. The circled N7 bases 
indicate potential sites for alkylation and inter-strand crosslink formation. 
The shaded rectangle represents the acridine chromophore. From 
Prakash et al., (1990). 
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In a study comparing the cytotoxicities of 9-aminoacridine mustards against 
untargeted mustards in murine leukaemia P388 and AA8 and UV 4 CHO derived cell 
lines up to a 100 fold increase in potency was observed for the targeted mustards. These 
compounds also showed good in vivo activity in mice bearing the p388 leukaemia cell 
line (Ferguson et al., 1989; Valu et al., 1990; Gourdie et al., 1990). 
Other groups have linked aliphatic nitrogen mustards to acridine chromophores. 
The linker chain of 9-[N-[n-[N-(2-chloroethyl)-N-methylamino ] alkyl] amino ]-2-
methoxy-acridine dihydrochloride was varied in length (alkyl (CH2)n; (n) = 2-6). When 
the cytotoxicity of the targeted mustards was compared to the parent compound 
mechlorethamine in human colon carcinoma HT -29 cells a 10-100 fold increase in 
potency was observed for the targeted mustards (Kohn et al., 1994). 
Attempts have also been made to improve the low crosslink to mono adduct 
ratio by synthesizing agents that could potentially alkyl ate both grooves. A series of 9-
aminoacridine-4-carboxamide derivatives substituted with an aniline mono-mustard at 
the 4- and 9-position of the chromophore were instead found to preferentially form 
monoadducts at guanine-N7 (Gourdie et al., 1991). Other examples of targeted 
bifunctional cross linking agents are the platinating acridine derivatives (Palmer et ai" 
1990; Mikata et al., 1998) and aniline mustard amsacrine derivatives (Fan et al., 1997). 
1.4.4.2 MORPHOLINO DOXORUBICIN ANALOGUES AS ALKYLATING 
AGENTS 
One of the more promising series of drugs to emerge recently are the morpholino 
doxorubicin derivatives. These compounds were originally synthesised by Acton et aI" 
(1984) in an attempt to overcome the toxicities and drug resistance associated with 
doxorubicin. They vary from doxorubicin in structure by a substituted morpholino ring 
at the 3' position (R) of the sugar moiety (see Fig. 1.13). In vitro analysis of the 
morpholino derivatives revealed that they are mostly non-cardiotoxic at effective anti-
tumour doses (Sikic et al., 1985) and display a lack of cross-resistance in doxorubicin 
resistant cell lines exhibiting MDR1 (drug resistance through the overexpression of the 
membrane glycoprotein, Pgp) and at-MDR (drug resistance through an altered 
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OH 
R\ = CN; R2 = H; Cyanomorpholino-(MRA-CN) 
R2 = OCH3; R\ = H; Methoxymorpholino-(MMDX) 
Fig. 1. 13 Morpholino doxorubicin derivatives MRA-CN and MMDX 
topoisomerase II enzyme) (see section 1. 5. 1. 1. and 1. 5.1. 2.), and in cisplatin resistant 
cell lines (Streeter et ai., 1986, Bielack et ai., 1995; van der Graaf et ai., 1995). MRA-
CN in particular is extremely cytotoxic, demonstrating between 100-1500 fold potency 
over doxorubicin (Johnston et ai., 1983; Bielack et ai., 1995). It has been postulated that 
the substituted hydrophobic morpholino ring increases the lipophililic character of these 
compounds and facilitates their transport through the cell membrane. MDRI is avoided 
by effectively altering the drug affinity for P-glycoprotein (Pgp), a drug efflux pump, 
and so a greater concentration of drug is accummulated and retained in both sensitive 
and resistant cells (Acton et ai., 1984; Johnston et al., 1987; Coley et ai., 1993). Despite 
this, in doxorubicin resistant cell line P388/ADR, the addition of verapamil (a Pgp 
inhibitor) restored not only the cytotoxicity of doxorubicin but also enhanced the 
cellular uptake of 4-Methoxymorpholino doxorubicin (MMDX) and 3'-deamino-3'-(3-
cyano-4-morpholinyl) doxorubicin (MRA-CN) although to a considerably lesser extent. 
These observations suggest that MDRI is not completely circumvented by these agents 
(Streeter et ai.,1986). MRA-CN is a DNA alkylating agent with the potential to 
crosslink DNA. Unlike MMDX does not require metabolic activation (Scudder et ai., 
1988; Jesson et ai., 1989). X-ray diffraction analysis demonstrated that the aglycone of 
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MRA-CN is intercalated between CG base steps with its morpholino ring lying in the 
minor groove (Gao et al., 1995). Site specific alkylation studies have revealed that 
R 
I ~CN 
C~H- ~ .... "" 
Fig. 1. 14 Proposed ring opening reaction of cyano morpholino to alkylate 
DNA via Schiffs base fonnation 
MRA-CN has a preference for runs of guanines at 5'GG sequences which are the sites 
of intra-strand crosslink fonnation, with less selectivity for 5'GC base pairs (Cullinane 
et al., 1991). More recently a mechanism by which MRA-CN alkylates DNA has been 
proposed whereby the drug undergoes structural rearrangement with the loss of the 
cyano group and the opening of the morpholino ring to alkylate DNA via an iminium 
ion intennediate (see Fig. 1.14). 
Whilst doxorubicin is known to inhibit topo II, studies indicate that MRA-CN 
has a cytotoxicity profile which mirrors that of camptothecin a topol inhibitor, 
particularly at high concentration (Wassennan et al., 1990). This may in part explain 
the ability ofMRA-CN to avoid at-MDR.(Bielack et al., 1995) 
1. 5 MULTI DRUG RESISTANCE MECHANISMS ASSOCIATED 
WITH ANTHRAQUINONE AND NITROGEN MUSTARD ANTI-
CANCER AGENTS 
1. 5.1. THE MULTI DRUG RESISTANCE (MDR) PHENOTYPE 
Multi drug resistance (MDR) is a major hindrance to the successful treatment of 
neoplastic disease. It is the process whereby the exposure to one drug induces cross-
resistance to a variety of agents to which the cell has not yet been exposed. MDR can be 
intrinsic, confering a cell's natural resistance to cytotoxic agents, or it can be acquired 
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through drug exposure. Generally, it is intrinsically resistant cells are the most difficult 
to treat as these often develop into a subpopulation of cells that maintain the resistance 
phenotype. 
In vitro studies have shown that MDR cells may differ from their drug sensitive 
counterparts by a number of factors: 1) Decreased accumulation of cytotoxic drugs and 
net drug binding; 2) changes in the expression of particular cellular proteins and 3) 
enhanced repair mechanism. These differences can occur individually or, as in many 
cases in combination (multifactorial resistance). It is therefore essential to understand 
how a tumour cell develops strategies to evade the cytotoxic effects of anticancer drugs 
in order to overcome the problem ofMDR. 
1. 5. 1. 1 MDRI AND MRP MEDIATED RESISTANCE 
To date there are two major mechanisms of resistance, MDRI and MRP, that are 
associated with the overexpression of membrane glycoproteins. Resistance has been 
shown to vary from in vitro to in vivo clinical settings, and has been linked in some 
cases to the overexpression or amplification of the MDRJ gene which encodes for P-
glycoprotein (Pgp) (Holzmayer et al., 1992) and/or of the MRP J gene which encodes 
the multi drug resistance-associated protein (MRP) (Kavallaris, 1997). Pgp and MRP 
are both energy dependent efflux pumps which act by binding and exporting drug from 
the cell in order to protect it from cytotoxic damage. The detrimental effect of this is to 
prevent sufficient quantities of chemotherapeutic drug from reaching its target. 
Despite only a 15% homology between their structures they are members of the 
same ATP-binding cassette superfamily of membrane proteins (Cole et al., 1992) and are 
capable of confering resistance to a similar though not identical, multiple range of 
chemotherapeutic drugs. These include natural products such as the 
epipodophyllotoxins, the anthracyclines and the vinca alkaloids (Grant et al., 1994). 
Their apparent identical function does not make them mutually exclusive as studies 
with the small cell lung cancer cell line, H69, have indicated that MRP and MDRJ may 
co-exist in the same cell type (Brock et al.,1995). 
Pgp has been isolated as an ATP-driven, trans membrane transporter protein 
with a molecular weight of 170kD (Endicott et ai., 1989). In vitro levels of MDRJ gene 
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expression have shown correlation with the degree of resistance within a cell type and 
transfection of MDRI into drug sensitive cells is sufficient to confer the MDRI 
phenotype (Veda et al., 1987). However, where no initial overexpression of Pgp has 
been observed it has been suggested that exposure of cells to cytotoxic drugs can induce 
the MDRI phenotype (Baas et al., 1990). 
The MRP 1 gene was cloned from a non-Pgp mediated multi drug resistant small 
cell lung cancer cell line and was found to code for an 190kDa membrane protein (Cole 
et al., 1992). It is expressed in a wide variety of normal and tumour tissues at both RNA 
and protein level (Stride et al., 1996). Low MRP mRNA expression has been detected 
in the brain, liver and small intestine, with moderate to high levels in lung, skeletal 
muscle, testis and ovary (Kruh et al., 1995). Despite this, the role of MRP in the failure 
of chemotherapy is poorly defined and so evidence of its true influence on MDR has yet 
to be established. 
However, recent studies of resistance have identified a possible role for MRP as 
the coordinator of an ATP-dependent glutathione S-conjugate carrier (GS-X pump), 
which is responsible for transporting glutathione and glucuronide conjugates out of the 
cell. Evidence for this mechanism was acquired by comparing levels of expression of 
MRP 1 with the ATP-dependent transport of glutathione conjugated compounds 
(Jedlitschky et al., 1996; Muller et al., 1994) and further substantiated by the finding 
that MRP expressing resistant cells accumulated more drug following treatment with 
buthionine sulfoximine (8S0), an agent that inhibits glutathione synthesis 
(Versantvoort et al., 1995). Others have found that the supression of MRP 1 expression 
results in hypersensitivity to natural cytotoxins but surprisingly not to alkylating agents 
which are specific substrates for intracellular glutathione conjugation (Lorico et al., 
1997). In support of this, Morrow et al., (1998) demonstrated that MRP alone failed to 
confer resistance to the nitrogen mustard chlorambucil, however, the combined 
expression of MRP 1 with glutathione-S-transferase isoenzyme A 1-1 (a-GST) acted in 
synergy to protect cells from the same bifunctional crosslinking agent. Hence, it has 
been postulated that MRP may participate in both drug detoxification and glutathione 
metabolism. 
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1. 5.1. 2 ALTERED TOPOISOMERASE II 
Overexpression of drug efflux pumps results in the removal of drugs from the 
cell before they reach their cellular target. Many topo II inhibitors are substrates for 
these efflux pumps and consequently resistance develops through decreased interaction 
with the enzyme topo II. However, alterations in the topo II enzyme itself may also 
induce resistance and in some cases the altered topoisomerase (at-MDR) mechanism has 
been shown to exist without MDRl and MRP 1 expression. In the absence of efflux 
pumps the drug is effectively excluded from the nucleus and is found sequestered in 
cytoplasmic structures away from its site of action (Zwelling et al., 1990; Whithoff et 
al.,1996; Consoli et al., 1997). 
Cell lines confering the at-MDR phenotype have been shown to form a reduced 
number of cleavable complexes which in tum leads to a lower frequency of strand 
breaks and a decrease in cytotoxicity (Harker et al., 1991; Fry et al., 1991). Others have 
demonstrated that differences in sensitivity between drug classes in resistant cells may 
be dependent on the ratio of topo II a to P in the cell, and to the isoenzyme preference 
of a compound. For example, cells made resistant to topo II inhibitor VM26 correlated 
with altered topo IIa levels (Mirski et al., 1993). Whilst low sensitivity to mitoxantrone 
has identified with a decrease in topo lIP, other groups have disputed this preference 
(Harker et al., 1991; Hammonds et al., 1998). 
The topo II status of a cell is also an important determinant of resistance. Slow 
growing tumours, which are notoriously difficult to treat, generally reside in the GO/G 1 
phase of the cell cycle where tapa IIa levels are mostly undetectable (Potmeisil et al ., 
1988; Woessner et al., 1991). As a result, several stress conditions such as hypoxia and 
glucose starvation have been linked to poor drug response through low topo II levels 
(Harris et al., 1992). 
at-MDR can occur as a function of reduced catalytic activity, reduced levels of 
the enzyme, and mutations and deletions (Deffie et al.,1989; Yu et al., 1997). In HL-
60IMX2 cells, resistance to mitoxantrone was defined by a decrease in topo II catalytic 
activity, undetectable amounts of topo lIP and the isolation of a novel 160kDa top a IIa 
protein located in the cytoplasm (Harker et al., 1991). Further studies identified that the 
novel protein was associated with a truncated tapa IIcr mRNA causing a disruption of 
28 
the carboxy tenninal of the enzyme and altering its cellular localisation to the 
cytoplasm (Harker et al., 1995a and 1995b, Mirski et al., 1995). Hence, drug cleavable 
complexes were fonned only with the reduced levels of topo IIa. in the nucleus. In 
support of this, it has been postulated that cytoplasmic topo II may also act as a drug 
'sump' delaying the drug from entering the nucleus (Whithoff et al., 1996). A number 
of mutations associated with drug resistance have been identified within the topo IIa. 
gene. These include alterations at the ATP binding domain which may impair the 
binding of ATP to the enzyme, and those near the active tyrosine which may prevent 
drug and/or topo II from binding to DNA. It is unknown whether these mutations are 
located within the drug interaction domain of topo II as many mutant enzymes display 
different and contradictory profiles of drug resistance (Osheroff et al., 1994). 
Furthennore, whilst in vitro experiments demonstrate the involvement of atMDR in 
drug resistance, there is little evidence to support gene mutation as a mechanism 
resistance in clinical specimens (Nitiss et al., 1996; Hsiung et al., 1996). 
Studies of topo II cellular levels and sensitivity to alkylating agents have 
generally shown an inverse correlation (Campling et al., 1997). For example, the 
increased resistance of Burkitt lymphoma cells to mechlorethamine coincided with 
reduced levels of DNA inter-strand crosslink fonnation and an approximate 4-fold 
increase in topo II activity compared to the sensitive cell line (Tan et al., 1987). Whilst 
in cisplatin resistant L 1210 murine leukaemia cells an increase in sensitivity towards 
topo II inhibitor amsacrine correlated with a 3-fold increase in topo II activity. 
Following the sequential addition of the two drugs an additive effect was seen in the 
sensitive cell line and a supra additive effect in the resistant cells (Barret et al., 1994). 
These results imply a causal relationship between topo II expression and resistance 
towards alkylating agents and is suggested to be linked to topo IIa. involvement with the 
damage recognition and repair of DNA (Larsen et al., 1998). 
1. 5.1. 3 DETOXIFCATION BY GLUTATHIONE AND ITS ROLE IN 
RESISTANCE 
The glutathione-S-transferases (GST's) are a family of cytosolic proteins that 
can catalyse the conjugation of xenobiotics and their electrophilic metabolites with the 
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endogenous tripeptide glutathione (aSH) (reviewed by Tew et at., 1994). For some 
nitrogen mustards the conjugation reaction with glutathione can also take place non-
enzymatically, the rate of the reaction increasing with pH (Bolton et at., 1993). As 
indicated in section 1. 5. 1. 1, GSH affects the efficacy and action of a variety of 
antineoplastic agents mainly through nucleophilic thioether formation or oxidation-
reduction reactions and thus plays a role in the detoxification and repair of cellullar 
injury. Mammalian GST isoenzymes have been grouped into three major classes a, Il 
and 7t on the basis of structural and functional characteristics (Armstrong et at., 1991). 
Early detection of resistance to mechlorethamine demonstrated that reduced inter-strand 
crosslinking in resistant Chinese Hamster Ovary (CHO) cells correlated with a three 
fold overexpression of GST activity in the absence of deficient repair or reduced drug 
accumulation (Robson et al., 1987). Elevated levels of aSH and aST were also found 
to contribute to the decrease in sensitivity to mechlorethamine in 9L rat brain tumour 
cells (Evans et al., 1987). More recently resistance to certain alkylating agents has been 
linked to the overexpression of one or more GST isoenzymes. Increased amounts of a-
GST have been observed in cell lines resistant to mechlorethamine (Lewis et al., 1988; 
Clapper et at., 1989). In contrast, the transfection of a-GST into MCF7 human breast 
cancer cells had no effect on sensitivity to chlorambucil, melphalan or cisplatin, infering 
that this particular isoenzyme is not a contributing factor in the resistance to these drugs 
(Leyland-Jones et al., 1991). These inconsistencies suggest that a loss of sensitivity may 
perhaps depend on the cell type and the individual drug used, and has led to the true role 
of GSH in the detoxification of alkylating agents to be questioned. When no GSH-
melphalan (L-P AM) conjugates were detected in rat or human perfused liver samples it 
was postulated that GSH may playa role in the repair of drug induced DNA damage 
rather than act as a detoxifying agent (Vahrmeijer et al., 1996, Britten et al., 1991). 
Glutathione is also involved in the detoxification and resistance to the 
anthracyclines and the anthraquinones. It has been implicated in the detoxification of 
mitoxantrone metabolites through conjugation with products from metabolic oxidation 
of its sidechains and anthraquinone chromophore (Mewes et al., 1993). MDR cell lines 
selected for doxorubicin resistance have displayed elevated or altered GSH levels 
(Deffie et al., 1988; Dajani et at., 1995) and the overexpression of 7t-GST isoenzyme 
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(Lee at al., 1989). The cellular increase in GST is not always accompanied by 
overexpression of Pgp (Lee et al.,I989; Cole et al.,I990) and because as it is not 
uniform within MDR cell lines its contribution to anthracycline resistance is thought to 
be secondary to that ofPgp MDR (Beck et al., 1990). 
1. 5.1. 4 DNA REPAIR 
The exact mechanism by which bifunctional DNA adducts are detrimental to the 
cell is unknown. Recent studies have indicated that it is likely that abortive attempts to 
replicate and/or repair damaged DNA leads to the formation of double-strand breaks or 
single strand gaps in the DNA causing chromosome aberrations and breakage during 
mitosis (Chaney et al., 1996). Conversely, another response to DNA damage is for the 
cell to trigger a significant increase in proficient adduct repair, the outcome being the 
creation of fewer cytotoxic lesions and resistance to chemotherapeutic agents. Lesions 
identified with nitrogen mustard DNA damage are mostly single base alkylations which 
produce monoadducts, and to a lesser extent, inter- and intra-strand DNA crosslinks (see 
section 1. 4. 1. 1). The response to such lesions is to activate one or more of the repair 
mechanisms available to the cell (see Fig 1.15). 
A) In direct repair, the cytotoxic drug methylation of the 0 6 position of a 
guanine (or 0 4 position of a thymine) base is directly repaired. That is, the cytotoxic 
lesion is removed from the base by transferring the alkyl group to a specific cysteine 
residue of the repair protein methylguanine-DNA methyltransferase (MGMT). The 
damaged base is restored without any further modification (Mitra et al., 1993). 
B) Base-Excision Repair (BER) and its role in repairing damage caused by 
alkylating agents involves the enzyme methylpurine-DNA glycosylase (MPG) (Sancar, 
1994). This enzyme is active against alkylated purines by removing the damaged base 
from the DNA. Apurinic/apyrimidinic (AP) lyase followed by AP endonuclease then 
act to release the deoxyribose sugar. The resulting gap is filled by DNA polymerase p 
(and to a lesser degree polymerase 3 and E) and closed by DNA ligase. BER, has been 
identified by the enhanced removal of inter-strand crosslinks and elevated levels of 
MPG, and has been implicated in the resistance of lymphocytes from CLL (chronic 
lymophocytic leukaemia) patients receiving nitrogen mustard treatment (Bramson et al., 
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Fig 1. 15 DNA repair mechanisms a) Direct Repair b) Base Excision Repair 
c) Nucleotide Excision Repair d) Mismatch Repair. RPA = Replication 
repair factor; TFIIH = transcription/repair factor; XP A, XPC, XPG, 
XPF-ERCCI = products of genes corresponding to xerodenna 
pigmentosum (XP) or excision repair cross-complementaing (ERCC) 
groups; Pol = DNA Polymerase; dNMP's = deoxynucleoside 
monophosphate. From Chaney et al.,(l996). 
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1995; Geleziunas et al.,1991). 
C) Nucleotide Excision Repair (NER) is dependent on ATP and the combination 
of six repair factors to remove lesions from DNA. The DNA damage created is incised 
on both sides of the lesion and excised as a 29-nucleotide long oligomer. The resulting 
gap is filled with DNA polymerase 0 or f; and closed with DNA ligase (Sancar et al., 
1994; Mu et al., 1995). NER is suggested to be the most likely mechanism of repair of 
bifunctional DNA damage because the creation of inter and intra-strand crosslinks 
involves more than one base (Chaney et al., 1996). The overexpression of the repair 
factor ERCC 1 (excision repair cross complementing group 1) was found to be 
associated with resistance to mechlorethamine in CHO cells and also to have a negative 
effect on sensitivity to cisplatin in human ovarian carcinoma cells (Bramson et al 
.,1993; Li et al., 1998 and 1999). 
D) Mismatch repair (MMR) plays a vital role in the postreplicative correction of 
DNA polymerase errors that have escaped proofreading during DNA replication, and in 
the control of the fidelity of genetic recombination (Modrich et al., 1996). It is different 
from the other repair systems as the lesions removed are undamaged nuc1eotides. 
Instead, the abnormality arises because the base is mispaired. For example, the 
deamination of methyl-cytosine produces a G.T mispair which will be further converted 
to a G.A mispair if a thymine is not correctly substituted for the cytosine prior to DNA 
replication (Griffin et al., 1994). MMR involves the excision of a long tract of DNA 
followed by synthesis of a repair patch of up to 1000 nucleotides. Exonuc1eolytic 
degradation of DNA is thought to be initiated from a nick in the strand generated from 
Okazaki fragments during the synthesis of the defective DNA strand (Modrich et al., 
1996). To date five genes that encode mismatch repair proteins have been identified. In 
normal human cells mispaired bases are recognised by two complexes: hMutSa 
(containing the hMSH2 subunit) and hMutS~ (human MutS homologue). These can 
activate the hMutLa (the human MutL homologue) heterodimer which consists of the 
proteins hMLH1(human MutL homologue 1) and hMPMS2 (human homologue of yeast 
post meiotic segregation gene 2). 
Unlike the previous examples gIven of nitrogen mustard resistance where 
enhanced repair correlates with a decrease in sensitivity, a defect in mismatch repair 
33 
results in resistance to DNA damaging agents. Two possible explanations have been put 
forward. In the first, the binding of the repair proteins to the DNA lesion may activate 
signal transduction pathways leading to cell cycle arrest and/or cell death (Hawn et al.. 
1995; Nehme et al .• 1997). Secondly, it may be the case that futile cycles of synthesis 
past the DNA lesion, followed by removal of the newly synthesised strand increases the 
probability of generating a large gap or strand break in the DNA which eventually leads 
to the induction of cell death (Fink et al .• 1996; Vaisman et al .• 1998). 
Following the in vitro selection of a human ovarian carcinoma cell line for 
cisplatin resistance, loss of mismatch repair activity arose through defects in the hMLHI 
subunit. In addition, defects in cells with no prior exposure to cisplatin were linked to 
loss of the hMSH2 subunit (Aebi et al., 1996). A number of topo II inhibiting agents 
such as doxorubicin and etoposide have also displayed low level resistance in mismatch 
repair deficient cell lines. Therefore, it has been suggested that MMR proteins may be 
involved in the detection of cleavable complexes and thus act to promote DNA damage 
(Drummond et ai., 1996). In contrast, no change in sensitivity was observed with the 
bifunctional nitrogen mustard melphalan suggesting that DNA adducts produced by 
these agents are not recognised by the MMR protein complex (Aebi et al., 1997). 
The development of cross-resistance between anti-tumour agents reduces the 
potential for maintaining reI event levels of chemotherapy. This is exemplified by the 
agents mitoxantrone and doxorubicin where resistance associated with either one of 
these agents tends to results in cross-resistance with the other. The development of 
multi-factorial resistance can lead to reduced sensitivity to drugs with completely 
different spectrums of activity and eventually hinders their use in combination therapy. 
In respect of this, the search for compounds that display good anti-tumour activity 
without the detrimental effects ofMDR continues. 
1. 6 TOXICITY AND RESISTANCE MODULATORS 
The resistance of cancer cells to chemotherapeutic agents can be caused by a 
number of mechanisms which result in the poor outcome of treatment. In an attempt to 
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overcome resistance, research has focused on the development of drugs that selectively 
inhibit the intracellular targets associated with resistance and hence potentiate the 
cytotoxic action of anti-cancer agents. 
One of the first resistance modulators to undergo trials against the MDRI gene 
product Pgp, was the calcium antagonist verapamil. The rationale behind the use of 
calcium channel inhibitors as modulators of resistance was that drug efflux is likely to 
be related to calcium transport across cellular membranes and therefore modulation of 
transport proteins within the membrane would also result in modulation of resistance. 
Although the mechanism of action of verapamil is not fully defined, it has been shown 
to inhibit Pgp by increasing its phosphorylated state (Endicott et al., 1989; Yusa et ai., 
1989). A number of groups have demonstrated that verapamil is an effective agent 
against anthacycline resistance. For example, in CHrC5, a resistant CHO cell line 
overexpressing Pgp, verapamil induced the redistribution of doxorubicin from the 
cytoplasm to the nucleus enhancing its cellular accumulation and restoring the 
cytotoxicity of the drug (Bellamy et al., 1988, Yusa et al., 1989). However, despite its 
early in vitro success, trials of verapamil with doxorubicin against advanced epithelial 
ovarian cancer demonstrated that the equivalent non-cytotoxic concentration required to 
inhibit resitance in vitro was toxic in plasma levels in vivo. As a result verapamil 
became less attractive as a resistance inhibitor because of its cardiotoxic potential at the 
in vivo inhibitory concentration (Echizen et al., 1985). More recently the D-isomer of 
verapamil (D-verapamil) which is 3-4 fold less cardiotoxic but is equipotent to racemic 
verapamil has shown good response in pancreatic cancer and it is currently undergoing 
clinical trials (Komek et al., 1995). Another example of a MDR modulator is 
Cyclosporine A a drug that functions to inhibit more than one mechanism of resistance. 
These include the inhibition of calmodulin, Pgp and the lowering of GSH levels 
(Twentyman, 1988). 
The development of inhibitors against alkylating agent resistance has mainly 
focused on identifying drugs that exert their action by affecting drug detoxifying 
conjugation. Examples of two such inhibitors are butathionine sulphoximine (BSO) and 
ethacrynic acid (ER). The drug BSO functions to irreversibly inhibit the enzyme y-
glutamyl cysteine synthetase (y-GCS) and thus decreases intracellular glutathione levels. 
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Consequently a reduced concentration of drug-GSH conjugates is formed and exported 
from the cell. The administration of BSO in combination with melphalan to patients 
with various cancers showed a good reduction in GSH levels with acceptable toxicity. In 
view of favourable results it is currently undergoing phase I clinical trials (0' Dwyer et 
at.,1992 and 1996). The diuretic ethacrynic acid reversibly inhibits the GST isoenzymes 
and serves to prevent enzyme catalysed drug conjugation with GSH (Ahokas et ai., 
1985; Giaccio et at., 1991). It has also shown effectiveness in phase I trials (O'Dwyer et 
at., 1991). 
Although many chemical modulators have proved effective in vitro, they have 
yet to show a significant reversal of MDR in the clinic. The poor response is partly 
related to the toxicity of these agents and also to the existence of more than one 
mechanism of resistance in cancer cells. Recently, a completely different approach to 
toxicity and resistance modulation has come to the forefront and this involves the use 
drug-containing liposomes. These microscopic capsules «100nm) are composed of a 
lipid bylayer membrane enclosing an active drug within a central aqueous compartment 
(Kim et at., 1993). By undergoing slow degradation the goal of the liposomes is to alter 
the tissue distribution and pharmokinetics of the drug, improving its efficacy and 
reducing its toxicity. Liposomes have no affinity for tumour cells but sequester within 
the tumour microvasculature slowly releasing drug into the immediate environment 
(Gabizon et at., 1994). Because they take longer than non-encapsulated drug to 
eliminate from the body an increased concentration of drug is found at the target site. 
This was exemplified by doxorubicin and mitoxantrone containing liposomes which 
have both demonstrated prolonged cytotoxicity in vitro (Law et al., 1996; Wiles et ai., 
1997) and in vivo (Chang et ai., 1997). Hence, the positive evidence following the use 
of liposomal drug increases the prospect for higher doses of drug to be administered 
during treatment which should lead to a more effective clinical outcome with reduced 
toxic side-effects. 
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1. 7. AIMS 
The previous work carried out concerning the anthraquinone DNA intercalating 
agents and bifunctional nitrogen mustard anti-cancer drugs has been summerised in the 
introduction (sections 1. 3 and 1. 4). From the information gathered it may be concluded 
that in order to achieve effective anti-tumour activity it is necessary to identify drugs that 
target and bind to their biological goals more efficiently. Such compounds could potentially 
improve drug potency and circumvent the problems associated with resistance (section 1. 
5). Several attempts have been made to develop intercalating agents that bind to DNA 
covalently and irreversibly inhibit the topo IT cleavable complex, an important cellular 
target of many anticancer drugs. Much of this previous work has focused on the synthesis of 
aliphatic and aniline nitrogen mustards linked to an acridine chromophore, an efficient 
intercalator (see section 1. 4. 4. 1 ). The acridine mustards have demonstrated a 
considerable increase in potency over non-targeted mustards and can therefore be 
considered as a basis for further synthetic development. The long established anti-tumour 
drug mitoxantrone a known topo II inhibitor, is one of the most effective drugs in clinical 
use today (see section 1. 3. 2. 1). It comprises of a planar tri-cyclic aromatic chromophore 
substituted on the 1,4 position with two basic alkyl amino side-chains. The ease of 
manipulation of the sidechains and the aromatic chromophore of the anthraquinones makes 
them ideal candidates for drug development as DNA targeted alkylating agents. 
The aims of this study are, therefore, to investigate the hypothesis that alkylating 
anthraquinones can irreversibly inhibit topo IT and evade the mechanisms of resistance 
associated with both intercalating and alkylating anticancer agents. This will be achieved 
by:-
[1] Synthesizing a number compounds consisting of an anthraquinone chromophore 
substituted with at least one alkylating alkylamino side chain. 
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[2] Detennining the covalent binding interactions of selected alkylating anthraquinones 
with DNA, in particular, their nucleotide sequence specificity and ability to crosslink DNA. 
[3] Comparing the intercalating ability and cytotoxicity in vitro of the alkylating 
anthraquinones to their non-alkylating anthraquinone analogues in resistant cell lines. 
[4] Providing infonnation concerning the effect of a selected number of alkylating and 
non-alkylating anthraquinone analogues on human topo lIa and p dependent yeast 
Saccharomyces cereviciae. 
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Chapter 2 SYNTHESIS AND ANALYSIS OF SUBSTITUTED 
ANTHRAQUINONES 
2. 1 INTRODUCTION 
The nitrogen mustards are a family of highly reactive antineoplastic agents which 
covalently bind with nuc1eophiles. Although DNA is their primary cellular target, their lack 
of specificity for it leads to diminished drug cytotoxicity and additional toxic side effects 
(see section 1. 4). In view of this, a number of groups have explored the potential for 
enhancing the specificity of the nitrogen mustards by combining their structure with a DNA 
affinic chromophore such as acridine. More significantly, when comparing non-targeted 
with targeted mustards, the increased cytotoxicity of the latter was determined to be a 
consequence of enhanced target selection (see section 1. 4. 4). 
The anthraquinone chromophore was chosen as the basis for the synthesis of the 
following DNA directed aliphatic nitrogen mustards as it is an integral constituent of a 
number of highly DNA affinic drugs such as mitoxantrone and AQ4, which exert their 
cytotoxicity through the inhibition of the enzyme topo II (see section 1. 2. 3). It is 
envisaged that a drug which comprises of an anthraquinone chromophore substituted with 
alkylating alkyl amino sidechain(s) would have both DNA specificity and covalent binding 
ability. 
By utilising an anthraquinone chromophore and altering side chain length and 
terminal substituent composition a series of mono substituted anthraquinones, 1,4 di-
substituted 5,8-dihydroanthraquinones (ametantrone analogues) and 5,8-
dihydroxyanthraquinones (mitoxantrone analogues) with mono and bis-alkylating side 
chains were synthesised. Furthermore, by making the terminal nitrogen on each side chain 
tertiary it was anticipated that synthesis of an N-oxide prodrug might be feasible. 
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2. 2 CHEMICALS AND REAGENTS 
All reagents purchased were of a minimum 95% purity. l-chloroanthraquinone, 
benzophenone, lithium aluminium hydride, bromoacetonitrile, bromoacrylonitrile, N-2-
hydroxyethy-N-methylamine, N-methylaminoethylenediamine, N-phenylaminoethylene-
diamine, boron triflouride etherate, N,N-dimethylethylenediamine, thionyl chloride, 
triphenylphosphine, triflouro acetic acid and 2-methoxyethanol were all supplied by Sigma-
Aldrich, Poole, Dorset. 2, 3-dihydroleucoquinizarin from Pfaltz and Bauer, UK. Ethylene 
oxide was supplied by Fluka Chemicals, Gillingham, Dorset. N,N-2-
hydroxyethylpropylenediamine obtained from Tokyo Kasei Chemicals, Hadfield, 
Derbyshire. Metachloroperoxybenzoic acid was obtained from Aldrich Rare Chemicals, 
USA. Leuco-l,4,5,8-tetrahydroxyanthraquinone was prepared from the method of 
(Greenhalgh et al., 1968) by Ketan Ruparelia, Pharmacy Dept, De Montfort University, 
Leicester. Chromatography column silica: particle size 35-70~ and 20-35~, was supplied by 
Fisher Scientific, Loughborough, England. Thin layer chromatography plates (Aluminium 
backed) supplied by Merck, Poole, Dorset, England. Reverse phase C8 Hplc column 
supplied by Bondapack, UK. 
All solvents were of analytical (HPLC) grade: Dichloromethane, Carbon 
tetrachloride, Chloroform, Ethanol, Methanol, Diethylether, Hexane, Toluene, Ethylacetate 
and Acetonitrile were supplied by Fisher Scientific, Loughborough, England. 
2. 3 SAMPLE ANALYSIS 
The UVNis absorbance of the drugs was recorded on a Beckman DU70 UVNis 
Spectrophotometer fitted with deuterium and tungsten lamps. The infra-red absorbance was 
recorded on a Nicolet 205 FT-IR Spectrometer. Proton NMR spectra were reproduced on a 
Brucker AC 250 MHz Nuclear Magnetic Resonance Spectrometer, by Dr M.Needham, 
Department of Chemistry, De Montfort University, Leicester. Fast Atom Bombardment 
(FAB+) Mass-Spectra sample identification was obtained on a V.G 70 SEQ Mass 
Spectrometer (Manchester, England) by J. Lamb, MRC Toxicology Unit, Leicester 
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University, UK. HPLC analysis of 2Pl was perfonned on a Waters SOl twin pump system 
linked to a gradient controller. The drug was eluted over 30 minutes under gradient control 
at a flow rate of ImVmin. The mobile phase gradient was raised from 100% dH20 (0.1 % 
TF A) at the start of analysis to 100% Methanol (0.1 % TF A) after 30 minutes sample 
elution. Sample detection took place through a Waters 410 UVNis Spectrophotometer at a 
wavelength of 2S4nm and all data was recorded on Millenium software. 
2. 4 EXPERIMENTAL 
2. 4. 1. SIDE CHAIN PREPARATION 
(1) N-(2-Hydroxyethyl)-N-methylethylenediamine (Kohn et al., 1994)* 
a) [N-(2-hydroxyethyl)-N-methylamino J acetonitrile. 2-Methylaminoethanol (1 Ocm3, 
0.12Smol) was warmed under nitrogen at a temperature between 40-S0°C. 
Bromoacetonitrile (4.0cm\ O.OSmol) was added dropwise to the flask and the reactants 
stirred vigorously over a period of 1 hour. The temperature of the reaction was then 
elevated to 110°C and the mixture allowed to stir for a further 2 hours. On cooling, water 
(20cm3) was added and the mixture extracted into dichloromethane (3x20cm3). The 
combined organic layers were dried over sodium SUlphate and the solvent removed under 
reduced pressure. Distillation by Kugelrohr at 8S-9SoC/SmmHg afforded the product 
impure as a colourless viscous oil (3.67g, 64.1 % yield). TLC (MeOHlCH2Ch I:S; Rr O. 6); 
Lit values*: IH NMR (CDCb) 8: 2.2S (s, 3H, CH3N), 2.S (t, 2H, CH2CN), 2.S8 (t, 2H, 
CH2N)' 3.6 (t, 2H, CH20H). 
The product was used without further purification in the following procedure. 
b) N-(2-Hydroxyethyl)-N-methylethylenediamine To a cooled suspension of lithium 
aluminium hydride (S.7g, O.1Smol) in dry tetrahydrofuran (lSOcm3) was slowly added [N-
(2-hydroxyethyl)-N-methylamino]acetonitrile (S.72g, O.OSmol) in dry tetrahydrofuran 
(5.0cm\ The mixture was stirred for 1 hour at O°C and then refluxed for a further 2.S 
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hours. After the reaction mixture had cooled, the following were added in succession; ethyl 
acetate (20cm\ distilled water (O.57cm\ 15% sodium hydroxide solution (O.57cm3) and 
distilled water (l.71ml). The mixture was then filtered under vacuum to remove the 
inorganic salts formed, the solvents removed under reduced pressure and the resulting 
filtrate partitioned between distilled water (100cm3) and chloroform (3x 100cm3). 
Distillation by Kugelrohr at 95-105°CI5mmHg afforded the product as a golden viscous oil 
of approximately 80 % purity (3.5g, 59.3% yield). TLC (MeOH/CH 2Ch 1:5; Rr 0.1); 'H 
NMR (CDCh) <5: 2.3 (s, 3H, CH3N) , 2.5(t, 2H,CH2N), 2.58 (t, 2H, CH2N), 2.8 (t, 2H, 
CH2NH2), 2.81 (bs, 2H, NH2CH2), 3.6 (t, 2H, CH20H). 
(2) N-(2-Hydroxyethyl)-N-methylpropanediamine (Kohn et al., 1994). 
a) [N-(2-HydroxyethyIJ-N-methyl-aminoJacrylonitrile The method and conditions 
employed in the synthesis of this compound follow the procedure for the synthesis of [N-(2-
hydroxyethyl)-N-methylamino ]acrylonitrile. The concentration of reactants used were; 2-
methylaminoethanol (11.4cmJ, 0.14mol), acrylonitrile (6.2cm3, 0.094mol). Kugelrohr 
distillation at 1 15-120°CI 0.25mmHg afforded a clear viscous oil (5.57g, 46.3% yield). TLC 
(MeOH/CH2Ch 1 :5; Rf o. 7); 'H NMR (CDCh) <5: 2.28 (s, 3H, CH3N) , 2.54 (t, 2H, 
CH1CN), 2.65 (t, 4H,CH2N), 2.8 (t, 2H,CH2N), 3.65 (t, 2H, CH10H). 
The product was used without further purification in the following procedure. 
b) N-(2-Hydroxyethyl)-N-methylpropanediamine. The reaction procedure and conditions 
follow those employed in the synthesis of N-(2-hydroxyethyl)-N-methylethylenediamine. 
Concentration of reactants used were; [N-(2-hydroxyethyl)-N-methylamino ]acrylonitrile 
(5.57g,0.049mol), lithium aluminium hydride (5.55g, 0.146mol). Distillation by Kugelrohr 
at 160-165°C, 0.25 mmHg afforded the product as a golden viscous oil of 80% purity (4.8g, 
74.2% yield). TLC (MeOHlCH2Ch 1:5; Rr O. 15); IH NMR (D20) <5: 1.8 (m, 2H, 




a) Monoacetylethylenediamine (Aspinall et al., 1949). Ethyl acetate (528.3g, 6.3mol) and 
ethylenediamine (1550.0g, 25.8 mol) were stirred together at room temperature for several 
days until the mixture had become homogenous. The unreacted ethyl acetate was removed 
under reduced pressure and the resulting product was collected by high vacuum distillation 
at l1SoC-130°C/SmmHg to give (272.4g, 44.6% yield). TLC (MeOHINH3 (4 drops); Rf 
0.6); 
The product was utilised in the next step of the reaction without identification or further 
purification. 
b) N-Acetyl-N,N-bis(2-hydroxyethylJethylenediamine. (Peck et al., 1961). 
Monoacetylethylenediamine (150.5g, 1.5mol) was dissolved into methanol (200cm3) and 
cooled to O°C by keeping the reaction flask on ice and by fixing a liquid nitrogen cold trap 
to the top of the condenser. To the flask was added ethylene oxide (194g, 4.4mol), the 
mixture stirred at O°C for 2.5 hours, and then at room temperature for 18h once the cold trap 
had been removed. Ethylene oxide (97.0g, 2.2mol) was again added at O°C using the same 
procedure and the mixture stirred at this temperature for 1.5 hours then at reflux for a 
further 6 hours. On cooling, the unreacted ethyl acetate was removed under reduced pressure 
and the resulting product collected by high vacuum distillation at 220-230°CIl.25mmHg, to 
give (265.2g, 52.3% yield). TLC (MeOHlCH2Ch, 1:1; Rf 0.5); IH NMR (CDCh) 0: 2.0 
(bs, 3H, CH3NCO), 2.6 (bt, 6H, 3xCH]NH2), 3.3 (bq, 2H, CH]NH2), 3.5 (t, 4H, 2CH]OH), 
3.7 (t, IH, NHCO), 4.5 (bs, IH, CH20H). 
*The product was utilised in the next step of the reaction without further purification. 
c) N,N-bis(2-Hydroxyethyl)ethylenediamine. To* N-acetyl-N,N-bis(2-hydroxyethyl)-
ethylenediamine (265.2g, 1.3mol) was added hydrochloric acid (5M, 180cm3) and the 
mixture refluxed for 6 hours. On cooling, the mixture was made basic to pH 8 with aqueous 
sodium hydroxide solution (1M), and the salt removed by precipitation with ethanol. All 
solvents were removed under reduced pressure and the final product collected at 
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approximately 80% purity by high vacuum distillation at 252-260°CI 5mmHg to give 
(81.3g, 39.4% yield). TLC (MeOHlCH2Ch 1:1; RrO. 1); IH NMR (CD30D) 8: 2.5 (t, 2H, 
CH2NH2), 2.7 (t, 6H, 3CH2N), 3.7 (t, 4H, 2CH20H). 
(4) N-(2-Hydroxyethyl)-N-phenylethylenediamine 
a) N-Phenylaminoethyl-N'-diphenylimine. To N-phenylethylenediamine (20.1 g, 0.15mol) in 
xylene (50cm3) was added benzophenone (2S.84g, O.l42mol) and a catalytic amount of 
boron trifluoride etherate (O.lml). The reaction mixture was heated to reflux and the molar 
equivalent of water formed removed by Dean and Stark azeotropic distillation. On cooling, 
distilled water (2xSOcm3) was added to extract the unreacted amine from the organic layer 
and following the removal of the organic solvent the product precipitated as a white 
crystalline solid (2S.6g, 58.0% yield). TLC (EtOH/CH2Ch 1 :5; Rr O. 2). 
The product was put forward to the next step of the reaction without identification or 
further purification. 
b) N-(2-Hydroxyethyl)-N-phenylaminoethyl-N'-diphenylimine. To a cooled solution of N-
phenylaminoethyl-N'-diphenylimine (25.6g, 0.08mol) in methanol (200cm3) was added 
ethylene oxide (11.3g, O.2Smol). The mixture was allowed to stir at O°C for 2.5 hours and 
then at room temperature overnight. Following this, ethylene oxide (5.28g, 0.125mol) was 
again added to the mixture at O°C for 1.5 hours and then the mixture further refluxed for 6 
hours. On cooling, the solvent was removed and the product dried under vacuum to give a 
white crystaline solid (21.5g, 78% yield). TLC (EtOHlCH2Ch 1 :5; Rr 0.7); 
The product was put forward to the next step of the reaction without identification or 
further purification. 
c) N-(2-Hydroxyethyl)-N-phenylethylenediamin e. 2-[N-(2-hydroxyethyl)-N-phenylamino]-
ethyl-N-diphenylimine (21.5 g, 0.06mol) was added to a mixture of hydrochloric acid (2M, 
200cm3) and methanol (SOcm\ and allowed to stir at room temperature for 12 hours. 
Following the removal of the methanol under vacuum, dichloromethane (2x200cm3) was 
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added to separate the cleaved benzophenone from the mixture and the product, a 
hydrochloride, was extracted into the acidic water layer. The water layer was then made 
basic to pH 8 with sodium hydroxide (5M), the water removed, and the inorganic salts 
separated from the product by precipitation in ethanol. The product a goldenlbrown viscous 
oil (B.pt. 225-235°C/ 5mmHg) of approximately 80% purity was isolated on removal of 
solvent (I0.3g, 91.3% yield). TLC (MeOHlCH2Cb 1:1; RrO.5); IH NMR (CD30D) 8: 3.2 
(t, 2H, CH2NH2), 3.6(t, 2H, CH20H) 3.8 (t, 4H, CH2N), 7.3 (t, 2H, Ar-H), 7.8 (t, IH, Ar-
H), 8.0 (d, 2H, Ar-H). 
2. 4. 2 SYNTHESIS OF MONO SUBSTITUTED HYDROXYETHYL-
AMINOANTHRAQUINONES 
(5) 1-[N-[2-[N-(2-Hydroxyethyl)-N-methylamino] ethyl] amino]-
9,10- anthracenedione (ZP1) 
To N-(2-hydroxyethyl)-N-methylethylenediamine (2,4g, 0.02mol) In 2-
methoxyethanol (IOcm3) was added l-chloroanthraquinone (0.5g, 2.05mmol) and the 
mixture refluxed for 6 hours. On evaporation of the solvents the resulting waxy solid was 
partitioned between dichloromethane (20cm3) and distilled water (3x20cm3) to remove any 
unreaeted amine. The separated organic layer was removed in vacuo and the crude product 
lyophilised. Purification by flash column chromatography (CH2Ch: EtOH, 9:1; TLC Rr 0.8) 
followed by precipitation from ethanol with dry diethylether gave on drying, the product as 
a red/orange powder (IOOmg, 15.3% yield). m.p.t05.9 - t06.8°C; IH NMR (CDCI) 8: 2.3 
(s, 3H, CH3N), 2.7 (t, 2H, CH2CH2N), 2.8 (t, 2H, CH2CH2N), 3,4 (t, 2H, CH2NHAr), 3.7 (t, 
2H, CH20H), 7.0 (d, tH, Ar-H), 7.5 (m, 2H, Ar-H), 7.7 (m, 2H, Ar-H), 8.2 (d, IH, Ar-H), 
8.3 (d, tH, Ar-H), 10.1 (t (broad), tH, NHAr); m/z FAB-MS (MeOH in 3-NBA) 325 
(M+Ht; IR Vmax (KBr) em,l 3600-3300 (OH), 1650 (C=O), 1040 (N-H); E" 
(MeOHIDMSO) = 4761cm,l; "'max (521nm) 
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(6) 1-[N-[3-[N-(2-Hydroxyethyl)-N-methylamino]propyl] amino ] 
-9,lO-anthracenedione (ZP150) 
For reaction procedure and conditions follow the method for the synthesis of ZPl. 
The reactants used were: l-chloroanthraquinone (0.2g, 0.82mmol) and N-(2-hydroxyethyl)-
N-methylpropanediamine (1.1g, 8.2mmol). Purification by flash column chromatography 
(CH2Ch: EtOH, 9:1; TLC RF 0.8) gave the product, a red powder (47.2mg, 17.5% yield). 
m.p. 98.S - 99.2°C; IH NMR(CDCh) 8: 1.8 (m, 2H, CH2CH2CH2), 2.3 (s, 3H, CH3N), 2.7 
(t, 2H,CH2N), 2.8 (t, 2H, HNCH2CH2N), 3.4 (t, 2H, CH2NHAr), 3.7 (t, 2H, CH20H), 7.0 
(d, 1H, Ar-H), 7.5 (m, 2H, Ar-H), 7.7 (m, 2H, Ar-H), 8.2 (d, 1H, Ar-H), 8.3 (d, IH, Ar-H), 
10.1 (t(broad), 1H, NHAr); mJz FAB-MS (MeOH in 3-NBA) 325 (M+Ht; IR Vmax (KBr) 
cm-I 3600-3300 (OH), 1650 (C=O), 1040 (N-H); Ex. (MeOHIDMSO) = 3514cm-1; "'max 
(S04nm). 
(7) 1-[N-[3-[N'-N"-Bis(2-hydroxyethyl)amino]propyl] amino] 
-9,1 O-anthracenedione (ZP233) 
To N.N-bis(2-hydroxyethyl)propanediamine (3.3g, 20.0mmol) in 2-methoxyethanol 
(IOcm3) was added 1-chloroanthraquinone (0.5g, 2.0Smmol) and the mixture refluxed for 6 
hours. On cooling the reaction mixture was partitioned between distilled water (3x20cm3) 
and dichloromethane (20cm3) to remove any unreacted amine, and the organic layer 
evaporated in vacuo. The product was dried under vacuum to give a solid shown by TLC 
(CH2Ch: EtOH, 8:2; RF 0.8) to contain unreacted 1-chloroanthraquinone (RF 9.5). The 
unreacted I-chloroanthraquinone was precipitated with methanol (IOcm3) and the required 
product isolated from the filtrate on evaporation of the solvent. The product was further 
purified by precipitation in methanol with dry ethereal hydrogenchloride, to give a red 
powder (7S.3mg, 10.2% yield). m.p. 91.2 - 92.2 DC. IH NMR (CDC h) peaks: 8 1.8 (m, 
2H, CH2CH2CH2), 2.3 (t, 6H, 3xCH2N), 3.4 (t, 2H, CH2NHAr), 3.7 (t, 4H, 2xCH20H), 7.0 
(d, lH, ArH), 7.S (m, 2H, ArH)' 7.7 (m, 2H, ArH), 8.2 (d, 1H, ArH), 8.3 (d, lH, ArH), 10.1 
(t(broad), 2H, NHAr); mJz FAB-MS (MeOH in 3-NBA) 369 (M+Ht; IR Vmax (KBr) cm-
l 
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3600-3300 (OH), 1650 (C=O), 1040 (N-H); EA, (MeOHIDMSO) = 1961 
(510nm). 
2.4.3. SYNTHESIS OF 1,4 DISUBSTITUTED-5,8-
DIHYDRO-HYDROXYETHYLAMINOANTHRAQUINONES 
(8) 1 ,4-Bis-[N-[2-[N'-(2-hydroxyethyl)-N'-methylamino] ethyl] amino] 
-9,10-anthracenedione (ZP242) 
Under nitrogen, leucoquinizarin (0.3g, 1.26mmol) was added to wanned N-(2-
hydroxyethyl)-N-methylethylenediamine (2.44g, 20.0mmol) and the reactants heated 
together at 60°C until TLC (MeOH; Rf 0.4) showed that the reaction had gone to 
completion (approximately 4 hours). Aqueous sodium hydroxide solution (15%, 0.2cm3) 
was then added to the cooled mixture and a brownlblack to blue colour change was 
observed. In order to fully oxidize, the reaction was left to stir in air overnight. To remove 
the unreacted amine the mixture was partitioned between dichloromethane (80cm3) and 
distilled water (3x80cm\ the organic layer separated and the solvent evaporated in vacuo 
and the product dried under vacuum to give a waxy-solid. Purification by flash column 
chromatography (MeOH: CH2Ch 1: 1; then MeOH). gave the product which was then 
further purified by precipitation from methanol with dry diethyl-ether to give dark 
bluelblack crystals (l05.7mg, 19.3% yield ).m.p.181.2-182.3 °C; !H NMR (DMSO) peaks: 
(5 2.5 (bs, 6H, 2xCH3N), 2.8 (bt, 2H, CH2CH2N), 3.0 (bt, 2H, CH2CH2N), 3.4 (bt, 2H, 
CH2NHAr), 3.7 (bt, 2H, CH20H), 7.5 (s, 2H, Ar-H), 7.7 (m, 2H, Ar-H), 8.2 (m, 2H, Ar-
NH), 10.7 (t (broad), 2H, 2xNHAr); mJz FAB-MS (MeOH in 3-NBA) 441 (M+Ht; IR 
Vmax (KBr) cm-! 3600-3300 (OH), 1590 (C=O), 1230, (N-H); EA, (dH20) = 7128 cm-! ; 
Amax (626nm) 
(9) 1,4-Bis-[N-[3-[N',N'-his(2-hydroxyethyl)amino] ethyl] amino] 
-9,1 O-anthracenedione (ZP232) 
Reaction conditions and procedure follow that for the synthesis of ZP242. The 
reactants used were N,N-bis(2-hydroxyethyl)ethylenediamine (3.7g, 20.0mmol) and 
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leucoquinizarin (0.3g, 1.26mmol). Purification hy flash column chromatography 
(MeOH:CH2Ch 1:1; RF 0.3) afforded the product as hluelblack crystals (132.3mg, 21.8% 
yield). m.p. 177.5 - 178.9°C; IH NMR (DMSO) peaks: 0 3.4 (bt, 8H, 4xCH2N), 3.5 (ht, 4H, 
2xCH2N), 3.85 (ht, 4H, 2xCH2NHAr), 4.0 (ht, 8H, 4xCH20H), 7.7 (s, 2H, Arl!), 7.85 (m, 
2H, Arl!), 8.3 (m, 2H, Arl!), 10.4 (t(hroad), 2H, 2xNHAr); m1z F AB-MS (MeOH in 3-
NBA) 501 (M+Ht; IR Vmax (KBr) em-I 3600-3300 (OH), 1590 (C=O), 1230 (N-H); E). 
(dH20) = 8060 em-I; Amax (624nm). 
(10) 1,4-Bis-[N-[3-[N',N'-his(2-hydroxyethyl)amino]propyl]a mino] 
-9,10-antbracenedione (ZP240) 
The reaction conditions and procedure follow that for the synthesis of ZP242. The 
reactants used were N,N-his(2-hydroxyethyl)propanediamine (3.64g, 20.0mmol) and 
leucoqinizarin (O.3g, 1.26mmol). Purification hy flash column chromatography 
(MeOH:CH2Ch, 3:7 then increase to 1:1; RF 0.4) afforded the product as hluelblack crystals 
(I 13.0mg, 17.6% yield). m. p. 137.6 -138.6 °C; IH NMR (DMSO) peaks: 0 1.8 (m, 4H, 
2xCH2CH2CH2), 2.3 (ht, 8H, 4xCH2N), 2.4 (ht, 4H, 2xCH2N), 3.4 (ht, 4H, 2xCH2NHAr), 
3.7 (ht, 8H, 4xCH20H), 7.7 (s, 2H, Arl!), 7.85 (m, 2H, Arl!), S.3 (m, 2H, Arll), 10.7 
(t(hroad), 2H, 2xNHAr); m1z FAB-MS (MeOH in 3-NBA) 529 (M+Ht; IR vrnax(KBr) em') 
3600-3300 (OH), 1590 (C=O), 1230 (N-H); E). (dH20) = 9964 em-I; Arnax (630nm). 
(11) 1,4-Bis-[N-[2-[N'-(2-hydroxyethyl)-N'-phenylamino]ethyl]amino] 
-9,10-antbracenedione (ZP245) 
The reaction conditions and procedure follow that for the synthesis of ZP242. The 
reactants used were N-(2-hydroxyethyl)-N-phenylethylenediamine (3.6g, 20.0mmol) and 
leucoquinizarin (0.3 g, 1.26mmol). To aid soluhility 2-methoxyethanol (1 Ocm3) was 
employed as a reflux solvent during this reaction. Purification hy flash column 
chromatography (EtOH: CH2Ch: Hexane 0.2: 8: 1.8; RF 0.45) afforded the product as a 
hlue powder (195.5mg, 27.5% yield). TLC (EtOH:CH2Ch. 0.1: 9.9; Rf 0.8); m.p 161.9 -
162.5°C; IH NMR (DMSO) peaks: 03.35 (ht, SH, 4xCH2N), 3.5 (ht, 4H, 2xCH2N), 3.6 
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(bt, 4H, 2xCH2NHAr), 3.7 (bt, 8H, 4xCH20H), 6.6 (m, 2H, 2xArl!), 6.8 (m, 4H, 4xArl!), 
7.2 (m, 4H, 4xArl!), 7.7 (s, 2H, Arl!), 7.85 (m, 2H, Arl!), 8.3 (m, 2H, Arl!), 10.7 (t(broad), 
2H, 2xNHAr); mJz FAB-MS (MeOH in 3-NBA) 529 (M+Ht; IR Vmax (KBr) em-I 3600-
3300 (OH), 1590 (C=O), 1580, 1510 (Ar); 1230 (N-H); Ei.. (MeOHIDMSO) = (13121); 
Amax (643nm). 




Under nitrogen, leuco-l,4,5,8-tetrahydroxyanthraquinone (O.2g, 0.7SmmoI) was 
added to warmed N-(2-hydroxyethyI)-N-methylethylenediamine (1.3g, 12.0mmol) and the 
mixture heated together at 60°C for 5 hours. Following the addition of aqueous sodium 
hydroxide solution (2M, 0.2em3) the mixture was exposed to air and further stirred at room 
temperature overnight. To remove impurities, flash column chromatography was performed 
(MeOH: CH2Ch: NH3, O.S: 9.4: 0.1; TLC: RF 0.2S) and the column solvents removed in 
vacuo. The resulting pure product was precipitated from methanol with dry diethylether and 
dried under vacuum to give a dark blue powder (87.1mg, 24.6% yield). m. p. 211.3 - 213.S 
DC; IH NMR(CDCh) 8: 2.3 (s, 6H, 2xCH3N), 2.7 (t, 4H, 2xCH2N), 2.8 (t, 4H, 2xCH2N), 
3.6 (t, 4H, 2xCH2NAr), 3.7 (t, 4H, 2xCH20H), 7.2 (s, 2H, Arl!), 7.4 (s, 2H, Arl!), 
10.6(t(broad), 2H, 2xNHArl!); mJz FAB-MS (MeOH in 3-NBA) 474 (M+Ht; IR V max 




The reaction procedure and conditions foIIow that for the synthesis of ZP26S. The 
reactants used were; N-(2-hydroxyethyl)-N-methylpropanediamine (I.4Sg, 1O.0mmol) and 
leuco-l,4,5,8-tetrahydroxyantracenedione (0.2g, 0.75mmol). Purification by flash column 
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chromatography (MeOH: CH2Ch: NH3, 0.25: 9.75: 0.05; TLC RF 0.5) afforded the product 
as a dark blue powder (45.1mg, 12.0% yield). m. p. 157 - 158°C; !H NMR(CDCh) 8: 1.9 
(m, 4H, 2xCH2CH2CH2), 2.35 (s, 6H, 2xCH3N), 2.7 (t, 4H, 2xCH2N), 2.8 (t, 4H, 2xCH2N), 
3.5 (t, 4H, 2xCH2NAr), 3.7 (t, 4H, 2xCH20H), 7.15 (s, 2H, ArH), 7.35 (s, 2H, ArH), 10.5 
(t(broad), 2H, 2xNHArH); mlz FAB-MS (MeOH in 3-NBA) 502 (M+Ht; IR Vmax (KBr) 




The reaction procedure and conditions follow that for the synthesis of ZP265. The 
reactants used were; N,N-bis(2-hydroxyethyl)ethylenediamine (2.0g, 10.0mmol) and leuco-
1,4,5,8-tetrahydroxyanthracenedione (0.2g, 0.7Smmol). Purification by flash column 
chromatography (MeOH: O.S% NH3; TLC RF 0.2S) afforded the product as a dark blue 
powder (94.2mg, 23.6% yield); m. p. 218.5 - 219.5 °C; IH NMR(CDCh) 8: 2.7 (t, 8H, 
4xCH2N), 2.9 (t, 4H, 2xCH2N), 3.5 (t, 4H, 2xCH2NAr), 3.7 (t, 8H, 4xCH20H), 7.1 (s, 2H, 
ArH), 7.3 (s, 2H, ArH), 10.6 (t(broad), 2H, 2xNHAr); mlz FAB-MS (MeOH in 3-NBA) 
533 (M+Ht; IR Ymax (KBr) cm"! 3600-3300 (OH), 1580 (C=O), 1230 (N-H); Ei. (dH20) = 
8876 em"!; Amax (606nm). 
(IS) 1,4-Bis[N-[3[N',N'-his(2-hydroxyethyl)amino]propyl]amino] 
-S,8-dihydroxy-9,10-anthracenedione dihydrochloride (ZP2SS) 
The reaction procedure and conditions follow that for the synthesis of ZP265. The 
reactants used were; N,N-bis(2-hydroxyethyl)propanediamine (2.16g, 10.0mmol) and leuco-
1,4,S,8-tetrahydroxyanthracenedione (0.2g, 0.7Smmol). Purification by flash column 
chromatography (MeOH: CH2Ch: NH3, 0.5: 9.S: Sdrops; TLC RF O.2S) afforded the product 
as a dark blue powder (128.1mg, 30.5% yield). m. p. 243.4 - 245.2 °C; !H NMR(DMSO) 8: 
1.75 (bt, 4H, 2x CH2CH2CH2), 2.5 (bt, SH, 4xCH2N), 2.6 (bt, 4H, 2xCH2N), 3.45 (bt, 4H, 
2xCH2NAr), 3.6 (bt, 8H, 4xCH20H), 7.2 (s, 2H, ArH), 7.6 (s, 2H, ArH), 10.6 (t(broad), 
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2H, 2xNHAr); mlz FAB-MS (MeOH in 3-NBA) 561 (M+Ht; IR Vmax (KBr) cm-
I 3600-
3300 (OH), 1580 (C=O), 1230 (N-H); Ei.. (dH20) = 9844 cm-
I
; Amax (612nm). 
(16) 1 ,4-Bis [N-[2-[N'-(2-hydroxyethyl)-N'-phenylamino ]ethyl] amino] 
-5,8-dihydroxy-9,10-anthracenedione (ZP254) 
The reaction procedure and conditions follow that for the synthesis of ZP265 the 
exception heing that the reaction mixture was heated at 100°C for 5 hours. The reactants 
used were: N-(2-hydroxyethyl)-N-phenylethylenediamine (1.98g, 10.0mmol) and leuco-
1,4,5,8-tetrahydroxyanthracenedione (0.2g, 0.75mmol). Following purification hy column 
chromatography (EtoAc: Hexane, 7.5: 2.5 increasing to 100% EtoAc; TLC RF 0.8) the 
product was washed in diethylether and filtered to give a deep greenlblue powder (74.6mg, 
16.7% yield). m. p. 178.5 - 179.5 °C; IH NMR (DMSO) peaks: 83.35 (ht, 8H, 4xCH2N), 
3.5 (ht, 4H, 2xCH2N), 3.6 (ht, 4H, 2xCH2NHAr), 3.7 (ht, 8H, 4xCH20H), 6.65 (m, 2H, 
2x ArH) , 6.8 (m, 4H, 4xArH), 7.2 (m, 4H, 4xArH), 7.2 (s, 2H, Arl!), 7.45 (s, 2H, ArH), 
10.7 (t(hroad), 2H, 2xNHAr); mlz FAB-MS (MeOH in 3-NBA) 596 (M+H)+; IR Vmax 
(KBr) em-I 3600-3300 (OH), 1590 (C=O), 1600, 1510 (Ar); 1230 (N-H); E" 
(MeOHIDMSO) = 15319 cm-I; Amax (681nm). 
2.4.5. SYNTHESIS OF UNSYMMETRICAL 1, 4-DISUBSTITUTED-5,8 DIHYDROXY 
HYDROXYETHYLAMINOANTHRAQUINONES 
(17) 1-[N-[2-[N'-(2-Hydroxyethyl)-N'-methylamino]ethyl] amino ] 
-4-[N"-[2-[N"',N"'-dimethylamino]ethyl]amino]-S,S-dihydroxy-9,10-anthracenedione 
(ZP257) 
Under nitrogen, leuco-l,4,5,8-tetrahydroxyanthraquinone (O.2g, O.75mmol) was 
added to warmed N-(2-hydroxyethyl)-N-methylethylenediamine (0.71g, 6.0mmol) and the 
mixture allowed to stir for 30min. To this was then added N,N-(dimethyl)ethylenediamine 
(O.194g, 2.2mmol) and the reaction allowed to proceed at 80°C for 5 hours. After cooling, 
aqueous sodium hydroxide solution (15%, 0.2cm3) was added and the reaction exposed to 
air and left to stir overnight at room temperature. The crude product was identified hy TLC, 
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isolated by flash column chromatography (MeOH: CH2Ch: NH3, 0.5: 9.5: 0.1; TLC 
(MeOH: CH2Ch) RF 0.35) and, following the removal of the solvent in vacuo, lyophilised 
to remove traces of water. Precipitation from methanol with dry diethylether and removal of 
trace solvent under vacuum gave a dark-blue powder (34.8mg, 10.5% yield). m. p. 207.5 -
209.5 °C; IH NMR(CDCh) 8: 2.7 (s, 9H, 3xNCH3), 3.1 (t, 4H, 2xCH2N), 3.3 (t, 2H, 
CH2N) , 3.9 (t, 4H, 2xCH2NHAr), 4.1 (t, 2H, CH20H), 7.1 (s, 2H, ArH), 7.3 (s, 2H, ArH), 
10.8 (t(broad), 2xH, NHAr); mJz FAB-MS (MeOH in 3-NBA) 443.2 (M+Ht; IR V max 
(KBr) em-I 3600-3300 (OH), 1580 (C=O), 1230 (N-H); E). = 7128 em-I; Amax (60Snm). 
(IS) 1-[N-[2-[N',N'-Bis(2-hydroxyethyl)amino]ethyl]amino]-4-[N"-[2-
[N"',N"'-dimethylamino] ethyl] amino]-S,S-dihydroxy-9, 10-anthracenedione (ZP27S) 
The reaction conditions and procedure follow that for the synthesis of ZP257. The 
reactants used were; N,N-bis(2-hydroxyethyl)ethylenediamine (0.67g, 3.6mmol), N,N-
(dimethyl)ethylenediamine (0. 1949, 2.2mmol) and leuco-l,4,5,S-tetra-
hydroxyanthraquinone (0.2g, 0.75mmol). Following purification by column 
chromatography (MeOH: CH2Ch : NH3, 0.5: 9.5: 0.1 increasing to 2: 8: 0.1; TLC RF 0.3) 
the product was isolated as a dark blue powder (60.03mg, 19.5% yield). m.p. 204.2-
205.DoC; IH NMR(CDCh/CD30D) 8: 2.4 (s, 6H, 2xNCH3), 2.9 (t, 4H, 2xNCH2), 3.0 (t, 
2H, CH2N), 3.6 (t, 4H, 2xCH2NHAr), 3.7 (t, 4H, 2xCH20H), 7.1(s, 2H, ArH), 7.3 (s, 2H, 
ArH), 10.6 (t(broad), 2xH, NHAr); mJz FAB-MS (MeOH in 3-NBA) 473 (M+Ht; IR V max 
(KBr) em-I 3600-3300 (OH), 15S0 (C=O), 1230 (N-H); E). = 7936 em-I; Amax (608nm) 
2. 4. 6. SYNTHESIS OF CHLOROETHYLAMINOANTHRAQUINONES 
(19) 1-[N-[2-[N-(2-Chloroethyl)-N-methylamino ]ethyl] amino] 
-9,10-anthracenedione hydrochloride (ZP293) 
Under nitrogen, triphenylphosphine (O.l6g, 0.6mmol) then carbon tetrachloride 
(0.28g, 1.8mmol) was added to a stirred solution of ZP 1 (0.1 g, 0.31 mmol) in 
dichloromethane (5.0cm3) and the suspension allowed to stir at room temperature for 24 
hours. The crude product was precipitated by the addition of dry ethereal hydrogen chloride 
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and the precipitate filtered and dried under vacuum. To remove unreacted 
triphenylphosphine, the product was dissolved into the minimum amount of 
dichloromethane/methanol (I: I) then precipitated by the addition of an ethanol/ethylacetate 
mixture (l: I) at 60°C and dried under vacuum. The product was isolated as a red powder 
(93.5mg, 80% yield). TLC (EtOH: CH2Ch, 0.5: 9.5; Rr 0.8); m. p. 207.1 - 209.2 DC; IH 
NMR (MeOD/CDCh) 3: 3.1 (s, 3H, CH3N) , 3.5 (bt, 2H, CH2CH2N), 3.7 (bt, 2H, 
CH2CH2N), 3.9 (t, 2H, CH2NHAr), 3.95 (t, 2H, CH2CI), 7.3 (d, IH, Ar-H), 7.7 (m, 2H, Ar-
H), 7.8 (m, 2H, Ar-H), 8.2 (d, IH, Ar-H), 8.3 (d, IH, Ar-H), 10.1 (t (broad), IH, NHAr); 
m/z FAB-MS (MeOH in 3-NBA) 343 (M+Ht; IR Vmax (KEr) cm"l 3550-3310 (NRH), 1600 
(C=O), 1230 (N-H); EJ.. (MeOHIDMSO) = 6963 cm"l; "'max (488nm). 
(20) 1-[N-[3-[N-(2-Chloroethyl)-N-methylamino ]propyl] amino]-
9,10-anthracenedione hydrochloride (ZP288) 
The reaction procedure and conditions follow that for the synthesis of ZP293. The 
reagents used were; ZP150 (0.05g, O.15mmol), triphenylphosphine (O.078g, 0.3mmol) and 
carbon tetrachloride (O.137g, 0.9mmol). The product was isolated as a red powder (35.5mg, 
60.2%). TLC (EtOH: CH2Ch, 0.5: 9.5; Rr 0.9); m. p. 205 - 207°C; IH NMR (MeOD) 8: 
2.25 (m, 2H, CH2CH2CH2), 3.1 (s, 3H, CH3N) , 3.4 (t, 2H, CH2CH2N), 3.54 (t, 2H, 
CH2CH2N), 3.7 (t, 2H, CH2NHAr), 4.0 (t, 2H, CH2C1), 7.3 (d, IH, Ar-H), 7.7 (m, 2H, Ar-
H), 7.8 (m, 2H, Ar-H), 8.2 (d, IH, Ar-H), 8.3 (d, IH, Ar-H), 10.1 (t (broad), IH, NHAr); 
m/z FAB-MS (MeOH in 3-NBA) 357 (M+Ht; IR Vmax (KEr) cm"1 3550-3310 (NRH), 
1600 (C=O), 1230 (N-H); EJ.. (MeOHIDMSO) = 1297.5 cm"l; "'max (498nm). 
(21) 1-[N-[3-[N,N-Bis(2-chloroethyl)amino]propyl]amino] 
-9,10-anthracenedione hydrochloride (ZP284) 
The reaction procedure and conditions follow that for the synthesis of ZP293. The 
reagents used were; ZP233 (0.05g, 0.136mmol); triphenylphosphine (0.071g, 0.27mmol) 
and carbon tetrachloride (0.246g, 1.62mmol). The product was isolated as a red powder 
(48.0mg, 80.3% yield). TLC (EtOH: CH2Ch, 0.5: 9.5; Rr 0.8); m. p. 194.5 - 196.5 °C; IH 
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NMR (MeOD) 8: 2.2 (m, 2H, CH2CH2CH2), 3.5 (t, 2H, CH2CH2N), 3.54 (t, 2H, 
CH2CH2N), 3.65 (t, 2H, CH2CH2N), 3.7 (t, 2H, CH2NHAr), 4.0 (t, 4H, 2xCH2Cl), 7.3 (d, 
IH, AI-H), 7.7 (m, 2H, AI-H), 7.8 (m, 2H, Ar-H), 8.2 (d, IH, Ar-H), 8.3 (d, IH, Ar-H); mlz 
FAB-MS (MeOH in 3-NBA) 405 (M+H)+; IR Vrnax (KBr) cm"! 3550-3310 (NRH), 1600 
(C=O), 1230 (N-H); E~ (MeOHIDMSO) = 7948 cm"l; Arnax (503nm). 
(22) 1,4-Bis [N-[2-[N'-(2-chloroethyl)-N'-methylamino] ethyl] amino ]-9,10-
anthracenedione dihydrochloride (ZP286) 
Under nitrogen, triphenylphosphine (O.086g, 0.33mmol), then carbon tetrachloride 
(0.15g, 1.32mmol) were added to a stirred solution of ZP242 (O.05g, O.11mmol) in a 
mixture of dichloromethane (4.0cm3) and acetonitrile (1.0cm\ and the suspension allowed 
to stir at room temperature for 48 hours. The crude product was precipitated by the addition 
of dry ethereal.hydrogenchloride and following the removal of solvent traces under vacuum, 
triphenylphosphine impurities were removed by initially dissolving the compound into the 
minimum amount of dichloromethane/methanol (1:1) and then precipitating with an 
ethanollethylacetate mixture (1:1) at 60°C. The product was isolated as a dark blue 
powder (47.4mg, 78.5% yield). TLC (EtOH: CH2Ch, 1: 9; Rr 0.6); m. p. 185.4 - 186.0 °C; 
!H NMR (MeOD/CDCh) 8: 3.1 (s, 6H, CH3N) , 3.6 (bt, 4H, 2xCH2CH2N), 3.7 (bt, 4H, 
2xCH2CH2N), 3.9 (t, 4H, 2xCH2NHAr), 3.95 (t, 4H, 2xCH2CI), 7.6 (s, 2H, AI-H), 7.8 (m, 
2H, AI-H), 8.3 (m, 2H, Ar-H), 10.1 (t (broad), IH, NHAr); mlz FAB-MS (MeOH in 3-
NBA) 477 (M+Ht; IR Vrnax (KBr) cm"! 3550-3310 (NRH), 1600 (C=O), 1230 (N-H); E~ 
(MeOHIDMSO) = 12027 cm"!; Amax (638nm). 
(23) 1,4-Bis[N-[2-[N',N'-bis(2-chloroethyl)amino]ethyl]amin0]-
9,10-anthracenedione dihydrochloride (ZP290) 
The reaction conditions and procedure follow that for the synthesis of ZP286. The 
reagents used were; ZP232 (O.05g, 0.09mmol), triphenylphosphine (O.144g, 0.5mmol) and 
carbon tetrachloride (0.32g, 2.lmmol). The product was isolated as a dark blue powder 
(35.4mg, 63.5% yield). TLC (EtOH: CH2Ch, 1: 9; Rr 0.8); m. p. 194 -196°C; !H NMR 
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(MeOD/CDCh) 0: 3.6 (t, 4H, 2xCH1CH2N), 3.64 (t, 8H, 4xCH1CH2N), 3.9 (t, 4H, 
2xCH2NHAr), 4.0 (t, 8H, 4xCH2Cl), 7.3 (d, IH, Ar-H), 7.7 (m, 2H, Ar-H), 7.8 (m, 2H, Ar-
H), 8.2 (d, IH, Ar-H), 8.3 (d, IH, Ar-H); rnIz FAB-MS (MeOH in 3-NBA) 575 (M+Ht; IR 
Vrnax (KBr) em-I 3550-3310 (NRH), 1600 (C=O), 1230 (N-H); E).. (MeOHIDMSO) = 
8570 em-I; Arnax (638nrn). 
(24) 1,4-Bis[N-[3-[N',N'-his(2-chloroethyl)amino]propyl]amino] 
-9,10-anthracenedione dihydrochloride (ZP289) 
The reaction conditions and procedure follow that for the synthesis of ZP286. The 
reagents used were; ZP240 (0.05g, 0.095mmol), triphenylphosphine (O.l5g, 0.57mmol); 
and carbon tetrachloride (0.346g, 2.28mmol). The product was isolated as a dark blue 
powder (44.9mg, 70.1% yield). TLC (EtOH:CH1CI1, 0.5:9.5; RfO.8); m. p. 187.2-188.9°C; 
IH NMR(CDCh/CD30D) 0: 2.2 (m, 4H, 2xCH1CH2CH1), 3.5 (t, 4H, 2CH1N), 3.6 (t, 8H, 
4xCH2N), 3.7 (t, 4H,CH2NAr), 3.9 (t, 8H, 4xCH2CI), 7.4 (s, 2H, ArH), 7.7 (m, 2H, ArH), 
8.2(m, 2H, ArH); rnIz FAB-MS (MeOH in 3-NBA) 603 (M+Ht; IR Vrnax (KBr) em-I 3550-
3310 (NRH), 1600 (C=O), 1230 (N-H); E).. (MeOHIDMSO) = 2171 cm-I; Arnax (642nrn). 
(25) 1,4-Bis[N-[2-[N'-(2-chloroethyl)-N'-methylamino] ethyl] amino] 
-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (ZP285) 
The reaction conditions and procedure follow that for the synthesis of ZP286. The 
reagents used were; ZP265 (0.05g, O.l1mmol); triphenylphosphine (O.08g, 0.32mmol) and 
carbon tetrachloride (0.19g, 1.2mmol). The product was isolated as a dark blue powder 
(52.5mg, 85.3% yield). m. p 201.2 - 203.1°C; TLC (EtOH: CH1C}z, 0.5: 9.5; Rf 0.8); IH 
NMR (CDCh/CD30D) 0: 3.0 (s, 6H, 2xCH3N), 3.5 (t, 4H, 2 x CH2NCH2), 3.6 (t, 4H, 2 x 
CH2NCH2), 3.9 (t, 4H, 2x CH2NHAr), 3.9 (t, 4H, 2 x CH2CI), 7.2 (s, 2H, ArH), 7.4 (s, 2H, 
Arl!), 10.6 (t(broad), 2H, 2xNHAr); rnIz FAB-MS (MeOH in 3-NBA) 509 (M+Ht; IR Vrnax 
(KBr) cm-I 3600-3300 (OH), 1580 (C=O), 1230 (N-H); E).. (MeOHIDMSO) = 27026 cm-
I; Arnax (666nrn). 
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(26) 1,4-Bis [N-[2-[N',N'-bis(2-chloroethyl}amino] ethyl] amino ]-5,8-dihydroxy-9,1 0-
anthracenedione dihydrochloride (ZP280) 
The reaction conditions and procedure follow that for the synthesis of ZP286. The 
reagents used were; ZP274 (0.05g, 0.09mmol), triphenylphosphine (0.147g, 0.56mmol) and 
carbontetrachloride (0.34g, 2.25rnmol). The product was isolated as a dark blue powder 
(45.6mg, 75.3% yield). TLC (EtOH: CH2Ch, 0.5: 9.5, Rr 0.85); m. p. 19l.6 -192.0°C; IH 
NMR (CDCh) i> 3.0 (m, 12H, 6xCH2N), 3.5 (t, 4H, 2xCH2NHAr), 3.7 (t, 8H, 2xCH2Cl), 
7.1 (s, 2H, ArH), 7.3 (s, 2H, ArH), 10.4 (t(broad), 2H, 2xNHAr); m1z F AB-MS (MeOH in 
3-NBA) 607 (M+Ht; IR Vmax (KBr) cm-
l 3600-3300 (OH), 1580 (C=O), 1230 (N-H); EA 
(MeOHIDMSO) = 8950 em-I; Amax (673nm). 
(27) 1,4-Bis [N-[3-[N'N'-bis(2-chloroethyl}amino] propyl]amino ] 
-5,8-dihydroxy-9,lO-anthracenedione dihydrochloride (ZP282) 
The reaction conditions and procedure follow that for the synthesis of ZP286. The 
reagents used were; ZP255 (0.05g, 0.79rnmol), triphenylphosphine (0.124g, 0.47mmol) and 
carbon tetrachloride (0.288g, 1.89mmol). The product was isolated as a dark blue powder 
(44.7mg, 80.7% yield); TLC (EtOH:CH2Ch , 0.5:9.5) Rr 0.85; m. p. 205.1 -206.5°C; IH 
NMR (CDCh/CD30D) i>: 2.2 (t, 4H, 2xCH2CH2CH2), 3.5 (t, 8H, 4xCH2N), 3.6 (t, 4H, 
2xCH2N), 3.7 (t, 4H, 2xCH2NHAr), 3.9 (t, 8H, 4xCH2CI), 7.1 (s, 2H, ArH), 7.3 (s, 2H, 
ArH), 10.6 (t(broad), 2H, 2xNHAr); m1z FAB-MS (MeOH in NBA) 635 (M+Ht; IR V max 





The reaction conditions and procedure follow that for the synthesis of ZP286. 
ZP275 (0.05g, 0.10mmol); triphenylphosphine (O.11g, 0.32mmol) and carbon tetrachloride 
(0.19g, 1.25mmol). The product was isolated as a dark blue powder ( 51.5mg, 83.2%); TLC 
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(EtOH: CH2Cb, 0.5: 9.5; Rf 0.75); m. p. 190.0 -192.l°C; IH NMR(CDCh/CD30D) 0: 
3.0(s, 6H, 2xNCH3), 3.4 (t, 4H, 2xCH2N), 3.6 (t, 4H,2xCH2N), 3.85 (t, 4H, 2xCH2NHAr), 
3.9 (t, 4H, 4xCH2CI), 7.1 (s, 2H, ArH), 7.3 (s, 2H, ArH), 10.6 (t(broad), 2H, 2xNHAr); 
mlz FAB-MS (MeOH in 3-NBA) 509 (M+Ht; IR Vmax (KEr) em-I: 3600-3300 (OH), 1580 
(C=O), 1230 (N-H); EA (MeOHIDMSO) = 14162 em-I; Amax (620nm) 
2. 4. 7 ATTEMPTED SYNTHESIS AND PURIFICATION OF SUBSTITUTED 
ANTHRAQUINONES 
(29) 1,4-Bis[N-[2-[N'-(2-chloroethyl)-N'-phenylamino]ethyl]a mino] 
-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (ZP292) 
The reaction conditions and procedure follow that for the synthesis of ZP286. The 
reagents used were; ZP254 (O.06g, O.lmmol), triphenylphosphine (O.lOg, O.4mmol) and 
carbontetrachloride (O.182g, 1.2mmol). A product was isolated as a blue-green powder 
identified by NMR as cyclised and/or mono chlorinated product. 
IH NMR (CDCh) peaks: impure () 3.6 (m, 8H, 4xCH2N), 3.8 (m, 8H, 2xCH2NAr; 
2xCH2CI), 6.8 (m, 6H, 2xArH), 7.1 (s, 2H, ArH), 7.2 (s, 2H, ArH), 7.3 (m, 6H, ArNH) 10.5 
(t(broad), 2H, 2xNHAr). 
(30) 1-[N-[2-[N-(2-Chloroethyl)-N-methylamino] ethyl]amino] 
-9,10-anthracenedione-N-oxide hydrochloride (ZP180) 
To a solution of ZP293 hydrochloride (0.04g,O.lmmol) in choroform (3ml) at ODC 
was added slowly a cooled solution of metachloroperoxybenzoicacid (mCPBA) (0.019g, 
0.11mmol) in chloroform (Iml). After 1 hour TLC showed that the reaction had gone to 
completion (approximately 80% conversion) and the resulting mixture was then 
precipitated with dry ethereal hydrogenchloride to give the N-oxide hydrochloride. 
Following flash column chromatography (100% chloroform) on neutral alumina the product 
was isolated in solution as a single spot as shown by TLC. After the removal of the column 
solvent under reduced pressure at a temperature of 40°C, TLC showed that the compound 
had broken down to form an impurity. By washing with three aliquots of hexane some of 
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the impurity was removed, the product dried and isolated as red crystals of approximately 
70% purity. IH NMR (DMSO) impure 0: 4.1 (s, 3H, CH3N), 4.4 (bt, 4H, 2xCH2CH]N), 
4.55 - 4.65 (bm, 4H, CH2N and CH2Cl), 7.8 (d, 1H, Ar-H), 7.9 (d, 1H, Ar-H), 8.1 (m, IH, 
Ar-H), 7.8 (m, 2H, Ar-H), 8.2 (d, 1R, Ar-H), 8.3 (d, IH, Ar-H), 10.1 (t (broad), IH, NHAr); 




(1) n = 2, RI = CH2CH20H, R2 = CH3 
(2) n = 3, R\ = CH2CH20H, R2 = CH3 
(3) n = 2, R\ = R2 = CH2CH20H 
(4) n = 2, RI = CH2CH20H, R2 = Ph 
Fig. 2. 1 Structure of alkyl amino side chains 
Two synthetic pathways were explored in the preparation of the vanous 
hydroxyethylamino side chains. In the first (Kohn et al.,1994), bromoalkanonitrile (alkano 
= (CH2)n; n = 2 or 3) was reacted with the secondary amine 2-(methylamino )ethanol to give 
the (N-methyl-N-hydroxyethyl)alkanonitrile. The nitrile group was then reduced to a 
primary amine with lithium aluminium hydride and the crude product distilled under high 
vacuum to give side chains (1) or (2). A different synthetic strategy was applied for the 
synthesis of sidechains (3) and (4). In the first method, ethylenediamine was monoprotected 
with ethylacetate (Aspinall, 1949) and the free primary amine reacted with excess ethylene 
oxide to give the acetyl protected N,N-bis-(hydroxyethyl)ethylenediamine (Peck et al., 
1959). Removal of the protecting group with dilute acid followed by high vacuum 
distillation afforded the product (3) as an oil. In the synthesis of (4), the primary amine of 2-
(N-phenyl)ethylenediamine was protected with diphenylacetophenone. Alkylation at the 
secondary amine with ethylene oxide and deprotection to isolate the product followed 
similar reaction conditions to the synthesis of (3) (Peck et al., 1959 and 1961). All 
sidechains were isolated with 60-80% purity and identified by HI NMR which 
corresponded with previous literature values. 
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The substitution of the sidechains onto the anthraquinone chromophore to give the 
mono (Fig. 2. 2), and the 1,4 disubstituted compounds as the 5,8-dihydro- and 5,8-
dihydroxyanthraquinones (Fig. 2. 3) followed the general synthetic procedure of Murdock 
et al., (1979) and Johnson et al., (1979). Synthesis of the 5,8 dihydro- and 5,8 
dihydroxyanthraquinones took place under a nitrogen atmosphere following the addition of 
the appropriate amine to leucoquinizarin or 5,8-dihydroxyleucoquinizarin, respectively. 
Monitoring the reaction by TLC showed the initial formation of a purple spot, the mono 
substituted product (approximate RF 0.75) and this was followed by the formation of a 
blue spot, the product (approximate RF 0.25). Air oxidation overnight, followed by column 
chromatography and recrystallisation gave the product as a blue powder. Mono substituted 
anthraquinones were isolated as a red/orange powder following recrystallization. 
The synthesis of the mixed sidechain compounds (Fig 2.4) was achieved according 
to the literature method of Krapcho et al., (1990) and Stefanska et al., (1989). Two side 
chains were required for this reaction and TLC showed the formation of three blue spots of 
approximate equal intensity, but with differing polarities. Isolation of the middle spot by 
column chromatography and recrystallisation gave the product as a blue powder. 
Conversion of the hydroxyethylaminoanthraquinones to chloroethylamino-
anthraquinones required the reaction to proceed at room temperature III 
triphenylphosphine/carbontetrachloride with dichloromethane as solvent. This method was 
adapted from Slagle et al., (1981). Following recrystallization, the 
chloroethylaminoanthraquinones were isolated in approximately 80% yield. By TLC the 
product was observed as a single spot with non-polar properties (RF 0.8). In some cases a 
difficulty was encountered when dissolving the starting material and therefore acetonitrile 
was added to the reaction to increase solubility. All compounds were identified by HI 






I Reflux in 2-
• methoxyethano1l6hr 
o 
o ZPl = R\ = CH2CH20H; R2 = CH3; n =2 
ZP150 = R\ = CH2CH20H; R2 = CH3; n =3 
ZP233 = R\ = R2 = CH2CH20H; n= 3 
o ZP293 = R. = CH2CH2Cl; R2 = CH3; n =2 
ZP284 = R\ = CH2CH2Cl; R2 = CH3; n =3 
ZP288 = R\ = R2 = CH2CH2Cl; n= 3 
Fie. 2. 2 General reaction scheme for the formation of mono anthraquinones 
a) substitution to give the hydroxyethylaminoanthraquinone 
b) halogenation to give the chloroethylaminoanthraquinone. 
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R OH 0 




ZP254= R. = CH2CHzOH; R2 = Ph; n =2 
ZP255 = R. = R2 = CH2CH20H; n= 3 
ZP265 = R. = CH2CHzOH; R2 = CH3; n =2 






ZP232 = R. = R2 = CH1CHzOH; 0 =2 





ZP280= R( = Rz = CHzCH1CI; n =2 
ZP282= R( = Rz = CH2CH1CI; 0 =3 
ZP285 = R( = CHzCHzCI; R2 = CH3; 
! (Ph )P/CCI chloroethylaminoanthraquinones: 3 4 R=H RT ZP286= R( = CHzCHzCI; Rz = CH3 0=2 
0=2 
ZP289 = R( = Rz = CH2CHzCJ; 0 =3 
ZP290 = R( = Rz = CHzCH2CI; 0= 2 
Fig. 2. 3 
B) 
General reaction scheme for the formation of 1,4 disubstituted 






Z'(CHZ)r("'l'~ OH OH 0 
1 
ZP257 = n = 2; R( = R2 = CH3; 
Heat together R = CH CH OH' D = CH 
Shr 3 2 2 • ''''' 3 
ZP275 = n = 2; R( = R2 = CH3; 
R3 = R. = CH1CH10H 
OH 0 
A) 




RT ZP281 = n = 2; R( = Rz = CH3; 
R3 = ~ = CH2CH2CI 
OH 0 HN/(CH2)n'N('R) 
'Rz 
B) 
OH 0 HN/ (
CH2)n'N/R3 
'~ 
Fig. 2. 4 Reaction scheme for the formation of unsymmetrical 1,4 
disubstituted anthraquinones to give 
a) hydroxyethylaminoanthraquinones and 
b) chloroethylaminoanthraquinones 
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2. 6 DISCUSSION 
2. 6. 1. SYNTHESIS OF HYDROXYETHYLALKYLAMINO SIDE CHAINS 
The synthesis of side chains (1) and (2) was adapted from the literature methods of 
Peck et al., (1959 and 1961) and Kohn et al.,(1994). Following SN2 substitution of the 
secondary amine onto a bromoalkanonitrile, the nitrile group was easily converted by 
reduction with lithium aluminium hydride to a primary amine. Because of the viscous 
nature and high boiling point of the product, difficulties were encountered during 
purification and therefore a second procedure was explored. 
The use of ethyl acetate to protect primary amines has previously been described by 
Aspinall, (1941). The ready availabililty of this common laboratory solvent meant that the 
protection procedure could be performed on a large scale. Ethylenediamine was stirred with 
ethyl acetate at room temperature over a seven day period (Fig 2. 5) and the mono-protected 
product distilled to remove impurities such as the disubstituted amine. The free primary 
amine was then dialkylated with an excess of ethylene oxide (Peck et al.,1959) to give the 
N, N'bis-(hydroxyethyl)tertiary amine (3) (Fig. 2 . 6) 
~j ~~ 
112N~~O~ ~4===_;;::-. H2N~Z'H 
o 
~H~NH2 .... + ~OH -










Fig. 2. 6 Reaction of primary amine with ethylene oxide to fonn 







(1 ~OH r-/0H 
.;;;:"'C=~- ~H~N~ ~"'=~ ... H2N~N~ 
/o~ OH (3) 0 OH 
H + H 
H+ +,)l 
OH 
Fig. 2. 7 Deprotection ofthe primary amine under acid conditions 
Although this synthetic route was successful, the length oftime required for the 
first step of the reaction to reach completion led to the search for an alternative protecting 
group for the synthesis of the N-2-(Hydroxyethyl)-N-phenylethylenediamine side chain (4). 
When considering ketones as protecting agents, it is necessary for the carbonyl group to be 
substituted with at least one aryl group so as to stabilise the protected product to 
decomposition (March, 1992). The ketone benzophenone was found to be appropriate as it 
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is selective for the primary amino function and it can easily be displaced when required. As 
N-Phenyl-ethylenediamine was the starting material for the reaction, the formation of the 
di-protected amine was precluded. Primary amines react with ketones via nucleophilic 
addition to the carbonyl group to form a tetrahedral intermediate (Fig. 2. 8) and this is 
followed by the loss of water to form an imine as the protecting group. In order to increase 
the rate of reaction, a catalyst, borontrifluoride etherate was employed and the water formed 
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R, r'- ..... BF3-
R/'\:+ ... 
NH2R 
H + BF3 , ..... 
R, to 





..... C=NR + BF3 + H20 
R 
Fig 2.8 Protection of primary amine with benzophenone 
2. 6. 2. CHROMOPHORE SUBSTITUTION REACTIONS 
Much of the synthesis of monosubstituted and 1,4-disubstituted anthraquinones 
revolves around the chemistry of aromatic nucleophilic substitution. Generally, compounds 
such as the halobenzenes are resistant to this type of reaction due to the electron rich nature 
of the aryl system. However, when an activating group such as a carbonyl or nitro group is 
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located ortho and/or para to the halogen, substitution can be rationalised by the SNAr 
mechanism (March, 1992) which takes place in two steps. The attacking species forms a 
bond with the substrate producing an intermediate complex and then the leaving group 
departs. The intermediates formed are similar to Meisenheimer salts (Fig. 2. 9). By 
comparison, the chemistry of mono-substitution onto the anthraquinone moiety is 
dominated by the electron withdrawing property of the two quinone carbonyl groups which 
generate a partial charge across the three rings and weaken the carbon-halogen bond, 




Fit:. 2.9 Formation of mono anthraquinones 
The synthesis of ZP1, ZP233 and ZP150 was achieved by treating 1-
chI oro anthraquinone with a ten fold excess of amine in the solvent 2-methoxyethanol, and 
the mixture refluxed for 6 hours. At first attempt this reaction was performed by heating the 
two reactants together as the amine, a viscous liquid, was thought suitable to act as both 
nucleophile and solvent. Despite a long reflux time, 48 hours, no improvement in yield 
above 10% could be achieved. The poor reactivity was initially attributed to the lack of 
absolute purity of the side-chains and the possibility of a more reactive nucleophile 
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substituting onto the chromophore, however this was not evident by TLC. Instead, 
visualisation under UV light revealed that a large amount of unreacted 1-
chloroanthraquinone was present in the reaction mixture indicating that the solubility of the 
starting material was poor. In view of this, a solvent, 2-methoxyethanol was selected to 
dissolve l-chloroanthraqinone at elevated temperatures (129°C) and allowed the reaction to 
be controlled at reflux. Only a 5% increase in yield was attained by using this solvent and 
so further modifications to the method were made. 
When various alkylamino side chains were reacted with 9-chloro-3-
methoxyacridine, Kohn et al., (1994) found that the hydrogen chloride displaced as a by-
product of the reaction was effectively protonating the primary amine side chain and 
preventing it from substituting onto the chromophore. Consequently, the chlorine atom of 
acridine was replaced with a phenoxy group which allowed couplings to proceed without 
the need for an excess of amine. This procedure was followed for the 1-
chloroanthraquinone, however poor reactivity with the phenol prevented this route from 
being further pursued. Instead, pyridine was added to complex the hydrogen chloride 
expelled. The outcome was to increase the overall yield by only 2% which suggests that 
protonation of the amine side chain was not a major concern regarding this reaction. As the 
final yield of 17% seemed the best available and provided adequate product for subsequent 
steps, no further work was done on this synthesis. 
The preparation of 5,8-dihydro and 5,8-dihydroxyanthraquinones has been described 
extensively in the literature (Zee-Cheng et al., 1978; Murdock et aI., 1979; Johnson et al., 
1979). Generally the reaction mechanism involves the condensation of leucoquinizarins 
(Fig. 2. 3 and 2. 4) with an excess amount of the appropriate amine. The initial reaction of 
the primary amine is at the quinone group on the I-position of the chromophore followed 
by the loss of water which results in the formation of an imine. This is followed by a second 
identical slow reaction at the 4-position. The intermediate imines (Schiff bases) are then 
oxidized in air or by the addition of a few drops of base to secondary aryl amines via 
internal rearrangement of the anthraquinone chromophore. The oxidation step can be 
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readilly monitored by TLC as a colour change from orangelbrown to blue is observed on 
conversion to products. 
When mitoxantrone is synthesised, reaction temperatures are maintained below 
SO°C as the N-monosustituted ethylenediamine side chain can readily cyclise onto the 2-
position of the anthraquinone ring to form the hydroxyethylamino-l ,2,3,4-tetrahydronaptho-
(2,3-f)-quinoxaline-7, 12-dione (see Fig. 1. 6) (Murdock et al., 1979). In contrast, the 
tertiary nature of the hydroxyl ethyl amino anthraquinone side chains prevents a similar intra-
molecular rearrangement from taking place. 
It is generally accepted that the reaction of an amine with leucoquinizarin generates 
a low quantity of product. As a consequence this has led to the pursuit for a more reactive 
anthraquinone chromophore substituted with functional groups that can be displaced more 
readily by the amine nucleophile. Krapcho et al., (1990) devised two methods to synthesise 
1 ,4-difluoro-5,8-dihydroxy-9, 1 O-anthracenedione which on further reaction gave 
mitoxantrone with a 78% yield. More recently Lee et al., (1999) described a five step 
synthesis to isolate AQ4 from the starting product 3, 6 dichloropthalic anhydride. Whilst 
being high yielding, the expense of these routes and the additional steps required in the 
preparation of the starting material make them relatively unattractive. 
2. 6. 3 SYNTHESIS OF CHLOROETHYLAMINOANTHRAQUINONES 
In the conversion of an alcohol to an alkyl halide, the reaction can be initiated either 
at the -C-O- bond or at the -O-H bond. As the hydroxyl is a poor leaving group it does not 
undergo SN2 reactions readily. To overcome this, much use is made of inorganic halides 
such as SOCh, PCls, PCb and POCb which form inorganic ester intermediates that can 
easily be displaced by a halide ion (Fig. 2. 10 and see March, 1992 for references). 
The reaction of an alcohol with thionyl chloride (acting as both solvent and 
nucleophile) follows a second order rate equation (Rate = k[ROH][SOChD with retention 
of configuration and proceeds via an SNi (internal nucleophilic substitution) mechanism 
(Fig 2. 10). The rate at which the alkylchlorosulphite intermediate breaks down to the 
product RCI is found to increase with increasing polarity of the solvent, and also with 
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increasing stability of the carbocation R + ,therefore, an ion pair, R+-OSOCI is thought to 
be involved. Following collapse of the ion pair to products, attack is likely to occur on the 
same side of R+ from which -OSOCI departed and as a result configuration is retained. If 









---:.~ RCI + HCI 
Fit!. 2. 10 SNi reaction of thionyl chloride with a hydroxyl group 
configuration. The HCI produced during the reaction complexes with the pyridine and C( 
then attacks from the back as expected for an SN2 reaction. 
Inorganic halides such as phosphorusoxychloride and thionyl chloride have been 
successfully employed in the synthesis of substituted acridine anti-tumour drugs (Peck et 
al., 1961; Kohn et al., 1994, Watanabe et al., 1989) and quinoline anti-malarial drugs (Peck 
et aI1959), with thionyl chloride being the more favoured reagent. Following the method of 
Kohn et al.. (1994), a 100 fold excess of thionyl chloride was reacted with the 
hydroxyethylaminoanthraquinone in the absence of air to give a mixture from which the 
product could not be isolated pure by recrystallisation. Purification by column 
chromatography proved highly problematical as the product could not be separated from the 
top of the silica column. In an effort to reduce impurities, attempted modifications to the 
procedure such as increasing the temperature of reaction to 40°C and the use of additional 
solvents such as dimethylformamide (Watanabe et al., 1989) and diethylether were 
investigated without success. An increase in the quantity of product formed was observed 
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when the starting material ZPl was protonated with ethereal hydrogen chloride prior to 
halogenation. Despite this, the impurities present could not be eliminated completely (see 
Appendix 3 for HPLC data) and therefore an alternative method for halogenation was 
explored. 
Triphenyl phosphine has for a long time been used in conjunction with carbon 
tetrachloride in the halogenation of alcohols (reviewed by Castro, 1983) such as in the 
synthesis of the chlorambucil analogue [3-(trifluoromethyl)chlorambucil] (Coe et al., 1997) 
which was achieved in good yield. The reaction proceeds in a two step mechanism which 
involves the initial formation of a cluster of ion pair intermediates stabilized by the 
positively charged phosphorous in one ion pair adjacent to a negative chloride from another 
ion pair and this is followed by intermediate decomposition (see Fig 2. 11) (Slagle et al., 
1981). It has been shown that decomposition proceeds unimolecularly with inversion of 
configuration and that the rate of formation of products is only slightly influenced by steric 
effects (Jones et al., 1978). When a solvent such as acetonitrile is used during the reaction 
halogenation is 
R = hydroxyethylaminoanthraquinone 
[(C6H5)3P~(R]+ + CHCl3 
cr 
Fig.2. 11 Synthetic route for the conversion of hydroxyethylamino-
anthraquinones to chloroethylaminoanthraquinones 
71 
reported to proceed very rapidly and the enhanced polarity is effective enough to change the 
kinetic order from unimolecular to bimolecular (Slagle et al.. 1981). This method of 
chlorination proved to be the most effective. resulting in 70-85% yield following 
recrystallisation for all compounds isolated. Only one compound ZP292 proved difficult to 
halogenate because of its poor solubility in the solvent dichloromethane. The NMR of this 
compound demonstrates that one side chain underwent chlorination to give the half mustard 
whilst the remaining material was unreacted ZP254 (starting material). 
Fig. 2. 11 describes the formation of the ion pair intermediate through nucleophilic 
attack onto a chlorine atom of carbon tetrachloride. In an opposing view. Castro et al., 
(1983) suggests that this step could only take place if a highly nucleophilic reagent such as 
aminophosphine replaced triphenylphosphine during reaction. as a strong nucleophile 
would allow complete charge transfer to the trichloromethyl anion to occur. Instead, in an 
amendment to the mechanism described in Fig. 2. 11, it was postulated that 
triphenylphosphine attacks the tetrachloromethane carbon and forms an ion pair with the 
displaced chloride anion. 
2. 6. 4 ATTEMPTED SYNTHESIS OF CHLOROETHYLAMINOANTHRAQUINONE N-
OXIDE HYDROCHLORIDE 
OH 0 
Fig. 2. 12 AQ4N 
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The drug AQ4N (Fig. 2. 12) was developed as a hypoxia selective bis-bioreductive 
prodrug which undergoes cellular reduction at the N-oxide to give a DNA binding agent 
that is cytotoxic through the inhibition of topo IT (Patterson, 1989, 1993). The inclusion of 
a neutral quarternary N-oxide salt in the drug structure considerably decreases the attraction 
of AQ4 for DNA and coincides with minimal prodrug cytotoxicity (Patterson, 1993). It was 
therefore anticipated that a similar but much improved spectrum of activity would be 
attained if a nitrogen mustard N-oxide could be linked to an anthraquinone chromophore. 
Previous reports of aryl mustard N-oxide synthesis demonstrated that the compounds 
generated were unstable. In acidic medium they reform to the original nitrogen mustard by 
loss of the tertiary amine oxygen, and in basic media they rearrange to the half mustard and 
a simple aldehyde (Degutis et al., 1972; Degutene et al., 1986, Tercel et al., 1995). 
Regarding this, an attempt was made to synthesize an N-oxide of the anticancer drug 
chlorambucil which was initially considered to be successful (Kirkpatrick et al., 1994). 
However, an investigation into its decomposition revealed that a stable hydroxylamine was 
formed as the major rearranged product in organic solvents and this had been isolated 
instead (Tercel et al., 1995). 
Fig. 2. 13 Proposed rearrangement of aliphatic bis-mustard N-oxides via a 
cyclic intermediate 
Despite the futile attempts to isolate an aryl mustard N-oxide, an aliphatic 
bifunctional mustard N-oxide of mechlorethamine (Nitromin) had been synthesised 
previously. Although aliphatic bifunctional mustard N-oxides are known to undergo fast 
rearrangement via a cyclic intermediate to give trisubstituted hydroxylamines (Fig. 2. 13), 
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nitromin has demonstrated increased stability and reduced cytotoxicity (30-40 fold) over 
mechlorethamine with some selectivity for hypoxic cells (Connors, 1988; White et al., 
1989). Furthermore, an investigation into the decomposition of monofunctional mustard N-
oxides in aqueous media revealed that they hydrolyse more slowly than their bifunctional 
equivalents (Owari et al.,1953). Based on this evidence it was considered possible to 
prepare a stable aliphatic chI oro ethyl amino anthraquinone N-oxide. The proposed starting 
point was the isolation of a simple mono functional N-oxide by reacting mono substituted 
chloroethylaminoanthraquinone ZP293 with mCPBA to form ZP180 (see Fig 2.14). 
RHN (ZP293) 
R = anthraquinone chromoohore 
Fig. 2. 14 Attempted synthetic route for the formation ofa mustard N-oxide 
This reaction followed a modified method of Patterson et al., (1989). The N-oxide 
was isolated pure (observed by TLC) following column chromatography but decomposed 
on solvent evaporation. Subsequent F AB+MS analysis showed that the mixture contained a 
molecular ion [M]+ peak consistent with the relative molecular mass of the mustard N-
oxide. However, it is unknown whether this was the desired product or the product of 
rearrangement to the hydroxylamine, as both compounds would give identical MS spectra. 
Because rearrangement of even the monofunctional anthraquinone mustard N-oxide proved 
facile, no further attempts at N-oxidation were made. 
To summarise, a number of hydroxyethylaminoalkylamino sidechains were 
synthesised and substituted onto an anthraquinone chromophore to give a series of mono 
substituted and 1, 4-disubstituted hydroxyethylaminoanthraquinones. The subsequent 
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coverslOn of the hydroxyethylaminoanthraquinones to chloroethylaminoanthraquinones 
involved initial attempts at halogenation using thionyl chloride. However, the large number 
of impurities produced from reaction and a difficulty in purification led to the choice of 
milder chlorinating reagent triphenylphosphine with carbontetrachloride. This method 
proved to be high yielding with few impurities and was therefore utilised to produce a series 
of derivatives that were put forward for further study. An attempt was also made to isolate a 
simple mono mustard anthraquinone N-oxide which, due its instability, led to the 
abandonment of further synthesis. 
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AN INVESTIGATION INTO THE MECHANISM 
OF ACTION OF ALKYLATING 
ANTHRAQUINONES 
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Chapter 3 DNA-BINDING STUDIES 
3.1. INTRODUCTION 
DNA intercalating ligands have the capacity to bind reversibly to DNA by insertion 
of an aromatic chromophore between DNA base pairs. One aspect of intercalative binding 
that influences anti-tumour activity is the drug binding strength with DNA (reviewed by 
Denny et ai, 1989). This principle is not always followed, as there are many intercalating 
agents that bind tightly to DNA but have no activity (Feigon et ai., 1984). Despite this, 
druglDNA binding which can be measured in terms of druglDNA association constant (K), 
drug dissociation rate (kd) from DNA (Gandecha et ai., 1985; Denny et ai.,1989) or more 
precisely the average residence time spent by the chromophore at a particular binding site 
(Denny et ai., 1990), has often demonstrated a positive correlation with cytotoxicity within 
a given class of compound (Denny et aI., 1989). 
A senes of novel chloroethylaminoanthraquinones and hydroxyethyl-
aminoanthraquinones were compared for their ability to intercalate into calf thymus DNA, 
and their DNA association constants (K) and frequency of base pair intercalation (n) 
determined. Futhermore, the effect of drug stabilisation of the DNA helix to thermal 
denaturation (T m) was investigated in order to distinguish between covalent and non-
covalent drug-DNA interactions. 
3. 2. CHEMICALS AND REAGENTS 
Calf thymus DNA was purchased from Sigma Chemicals, London, UK. Tris, 
hydrochloric acid and sodium chloride were purchased from Fisher Scientific, 
Loughborough, UK. All drug samples were stored as a dry powder and dissolved into 
DMSO to give a 50llM stock solution prior to being further diluted to the specified 
concentration in the appropriate buffer. 
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3.3 METHODS 
For preparation of DNA solution and high and low ionic strength buffers see 
appendix 1 and 2 respectively. 
3.3.1. DETERMINATION OF DRUGIDNA ISOSBESTIC POINT 
A series of DNAIDrug ratios (0, 0.2, 0.5, 1, 2, 5, 10, 15 to 1) were prepared by 
varying the concentration of DNA from 0 to 2.25xlO-4M against a constant concentration of 
drug 1.5x 1O-5M. To eight 10ml volumetric flasks was added drug (1.5x 1O-5M) and high 
ionic strength buffer to give a final volume of 9ml. The approprate ratio of DNA was then 
carefully added to each flask and the final solution accurately made up to 10ml with buffer 
and mixed by single inversion. The spectra of each concentration ratio was recorded in the 
visible region (350-700nm), and superimposed to give eight overlapping spectra. This 
method was repeated using low ionic strength buffer. 
3.3.2. DETERMINATION OF THE BINDING CONSTANT OF DRUG WITH DNA 
A stock solution of DNA (l x 1 0-3M) in high ionic strength buffer was prepared 
according to appendix 1. The drug (2.5xlO-5M) in buffer (3ml) was added to a lcm 
pathlength quartz cuvette and its absorbance measured to determine the drug A.max• DNA 
stock solution was serially pipetted into the drug solution at volumes of: 12x101lI, 6x20IlI, 
8x40JlI and 4x 1 OOJl!' After each addition the solution was stirred and left to equilibrate for 
10 minutes after which, the absorbance at the Amax of the drug was taken. All data were 
reproduced in triplicate. 
3.3.3 DETERMINATION OF THE THERMAL DENATURATION OF DNA 
Low ionic strength buffer (3ml) and distilled (5.5ml) was added to a 10 ml 
volumetric flask and degassed by sonication for 30 min. A solution of DNA (3.2x 1O-6M) in 
low ionic strength buffer (0.6ml) was slowly added to the flask and the remaining volume 
made up to 10 ml with dH20. The solution was mixed by a single inversion of the flask and 
pipetted into two lcm pathlength quartz cells, the reference and sample cells. The 
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temperature of the reference cell was maintained at room temperature whilst the sample cell 
temperature was raised to SO°C and the solution left to equilibrate for IS min. The 
absorbance of the DNA was monitored at 260nm as the sample cell temperature was raised 
at a rate of 1°C/min and readings taken at 1°C intervals from SO°C-85°C. All data were 
reproduced in triplicate. 
3.3.4 DETERMINATION OF THE THERMAL DENATURATION OF DNA IN THE 
PRESENCE OF HYDROXYETHYLAMINOANTHRAQUINONE 
Low ionic strength buffer (O.7Sml), dH20 (6mI) and drug (8.Sx 1 0·8M ) was added to 
a 10ml volumetric flask and degassed by sonication for 30min. DNA (8.5x10·7 M) in low 
ionic strength buffer (O.6ml) was slowly added to the flask and the volume made up 
accurately to 10ml with dH20 to give a final DNA:drug ratio of 1 0: 1. The solution was 
mixed by single inversion of the flask and pipetted carefully into two I cm pathlength quartz 
cells, the reference and sample cells. The temperature of the reference cell was maintained 
at room temperature whilst the sample cell temperature was raised to 60°C and the solution 
left to equilibrate for 15 minutes. The absorbance of the DNA was monitored at 260nm as 
the sample cell temperature was raised at a rate of 1°C/min and readings taken at 1 °C 
intervals from 60-1 OO°C. All data were reproduced in triplicate. 
3. 3. 5. DETERMINATION OF THE THERMAL DENATURATION OF DNA IN THE 
PRESENCE OF CHLOROETHYLAMINOANTHRAQUINONE 
Low ionic strength buffer (O.75ml) and dH20 water (6ml) were added to a 10ml 
volumetric flask and degassed by sonication for 30min. To this was added the drug (8.Sx 1 O· 
8 M) and then the DNA (8.5x10·7 M) and the volume made up accurately to 10ml with 
dH20 water. The solution was mixed by single inversion of the flask and pipetted into two 
lcm pathlength quartz cells, the reference and sample cells. The temperature of the 
reference cell was maintained at room temperature whilst the sample cell temperature was 
raised to 60°C and the solution left to equilibrate for 15 minutes. The absorbance of the 
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DNA was monitored at 260nm as the sample cell temperature was raised at a rate of 
1°C/min and readings were taken at 1 °C intervals from 60-100°C. 
All data were reproduced in triplicate. 
3. 4. RESULTS 
3. 4. 1 DETERMINATION OF ISOSBESTIC POINT 
DNA intercalating agents such as the anthraquinones absorb in the visible region of 
the electromagnetic spectrum to give characteristic absorption spectra. If the spectra derived 
from the addition of varying concentrations of DNA to a single concentration of drug is 
superimposed onto the spectrum of the drug alone, the absorbance wavelength at which all 
the spectra cross is termed the isosbestic point. This may be achieved if there are only two 
species in solution, that is, free drug and DNA bound drug. The point at which DNA is fully 
bound with drug corresponds to no further decrease in the extinction coefficient at the "'max 
of the free drug. 
The isosbestic behaviour of eight hydroxyethylaminoanthraquinones was 
determined in high ionic strength buffer (0.5M NaCl). Unlike the 1, 4-disubstituted 
anthraquinones (Fig. 3.1 and Fig. 3. 2) the mono derivatives showed no apparent affinity for 
calf thymus DNA. The 5, 8-dihydroanthraquinones could be distinguished from the 5, 8-
dihydroxy derivatives by the position of their isosbestic point, 639 nm and 618 nm 
respectively (Table 3. 1). Furthermore, the spectral shifts for the 5, 8-
dihydroxyanthraquinones were up to 50% greater than for the 5,8-dihydroanthraquinones 
indicating enhanced chromophore 7t- orbital interaction with the DNA base pairs. 
In contrast to the other compounds tested ZP274, a 5,8-dihydroxyanthraquinone 
substituted with two hydroxyethyl groups per side chain gave an isosbestic point at the four 
lowest drug concentrations in low ionic strength buffer (0.05M) (Fig. 3. 3). This behaviour 
has been observed previously (Kapusczinski et al., 1985) and may be related to the 
80 
preference of this compound at high druglDNA concentration to bind electrostatically to the 
surface of DNA. 
The isosbestic behaviour of ZP254 was not determined as drug precipitation 
occured on addition to buffer. The bulky phenyl groups attached to the side chains of ZP254 
increase its lipophilic character and therefore make it poorly soluble in water even if the 
concentration ofDMSO in buffer is raised to 10%. 
The spectra of ZP285 (Fig. 3. 4) is representative of the effect of the 
chloroethylaminoanthraquinones on DNA binding. At each increasing DNA concentration 
the drug absorbance showed no change in A.max but demonstrated a large change in its 
visible region when compared to the 1,4-disubstituted-5,8-dihydroxy-
hydroxyethylaminoanthraquinones (Fig. 3. 2). When the same concentration of drug was 
added to distilled water in the absence of salt and buffer, the characteristic 1, 4-disubstituted 
anthraquinone spectra was re-gained (Fig. 3. 5). This indicates that high ionic strength 
buffer may adversely affect the intercalation of the chloroethylaminoanthraquinones and 
reduce their affinity for DNA. 
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Table 3.1 The effect on visible absorbance following the addition of the 
h~drox~eth~anthraguinones to calf thymus DNA. 
LP Shift in Amax 
Compound (nm) (nm) 
ZP232 639 10 
ZP240 639 20 
ZP242 636 17 
ZP255 618 20 
ZP257 618 18 
ZP265 618 20 
ZP274* 618 nJd 
ZP275 618 17 
LP = Isosbestic point (nm); shift in Amax (nm) from free drug to fully intercalated DNA. 
nJd= not determined, * isosbestic point determined in low ionic strength buffer (O.05M). 
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Fig 3. 1 Spectral shift in visible absorbance following the addition of increasing 
concentrations of calf thymus DNA to 5,8- dihydro-
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Fig 3. 2 Spectral shift in visible absorbance following the addition increasing 
concentrations of calf thymus DNA to 5,8-dihydroxy-
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Fig 3. 3 Spectral shift in visible absorbance following the addition of increasing 
concentrations of calf thymus DNA to 5,8-dihydroxy-
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Fig 3. 4 Effect on visible absorbance following the addition of increasing 
concentration of calf thymus DNA to chloroethylamino-
anthraquinone ZP285. Determined in high ionic strength buffer. 
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Fig 3. 5 The visible absorbance spectrum of ZP285 in dH20 
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3. 4. 2 SPECTROPHOTOMETRIC TITRA nON STUDIES 
In order to proceed with the spectrophotometric titration assay it is essential that 
each drug produces an isosbestic point (sec section 3. 4. 1) and that both free and bound 
drug obey Beer-Lamberts Law over the drug concentrations used. 
Following the addition of an increasing concentration of DNA to a fixed 
concentration of drug. intercalation can be identified by a decrease in absorbance at (Amux) 
of the free drug and a visible absorbance shift to longer wavelengths as a result of 
peturbation of the 1t and 1t* orbital energies on binding. The extent and nature of DNA 
binding can be quantitated using the Scatchard equation which can be applied to 
intercalating species. By taking absorbance readings at the Amax of the free drug and 
plotting ric vs r, where r = (concentration of ligand bound/concentration of DNA) and c = 
concentration of free ligand, the extent of DNNdrug association can be dctermined 
(Plumbridge et al., 1978; Bell et al., 1989). The negative slope corresponds to the affinity 
constant (Kd, whilst the fraction of drug molccule bound per DNA base pair (n) can be 
determined at the x intercept (Fig. 3. 6) 
All titrations were performed in triplicate and in high ionic strength buffer to 
maintain the conditions of the drug isosbestic point determination where surface binding is 
excluded. At low concentrations of DNA, intercalative binding was shown to be negligible. 
Conversely, at high DNNlow drug concentration ratio intercalation predominates, and the 
graph tends towards a steep negative slope. The KJ values for the 5,8-
dihydroxyanthraquinone analogues were in the order of 1 06M-J, whilst the KI values for the 
5,8-dihydroanthraquinones were 106 _107M-I (Table 3.2). 
The number of drug molecules bound per molecule of DNA (n) did not vary 
significantly amongst compounds of the same substituted chromophore. The 5,8 
dihydroanthraquinones intercalated at every 8.3 base pairs of DNA (n = 0.12) whilst the 5,8 
dihydroxyanthraquinones intercalated at approximately every 6.6 base pairs (n = 0.15). 
The DNA affinity of the chloroethylaminoanthraquinones was not determined as the 
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Fig. 3.6 Scatchard detennination of the binding affinity ofZP265 with calf 
thymus DNA. The data shown represents the average of 
triplicate experiments. K\ = drugIDNA association constant; 
n = fraction of drug molecule intercalated per base pair site 
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Table 3. 2 The affinity of the hydroxyethylaminoanthraquinones for calf thymus DNA. 
Compound KI(M-1) n 
ZP232* 3x106 0.12 (8.3) 
ZP240* 7x106 0.12 (8.3) 
ZP242* 1x107 0.12 (8.3) 
ZP255 3x106 0.15 (6.6) 
ZP257 2x106 0.175(5.7) 
ZP265 3xl06 0.14 (7.1) 
ZP274 2x106 0.15 (6.6) 
ZP275 2xl06 0.15 (6.6) 
Data determined at the Amax of drug. Kl represents the DNA intercalation association 
constant and is expressed as the mean of three replicates; n is the fraction of drug molecule 
bound per DNA base pair and is expressed in parenthesis as the frequency of drug-base pair 
intercalation .... denotes 5, 8-dihydroanthraquinone. 
3.4.3 DNA THERMAL DENATURATION TEMPERATURE STUDIES 
The DNA melting temperature (T m ) was assayed according to the method of Tong 
et al.,( 1978). T m is defined as the temperature at which half of the concentration of DNA 
has denatured to single strands and can be derived by plotting absorbance vs temperature. 
By subtracting the T m for DNA alone from the T m for DNA intercalated with drug, the 
degree of helix stabilisation towards denaturation can be determined as I1Tm• 
All analysis was performed in triplicate in low ionic strength buffer. Calf thymus 
DNA with no drug gave a T m value of 70.5 ± 0.5 °C. 
The efficiency of helix stabilisation by the hydroxyethylaminoanthraquinones 
followed the general trend (least efficient) monoanthraquinones < 5,8-
dihydroanthraquinones < 5,8-dihydroxyanthraquinones (Table 3. 3). The weakest drug 
proved to be monosubstituted ZPl which showed poor binding with DNA, giving a I1Tm of 
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0.4 °C. In contrast, the 1,4-disubstituted-5,8-dihydroxyanthraquinone ZP265, was the most 
effective drug, increasing DNA denaturation by 19.7 °C. Fig 3. 7 compares the effect of 
increased chromophore substitution on helix stability by showing the T m plots for three 
drugs ZPI, ZP242 and ZP265 substituted with the (N-(2-hydroxyethyl)-N-
methylamino)ethylenediamine sidechain (Fig. 3. 8). The effect of increasing the number of 
hydroxyethyl groups from one to two per side chain resulted in reduced DNA binding. This 
coincides with data derived from the isosbestic behaviour of ZP274 and the assumption that 
surface binding predominates with this compound. The evidence from the thermal 
denaturation studies of the hydroxyethylaminoanthraquinones therefore indicates that the 
chromophore 5,8 substituted hydroxyl groups and the structure of the side chain both affect 
the extent of drug-DNA binding. 
The chloroethylaminoanthraquinones showed a general trend of weak helix 
interaction (Table 3. 4) suggesting that with the exception ofZP281 (L~Tm 10.1) (Fig 3. 11) 
they appear to have poor affinity for DNA. A possible explanation for this is discussed in 
(section 3. 5.) 
Two compounds ZP254 and the chloroethylaminoanthraquinone ZP280 precipitated 
on addition to buffer and so determination ofTm was not possible. 
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Fig. 3. 7 Demonstrates the effect of increasing temperature on the UV 
absorbance of calf thymus DNA (at A260) in the 
presence ofZPl, ZP242 and ZP265. The data shown for each 
compound is the average of triplicate experiments. 
ZPl: R\; R2 = H; R3 = H 
ZP242: RJ = R2; R3 = H 
ZP265: RJ = R2; R3 = OH 
Fig 3. 8 Shows the chromophore side chain substitution pattern of. 
ZPl, ZP242 and ZP265 
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Table 3. 3 The effect of hydroxyethylaminoanthraquinones on the denaturation 
temperature of calf thymus DNA. 
Compound TmeC) IlTm(OC) 
ZPI 70.9 (± 0.27) 0.4 
ZP240 74.5 (± 0.21) 4.0 
ZP242 81.7 (± 0.15) 11.3 
ZP255 83.3 (± 0.35) 12.8 
ZP257 80.1 (± 0.1) 10.5 
ZP265 90.2 (± 0.22) 19.7 
ZP274 81.5 (± 0.21) 11.0 
ZP275 84.0 (± 0.32) 13.5 
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Fie 3. 9 The effect of increasing temperature on the UV absorbance 
of calf thymus DNA (/...260) in the presence of 
chloroethylaminoanthraquinone ZP281. The data shown 
is the average value of triplicate experiments. 
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Table 30 4 The effect of chloroethylaminoanthraquinones on the denaturation 










72.2 (± 0.1) 
76.2 (± 0.53) 
77.7 (± 0.4) 
73.8 (± 0.41) 
75.9 (± 0.37) 
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T m determined at the 1...260 DNA and expressed as the mean triplicate value (± s.d). 
nJa = not applicable. 
30 50 DISCUSSION 
3. 5. 1. ISOSBESTIC BEHAVIOUR OF THE NOVEL ANTHRAQUINONES 
A property of substituted anthraquinones is to bind DNA by the process of 
intercalation which is manifest by a characteristic drug visible absorbance shift to longer 
wavelengths (bathochromic shift) and a decrease in the molar extinction at the Amax of the 
free drug (hypochromic shift) (Waring et ai., 1981). When the drug becomes intercalated 
into DNA, it is stabilised within the hydrophobic interior of the helix by charge transfer 
forces, van der Waals and hydrophobic interactions. The effect of these are to alter the 
electron density of the chromophore and its absorbance properties. Anthraquinones 
containing basic amine side chains can also bind to DNA through ionic interaction. This is a 
weaker mode of binding compared to intercalation and occurs at physiological pH between 
the positively charged amino group on the sidechains and the anionic phosphate groups of 
the DNA backbone (reviewed by Baguely 1991, Pohle et ai., 1990). 
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Studies of the novel hydroxyethylarninoanthraquinones showed that 1,4-
disubstituted 5,8-dihydro and the 5,8-dihydroxy but not the I-substituted compounds gave 
isosbestic points in high ionic strength buffer (O.5M NaCl). The effect of high salt 
concentration is to neutralise the anionic charge of the DNA phosphate backbone with 
positively charged sodium ions and this discourages the drug from binding to the surface of 
the DNA but at the same time allows intercalative binding to continue (Lown et al., 1985; 
Bell et al., 1989). Evidence of electrostatic binding was apparent in low ionic strength 
buffer as the majority of the drugs lost isosbestic behaviour suggesting that significant 
surface binding had occured. In view of this, the DNA binding affinity of the novel 
anthraquinones was determined in high ionic strength buffer. It is also worth noting that 
others have shown that the presence of an isosbestic point can be dependent on the buffer 
used (Kapusczinski et al., 1981; Lown et al., 1985). 
ZP274, comprising of two hydroxyethyl groups per side chain would only give a 
partial isosbestic point in low ionic strength buffer at the four lowest drug concentrations. It 
has previously been stated that intercalation is encouraged at a low drug to DNA ratio and 
the subsequent loss of an isosbestic point may be attributed to the ability of the drug to 
surface bind DNA at high druglDNA ratios (Kapuczinski et al., 1985). The paucity of DNA 
binding sites may also encourage drug aggregation. Surface binding encourages 'self 
association' between drug molecules which stack on top of one another (dimerisation) 
through chromophore hydrophobic interactions and reduce the number of accessible 
intercalation sites. The outcome of this is to promote additional secondary binding and a 
species with absorption properties which differ from the intercalated drug (Kapusczinski et 
al., 1985). In the case of ZP274 it is possible that the partial isosbestic point occured as a 
result DNA surface binding alone as at high ionic strength a complete loss of isosbestic 
behaviour was observed. From this evidence it can be postulated that intercalation as a 
single binding mode does not take place for this drug. 
The mono substituted anthraquinones eg ZP1, ZP150 and ZP233 showed a lack of a 
consistent single interaction with DNA. Because they possess only one side chain this 
structural configuration allows for a number of intercalative binding modes to take place. 
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Islam et al., (1985) demonstrated that I-substituted anthraquinones can intercalate either 
parallel or perpendicular to the DNA axis with the sidechain in the major or minor groove 
of DNA and may therefore produce more than one DNA binding species in solution. 
At high ionic strength the chloroethylaminoanthraquinones failed to show isosbestic 
behaviour. Instead at each DNA concentration they gave identical spectra which in contrast 
to the hydroxyethylaminoanthraquinones showed a large change in the visible region 
coinciding with a shift to shorter wavelengths (Fig. 3. 4). By comparison, at the same 
concentration of free drug in distilled water (no buffer or salt) the characteristic 
anthraquinone spectra was observed (Fig. 3. 5). A similar shift in spectrum profile was 
obtained in the theoretical calculation of mitoxantrone dimers (Kapusczinski et a!., 1985). 
Considering this, it may be postulated that high ionic strength promotes drug chromophore-
chromophore hydrophobic interactions. These may lead to drug dimerisation and reduced 
DNA interaction, perhaps as a consequence of the high lipophilic nature of the 
chloroethylaminoanthraquinones. As a further suggestion, the lack of crossover points for 
spectra at high and low druglDNA ratios does not necessarily indicate that intercalation did 
not take place because under certain conditions such as high ionic strength, free and bound 
drug may differ significantly to never give an isosbestic point. 
3. 5. 2 ANALYSIS OF THE DNA BINDING CONSTANT (K1) FOR THE 
HYDROXYETHYLAMINOANTHRAQUINONES 
The determination of DNA affinity constants for the 
hydroxyethylaminoanthraquinones followed the method of Lown et a!., (1985); Bell et al., 
(1989). This assay involves reverse titration where the DNA is added to and initially 
becomes saturated with drug. As DNA concentration increases, intercalation rather than 
surface binding predominates. Kapuscinski et al., (1985) stated that this method can 
promote DNA condensation and precipitation which compromises accuracy, however, this 
effect was not observed in this study or that ofLown et al., (1985). 
The DNA association constant values (K1) for the 1,4-disubstituted-5,8-
dihydroxyanthraquinones were in the range 106M-I at high ionic strength. This data is in 
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agreement with Lown et al., (1985) who found that mitoxantrone and its congeners bound 
duplex DNA in the range (0.16-2.35)x 106M- t , whilst the 5,8-dihydroanthraquinone 
derivatives such as ametantrone gave 10 fold lower values. The present study provided 
contrary results when the two classes of drug were compared as the 5,8-
dihydroanthraquinones produced the higher (K1) values (Table 3. 2) which is consistent 
with the data derived by the titration method of Kapuczinski et al., (1985). Because DNA 
affinity is an equilibrium measure of the extent of drug attraction for DNA it may be 
affected by the choice of buffer or ionic concentration (Chaires et al., 1982). This 
inconsistency has led others to suggest that the dissociation rate of a drug from DNA is a 
better indication of DNA affinity (Denny et al., 1990). 
When a comparison was made between the 1,4-disubstituted-5, 8-dihydro- and the 
5,8-dihydroxyanthraquinones and the frequency of drug base pair intercalation (n) the latter 
were found to intercalate into DNA on average every 6.6 base pairs, an increase of 
approximately two base pairs over the 5, 8-dihydroanthraquinones. Previous studies by 
Lown et al., (1985); Kapuczinski et al., (1985) confirm this trend but demonstrated that 
mitoxantrone intercalates into DNA at approximately every 2.9 base pairs consistent with 
the neighbour exclusion model. This model suggests that the binding of one drug molecule 
to one site influences the binding of subsequent molecules by preventing binding at nearby 
sites either through physical blockage or by steric alterations of the DNA helix. Although 
the novel dihydroxyanthraquinones would be expected to have a similar intercalative 
binding frequency to mitoxantrone, it has been suggested that high ionic strength can reduce 
the number of binding sites by lowering the affinity of the drug for DNA (Chaires et al., 
1982). 
From the DNA-drug affinity data it can be shown that the chromophore hydroxyl 
groups influence the equilibrium towards DNA-drug formation. This is particularly evident 
when comparing compounds with identical sidechains such as ZP242 and ZP65, and can 
been explained in a number of ways. The perpendiCUlar mode of intercalation which is 
favoured by 1,4 disubstituted anthraquinones (see section 1. 3. 2. 2) orientates the 
chromophore hydroxyl groups such that they are able to penetrate the helix through to the 
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minor groove. The effect of this is to cause the disengagement of the chromophore from 
DNA to be energetically unfavourable and so considerably slower (Denny et al., 1989). 
Prolonged chromophore retention times have also been attributed to the formation of 
intramolecular hydrogen bonds between the chromophore 5,8-hydroxyl groups and the 
quinone carbonyl groups. These bonding interactions increase the lipophilic character of 
the drug and its affinity for the hydrophobic interior of DNA (Patterson, 1993). 
Furthermore, the hydroxyl groups are suggested to introduce planarity to the chromophore, 
which is in contrast to ametantrone where the unsubstituted ring is slightly buckled. As a 
result the planarity of mitoxantrone has been suggested to enhance base pair interaction at 
the intercalation site (Mazerski et al., 1998). 
The consistency of data within each series of drugs i.e 5,8-dihydro or 5,8-
hydroxyanthraquinone, shows that sidechain interactions playa minor role (if any) during 
the intercalation process at high ionic strength. The mode of action of the 5,8- dihydro and 
5,8-dihydroxy-anthraquinones is therefore consistent with intercalative binding. 
3. 5. 3. EFFECT OF THE HYDROXYETHYLAMINOANTHRAQUINONES ON 
STABILISATION OF THE DNA HELIX TO THERMAL DENATURATION 
The DNA molecule is made up of two complementary strands consisting of a sugar 
phosphate backbone and purine/pyrimidine base pairs which are held together by hydrogen 
bonding. On heating, the DNA inter-strand hydrogen bonds break causing denaturation of 
the double helix which leads the formation of single-stranded DNA. Drug molecules that 
reversibly intercalate into DNA stabilize the helix such that more energy (a higher 
temperature) is required to cause denaturation. This effect can be measured by monitoring 
the change in absorbance with temperature at 260nm, the absorbance maximum for duplex 
DNA. 
As all the drugs were assayed in low ionic concentration, it is therefore assumed that 
electrostatic binding in addition to intercalation contributes to the results obtained. The 
hydroxyethylaminoanthraquinones displayed a number of characteristics; drugs related by 
sidechain such as ZP1, ZP242 and ZP265 gave approximately lOoC rise in temperature 
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with each substitution onto the chromophore (Fig. 3. 7). The increasing order of drug-DNA 
stability followed the trend, mono substituted anthraquinone < 5,8-dihydroanthraquinone < 
5,8-dihydroxyanthraquinone (both 1, 4-disubstituted). This is in agreement with the DNA 
dissociation knietics of substituted anthraquinones (Gandecha et al., 1985; Denny et 
al.,1990). Drugs with two hydroxyethyl groups per sidechain such as ZP274, ZP240 and 
ZP255 demonstrated considerably reduced ~ T m values. It is likely that the hydroxyethyl 
side chains of these compounds predispose them to increased hydrophilicity and 
preferential electrostatic binding to DNA. Since these interactions are external to the DNA 
duplex, low ~ T m values would be expected. 
1,4 disubstituted anthraquinones comprising of the (N-(2-hydroxethyl)-N-
methylamino )ethylenediamine sidechain gave the highest overall ~ T m values (Fig. 3. 8 and 
Table 3.3). ZP265 stabilised the helix by 19.7°C. In comparison, under similar conditions 
mitoxantrone stabilises DNA by 15.9 °c (Johnson et al., 1979). At physiological pH the 
secondary amine side chains of mitoxantrone become protonated and interact with the 
negatively charged DNA-phosphate groups. Additional hydrogen bonding may occur 
between the drug side chain hydroxyl groups and the base pairs in the vicinity of the 
intercalation site (Bailly et al., 1996; Mazerski et al., 1998). In view of this, it is likely that 
ZP242 and ZP265 display a similar mode of base pair side chain interaction to 
mitoxantrone. Furthermore, as the tertiary methyl amine side chains increase drug 
lipophilicity they may essentially enhance DNA binding by making the drug more attractive 
to the DNA helix. 
3. 5. 4. EFFECT OF THE CHLOROETHYLAMINOANTHRAQUINONES ON 
STABILISATION OF THE DNA HELIX TO THERMAL DENATURA lION 
At first sight, the data from chloroethylaminoanthraquinone-DNA interaction 
suggests that these compounds are weak, reversible DNA binding agents. This contrasts 
with the DNA alkylation studies of Chapter 4 which demonstrated that they inhibit DNA 
strand separation at nanomolar concentrations which is up to 100 fold less than in this 
assay. In view of this, it is likely that the formation of drug-DNA inter-strand crosslinks 
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takes place but too few crosslinks are created to stabilise the helix effectively. The 
consequence of drug crosslinking DNA is to prevent thermal denaturation (Hartley et al., 
1991), reducing the formation of single strand DNA rather than altering Tm and it can be 
directly linked to the number of crosslinks fonned. Any hydrolysed drug would be expected 
to bind DNA non-covalently and detennine the outcome of helix stability at the absorbance 
wavelength stated. Studies with nitrogen mustards such as melphalan have shown that the 
dihydroxyethylamine is the product of reaction under aqueous conditions (Bolton et al., 
1993). When fully hydrolysed the chloroethylaminoanthraquinones would be expected to 
fonn hydroxyethylaminoanthraquinones which have generally engendered good helix 
stability (Table 3. 3). These products of hydrolysis would probably be present in low 
concentration and so would have little effect on the helix stability. Additionally, mono- and 
perhaps intra-strand alkylations of the helix may take place (Osborne et al., 1995). This 
fonn of covalent binding is unable to inhibit DNA strand separation and further to this may 
orientate the drug in such as way as to prevent it from intercalating into DNA. 
Of the chloroethylaminoanthraquinones, ZP281 gave the highest fl. T m (10.1 °C). The 
unsymmetrical nature of this compound restricts bis-alkylation of DNA to one side chain as 
its second arm is identical to the side chains substituted onto AQ4 (Fig. 2.12), a drug that 
has demonstrated high affinity for DNA (fl.Tm 17.5°C) (Patterson, 1993). Because ZP281 
creates fewer inter-strand crosslinks (demonstrated in Chapter 4) it is likely to have a 
greater effect on DNA thennal melting temperature through the formation of a higher 
concentration of single-strand alkylations that are enhanced by the non-covalent interaction 
of its second side chain. 
In summary, the hydroxyethylaminoanthraquinones showed good affinity for DNA 
consistent with both intercalative binding and lome interactions. The 
chloroethylaminoanthraquinones with the exception of ZP281, demonstrated poor binding 
implying that intercalation may not be the primary mechanism by which these compounds 
interact with DNA. Results in Chapter 4 will suggest that rather than being poor DNA 
binders, the chloroethylaminoanthraquinones irreversibly alkylate DNA. 
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Chapter 4 DNA ALKYLATION STUDIES 
4. 1 INTRODUCTION 
Rational anticancer drug development faces a dilemma that most drugs have 
multiple sites of action and it is not known which of these contribute to therapy or to 
toxicity. It is therefore beneficial to attempt to select compounds with a restricted range of 
action but without reduced anti-tumour activity. Bifunctional nitrogen mustards are 
extremely cytotoxic through their ability to form covalent intra and/or inter-strand 
crosslinks with DNA. However, their high reactivity and lack of target specificity often 
leads to reaction with other cellular nucleophiles and to a reduced concentration of drug 
reaching its target site (see section 1.4). 
Nitrogen mustards linked to an acridine chromophore have previously demonstrated 
improved selectivity for DNA and an altered drug base pair specificity compared to non-
targeted mustards (Mattes et al., 1986). The novel chloroethylaminoanthraquinones are a 
series of drugs which have the capacity to both intercalate and alkylate DNA. To establish 
the extent of their covalent binding nature, the DNA base pair alkylation preference of these 
compounds and their ability to inter-strand crosslink DNA was determined. 
4. 2. CHEMICAI.JS AND REAGENTS 
Plasmid DNA pBR322 (O.25u1JlI), T4 polynucleotide kinase (SulJlI), BAM HI 
(10u/JlI) and Sal I (IOu/JlI) restriction enzymes were purchased from Northumbria 
Biologicals Ltd. y32p_ATP (500Ci/mmol), primer (lOpmlJlI), dNTP mix (2.5mM), MgCh 
(25mM), gelatin (0.2%), Bacterial Alkaline Phosphatase (BAP) (150u/JlI), Bacterial 
Alkaline Phosphatase reaction buffer (BAP buffer 5x), lOx buffer, React 3 buffer (lOx), 
DNA stop solution, Forward reaction buffer (5x), were obtained from Amersham Biotech 
Ltd, St. Albans, Herts. Taq DNA polymerase (x50) (0.1 u/JlI) was purchased from Promega, 
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London BIO-Spin chromatography column and BIORAD 583 gel drier were obtained from 
BIO-RAD Laboratories, Kent, UK. Ammonium persulphate (APS), N, N, N', N'-
tetramethylethylenediamine (TEMED), sequagel 6, complete mix, mineral oil and 
mechloroethamine (N-methyl-N,N-bis(2-chloroethyl)amine) were purchased from Sigma 
Chemicals, London, UK. The control mechlorethamine was made up to the appropriate 
concentration in 0.1 M hydrochloric acid and stored at -20°C prior to use. The agents ZP281, 
ZP282, ZP285 and ZP289 were synthesised as described in section 2. 4, made up to the 
appropriate stock solution concentration in DMSO and stored at -20°C prior to use. 
u = unit activity. 
Strand separation buffer, TEo A buffer, TEA buffer, TBE buffer and formamide dye were 
all prepared according to appendix 2. 
4.3. METHODS 
See appendix 1 for preparation of DNA 
4.3. 1 DETERMINATION OF DNA SEQUENCE SPECIFIC ALKYLATION USING 
THE POLYMERASE CHAIN REACTION (PCR) 
The following constituents were added to an eppendorf containing the labelled 
primer (for preparation see appendix 1) and mixed: 0.2% gelatin (55J.lI), 25mM MgClz 
(220J.ll), lOxbuffer (110J.l1), 2.SnM dNTP mix (110J.ll) and dH20 (SSJ.ll). The mixture (SOJ.l1) 
was placed into a PCR tube containing the drug-treated DNA (see appendix 1) (40J.ll) and 
the enzyme DNA Taq polymerase (xSO) (10J.ll) which was diluted into dH20 (1 in 50) prior 
to use. Each tube was covered with mineral oil and the PCR set to cycle 36 times at 94°C 
for 1 min, S8°C for 2 min, nOc for 1 min and an additional 1 min per cycle, a total of 3 h. 
The ten samples were then transfered into sterile eppendorfs and the DNA precipitated and 
dried as described in appendix 1. Each dried sample was re-suspended in formamide dye 
(4J.lI), heated to 95°C for 2 min and cooled in an ice-bath to denature the DNA. The samples 
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were loaded onto the gel (see appendix 2) and electrophoresis was performed in TBE buffer 
over 3 h at 3000V, 55°C using vertical glass electrophoresis plates. The resulting gel was 
then transfered onto Whatman 3MM filter paper, covered and dried under pressure on a 
BIO-RAD 583 gel drier for approximately two hours. Once dry, the gel was exposed onto a 
Kodak X-ray film at -70°C for 24 h before developing. 
4. 3. 2. DETERMINATION OF THE FORMATION OF DNA INTER STRAND 
CROSSLINKS 
To each sample was added: 32P-radiolabelled DNA (lOOng/lOJlI), drug: ZP281, 
ZP282, ZP285 or ZP289 (1 JlI) in DMSO to give final assay drug concentrations of 0.1 nM, 
InM, 10nM and 100nM, TEoA buffer (5Jll) and the total volume made up to 50JlI with 
dH20. Following incubation at 37°C for lh the reaction was terminated by the addition of 
DNA stop solution (lOJlI) to each sample. The DNA was precipitated by the addition of 
95% ethanol (l80J.lI) and centrifuged at 1300rpm for 15 min. This precipitation process was 
repeated and the resulting pellet dried by lyophilisation. Each dried sample including the 
control sample of drug untreated DNA were resuspended in strand separation buffer (lOJll), 
heated at 95°C for 2 min in order to denature the DNA, then immediately chilled in an ice-
water bath to prevent the DNA strands rejoining. A sample of undenatured DNA, the 
second control, was not heated, and instead was dissolved in formamide dye (lO/-1l). An 
0.8% agarose gel approximately 1 cm thick was prepared in TEA buffer (also used as the 
running buffer) and the samples subsequently loaded. Electrophoresis was performed 
overnight using a horizontal gel kit at 40 V. The resultant gel was dried for 2 h at 9SoC onto 
one layer of Whatman 3MM paper (covered in film wrap) in a BIO-RAD 583 gel drier 
connected to a vacuum. Autoradiography was performed using Kodak Medical X-ray film 
for 24 hat -70°C. 
100 
4. 4. RESULTS 
4. 4. 1 DNA SEQUENCE SPECIFIC ALKYLATION STUDIES 
A synthetic 20 base oligonucleotide primer complimentary to bases 621-640 of the 
273 base pair BamH USal I fragment ofpBR3222 (bases 375-650) was 5' end labelled and 
annealed to the DNA. Following extension with Taq DNA polymerase a full length 
fragment of 263 base pairs was produced. The alkylating concentration of each compound 
was determined by identifying the lowest level of modification per DNA fragment (usually 
one base pair) in order to enable qualitative comparisons to be made (Ponti et al., 1991). 
Four chloroethylaminoanthraquinones ZP281, ZP282, ZP285 and ZP289 were 
examined for their ability to block the progress of DNA Taq polymerase. Fig 4. 1 shows the 
result of drug alkylation at four assay concentrations 5nM, 10nM, 50nM and 100nM against 
full length DNA and a control, mechlorethamine (2.5~M). The unmodified DNA showed 
complete elongation with only a few sites of early termination. In contrast, the four 
alkylating anthraquinones showed inhibition of DNA elongation consistent with DNA 
alkylation at all concentrations tested. 
All sites of alkylation occured at guanine bases, consistent with previous studies of 
nitrogen mustards (Ponti, et al., 1991). When alkylation patterns were compared between 
the targeted and non-targeted mustard mechlorethamine, a difference in guanine selectivity 
was observed (Table 4. 1 and Fig. 4. 1). The chloroethylaminoanthraquinones demonstrated 
a preference for guanines adjacent to a 5' pyrimidine (5'PyG), particularly isolated 
5 'PyGPy sites, which are sites of weak alkylation by nitrogen mustards (Kohn et al., 1987). 
At the following sequences 5'-CGGGGGA-3' (bases 534-539); 5'PyGG (bases 506, 579 
and 582) the chlorethylaminoanthraquinones preferentially alkylated at the 5'guanine 
base(s) whilst mechlorethamine selected the 3'side. At triplet guanine sequences 5'CGGGC 
(bases 471-473 and 486-488), the middle guanine was the most intense for all compounds 
and is consistent with the central guanine of a run of three being the most electronegative 
base (Pullman et al., 1981). 
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Two distinguishing alkylation patterns separated the four compounds into two 
groups on the grounds of side chain length. These occured at (bases 511-513 and 579-580). 
In the first instance, at the sequence 5' GGGT, ZP282 and ZP289 (both containing 
propylene side chains) alkylated preferentially at the 3' guanine, whilst no reaction was 
observed for ZP281 and ZP285. At the second sequence, 5'GG, both guanines were 
alkylated by ZP282 and ZP289, whilst ZP281 and ZP285 (containing an ethylene side 
chain) selectively alkylated the 5'guanine. Both examples are sites of relatively weak 
alkylation. 
The concentration (5nM) of chloroethylaminoanthraquinone drug required to 
alkylate DNA was found to be 500 fold less than that for mechlorethamine (2.5J.lM) 
suggesting that the chloroethylaminoanthraquinones have high specificity for DNA. 
Furthermore the selection of 5'PyG sites implies that they have the potential to form a high 
degree of inter-strand crosslinks. 
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5 7 
Fig 4. 1 Gel electrophoresis ofthe sites of most frequent alkylation by the 
chloroethylanthraquinones. Lane 1, unmodified DNA; 
Lane 2, Mechlorethamine (2.5J..tM); Lane 3-6, ZP281; 
Lane 7-10, ZP282; Lane 11-14, ZP285; Lane 15-18, ZP289. 
Increasing concentration of drug (left-right): 0.005,0.01,0.05 and 
O.lJ..tM 
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Table 4. 1 Sites of most intense alkylation by the chloroethylaminoanthraquinones and 
mechlorethamine at pBR322 DNA fragment (base pairs 375-650). 
Alkylation Mechlor-
site (bp. no) etharnine ZP281 ZP282 ZP285 ZP289 
471-473 5'CGGGC 5'CGGGC 5'CGGGC 5'CGGGC 5'CGGGC 
511-513 5'GGGT nd 5'GGGT nd 5'GGGT 
529 nd 5'CGT 5'CGT 5'CGT 5'CGT 
535-539 5'GGGGG 5'GGGGG 5'GGGGG 5'GGGGG 5'GGGGG 
546-548 5'TGGGC nd 5'TGGGC 5'TGGGC 5'TGGGC 
550 5'CGC 5'CGC 5'CGC 5'CGC 5'CGC 
565 nd 5'TGC 5'TGC 5'TGC 5'TGC 
577 5'TGC 5'TGC 5'TGC 5'TGC 5'TGC 
579-580 5'CGGC 5'CGGC 5'CGGC 5'CGGC 5'CGGC 
582-583 5'CGGC 5'CGGC 5'CGGC 5'CGGC 5'CGGC 
The highlighted 'G' denotes the sites of most reactivity by each compound. 'nd' denotes 
alkylation not detected. Bp.no (base pair number) 
4. 4. 2 DNA INTER-STRAND CROSS LINKlNG STUDIES 
The agarose gel assay is a reproducible method for the in vitro measurement of 
DNA inter-strand crosslinks. The principle of the reaction is that double stranded/or drug 
crosslinked DNA runs at a slower rate through agarose gel compared to denatured DNA 
which effectively runs as two mobile single strands. The extent of crosslinking can be 
calculated by quantification of the double and single-stranded DNA produced in each 
sample lane (Hartley et al .. 1991). 
Linearised plasmid pBR322 DNA was reacted with increasing concentrations of 
drug O.lnM, lnM, 10nM, 100nM. By comparing drug treated DNA samples with the 
untreated controls which were single stranded (denatured) DNA, and double stranded DNA, 
the inhibition of DNA strand separation could be determined at each concentration for the 
chloroethylaminoanthraquinones ZP28l, ZP282, ZP285 and ZP289. A dose dependent 
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increase in formation of inter-strand cross-links was observed with 100% cross-linking for 
each compound at the highest concentration of 100nM. ZP282 and ZP285 proved to be the 
most effective inter-strand cross-linking agents preventing over 50% strand separation at 
the lowest concentration O.lnM. Whilst, ZP281 was the least effective creating mostly 
single stranded DNA at O.lnM. The order of increasing reactivity was found to be ZP281 < 
ZP289 < ZP285 = ZP282 (most reactive). The data from this assay indicates that at the 
concentrations of drug used all of the compounds assayed have the ability to form inter-
strand cross-links and may potentially be active as DNA cross-linking agents in vivo. 
1 2 3 4 5 6 7 8 9 10 1112 13 14 15 16 17 18 
Single Stranded DNA 
Double Stranded DNA 
Fig 4.2 Autoradiograph of the effects of chloroethylaminoanthraquinones on 
DNA strand separation inhibition. Lane 1, double stranded DNA, no 
drug; Lane 2, single stranded DNA; Lane 3-6, ZP281; Lane 7-10, 
ZP282; Lane 11-14, ZP285; Lane 15-18, ZP289. Increasing 
concentration of drug (left to right): O.l, 1.0, 10.0 and 100nM 
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4.5. DISCUSSION 
4. 5. 1 IDENTIFICATION OF CHLOROETHYLAMINOANTHRAQUINONE-DNA 
SEQUENCE SPECIFIC ALKYLATION SITES 
Nitrogen mustards such as mechlorethamine alkyl ate DNA through the formation of 
an aziridinium ion, a positively charged intermediate. By calculating the molecular 
electrostatic potential (MEP) of each base, Pulman et al., (1981) identified that the most 
electronegative site on DNA is the nitrogen at the seven position of guanine (G N7) in the 
major groove. Furthermore, within contiguous guanines the central guanine was found to be 
the most electronegative and therefore the likely target of these agents. By use of gel 
electrophoresis techniques subsequent studies with various nitrogen mustards such as 
mechlorethamine and L-phenylalanine mustard (L-P AM) were able to confirm this 
evidence (Kohn et al., 1987; Mattes et al., 1986; Ponti et al., 1991). 
ZP281 n = 2, R = OH, R\ = R2 = -CH2CH2CI, RJ = ~ = CH3 
ZP282 n = 3, R = OH, R\ = R2 = RJ = ~ = -CH2CH2CI 
ZP285 n = 2, R = OH, R\ = R3 = -CH2CH2CI, R2 = ~ = CH3 
ZP289 n = 3, R = H, R\ = R2 = R3 = ~ = -CH2CH2CI 
Fig. 4. 3. The structure of chloroethylaminoanthraquinones ZP281, ZP282, 
ZP285 and ZP289 
Reaction of the chloroethylaminoanthraquinones ZP281, ZP282, ZP285 and ZP289 
(Fig. 4. 3) with DNA showed that alkylation took place at most guanine bases but was most 
prominent at those adjacent to a 5'pyrimidine (cytosine or thymine). This was in contrast to 
mechlorethamine which generally preferred to alkylate the 3' guanine within a run of 
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guanines. This difference in base pair selectivity may be attributed to the influence of the 
DNA affinic anthraquinone chromophore. Altered sequence selectivity for DNA directed 
alkylating agents has been observed before. The reactivity of quinacrine mustard (Fig. 1.12) 
was found to depend on the two bases 3' to the reactive guanine and this is where 
intercalation was suggested to take place (Kohn et al., 1987). This proposal was later 
amended when Kohn et al., (1994) realised that such a model would impose major 
structural distortion of the DNA. Instead it was postulated that aliphatic mustards linked to 
a chromophore by a short spacer chain, typically 2-3 carbons, would most likely react with 
an immediately adjacent guanine on either side of the intercalation site depending on the 
flanking bases as these affect the reaction site conformation. By comparison the 
chloroethylaminoanthraquinones also contain short aliphatic spacer chains. Their preference 
for 5 'PyG sites implies that intercalation may occur directly in between these two bases, 
with alkylation taking place at the 3' guanine. 
To support the importance of the anthraquinone chromophore in DNA directed 
covalent binding, the DNA intercalation preference of mitoxantrone has been identified 
with 5'(NT)CG triplet base pairs (Bailly et al., 1996; Panousiss et al .. 1994). Two bases in 
this sequence correspond to the 5'PyG sites found for the mustard anthraquinones. Studies 
of acridine mustards have also suggested that the choice of chromophore may direct the site 
of alkylation. For example, 9-aminoacridine shows preference for intercalation at 5'PyPu 
base pair sites (Neidle et al., 1984) and this correlates with the prefered 5'GCPu sites of 
alkylation by acridine mustard (Prakash et al., 1990). Furthermore, the proposed 
mechanism of initial non-covalent binding followed by alkylation of nearby base pairs is 
consistent with that first postulated by Creech et al., (1972). 
Little variation existed between the alkylating patterns of the four novel drugs 
except at two sites. In both cases the same two compounds could be placed together in 
terms of sequence specificity, ZP282 and ZP289 containing three carbons and ZP281 and 
ZP285 containing two carbons. Previous studies have demonstrated the importance of the 
length of the side chain (see Table 4.2). For example, when aniline mustards linked to an 
acridine chromophore contained side chain linkers greater than three methylene groups in 
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length the alkylation specificity of these compounds changed from guanine to adenine (see 
Table 4. 2; Ferguson et al., 1992). A series of short chain aliphatic mustards linked to 
acridine were found to be more DNA base pair specific than the longer side chain ~alogues 
which alkylated additionally at 5'GT sites (Kohn et al., 1994). Short sidechains are thought 
to confer a degree of rigidity in the intercalation mode and can therefore restrict the number 
of accessible nucleophilic sites available for alkylation. 
Table 4. 2 Summary of the prefered DNA alkylation sites determined for chromophore 



















Kohn et al., 1986 
Ponti et al., 1991 
Kohn et al., 1994 
Prakash et al., 1990 
Ferguson et al., 1992 
(s) denotes compounds with short linker chains. (1) denotes compounds with long linker 
chains >3. 
Although the chromophore is thought to directly influence the site of covalent 
binding, it is likely that intercalation is not mandatory for alkylation to take place. Such 
reactions with DNA may perhaps be found at sites that are consistent with intense 
mechlorethamine binding. 
Some of the most intense reactivity by the mustard anthraquinones occured at lone 
guanines flanked either side by a pyrimidine base. Previous studies have demonstrated that 
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isolated 5'GC sequences are usually weakly reactive because the amino group of the 
adjacent cytosine exerts a positive electrostatic field in the vicinity of GN7 rendering it less 
electronegative (Kohn et al., 1987). To date only the non-intercalating drug uracil mustard 
has shown selectivity for this site (Mattes et al., 1986). In respect of this, it may be possible 
that the anthraquinone chromophore reduces the electrostatic influence of the adjacent 
cytosines and reinstates the electronegativity of the guanine making it more reactive. 
However, an alternative suggestion is that the high incidence of alkylation at these sites may 
result from intercalation taking place either side of the reactive guanine. 
ZP289, was the most weakly reactive compound and this can be related to the lack 
of hydroxyl groups on the 5 and 8 position of its chromophore. These groups slow the rate 
of chromophore disengagement from DNA (Denny et al., 1990) and consequently increase 
the probability of alkylation taking place at nearby base pairs. 
Based on the lowest effective chloroethylaminoanthraquinone drug concentration 
used, the reaction concentration of quinacrine mustard (Ponti et al., 1991) and 
mechlorethamine required to alkyl ate DNA was found to be 100 and 500 fold greater, 
respectively. In the first example, this may be a reflection of the weaker DNA affinity of the 
acridine chromophore compared to the anthraquinone chromophore (Feigon et al., 1984; 
Denny et al., 1989). Nevertheless, the important evidence to arise from this study is that the 
mustard anthraquinones have greatly enhanced selectivity for DNA over non-targeted 
mustards. Furthermore, reaction specificity at 5'PyG and isolated 5'PyGPy sites suggests 
that the chloroethylaminoanthraquinones are potentially selective for sites at which inter-
strand crosslinks maybe formed, that is 5'CG base pairs. 
4. 5. 2. EFFECT OF CHLOROETHYLAMINOANTHRAQUINONES ON THE 
INHIBITION OF DNA STRAND SEP ARA nON 
The anti-tumour activity of the nitrogen mustards is defined by their ability to form 
inter-strand and intra-strand crosslinks with DNA. Of these lesions, inter-strand crosslinks 
are considered to be the more relevant despite the fact that they make up only 4-7% of the 
total number of adducts formed by mechlorethamine (see section 1. 4)(Kohn et al., 1966). 
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Fig. 4. 4 A representation of ZP285 intercalated into and forming an 
inter-strand crosslink between a 5'CG base pair 
The mustard anthraquinones were able to inhibit DNA strand separation with 
varying degrees down to sub-nanomolar concentrations. This confirms the earlier 
observation (see section 4. 5. 1) that the anthraquinone chromophore plays an important 
role in directing the mustard function towards DNA and potential sites of inter-strand 
crosslink formation through 5'PyG base pair selectivity. Studies with aniline mustard 
attached to various acridine chromophores have also demonstrated greatly improved 
inhibition of strand separation over their respective untargeted parent mustard (Prakash et 
at., 1990). 
The order of increasing reactivity of the chloroethylaminoanthraquinones was found 
to be ZP281 < ZP289 < ZP285 = ZP282. This reflects the fact that ZP281 contains only 
one alkylating sidechain and so may preferentially react with one strand of DNA to form a 
greater number of intra-strand crosslinks. These do not prevent strand separation. In 
contrast, ZP282, ZP285 and ZP289 are capable of alkylating each DNA strand with separate 
side chains which predisposes them to a greater range of nucleophilic sites on DNA and 
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hence an increased chance of inter-strand crosslink formation. Despite this, ZP281 is an 
extremely effective inter-strand crosslinking agent suggesting that the bifunctional nature of 
its mustard side chain is sufficient in length to alkylate across two strands of DNA. 
Early studies of DNA sequence specific alkylation identified 5'GC sequences as 
sites of inter-strand crosslink formation (Mattes et at., 1986). More recently, it has been 
shown that 5'GNC (N=any base) complementary strands are the actual sites of crosslink 
formation for nitrogen mustards such as mechlorethamine and L-PAM (Osborne et at. 
1993, Rink et at., 1993). To achieve this crosslink the DNA duplex has to bend and distort. 
It can be argued that if intercalation takes place previous to DNA alkylation the DNA bases 
will become separated a further 3.4 angstroms (Lerman, 1961) to accommodate the 
anthraquinone chromophore, and this increase in distance may prevent alkylation accross 
three base pairs. Further to this, it has been noted that compounds with a short linker chain 
are restricted to reaction at nearby nucleophilic sites (Kohn et at., 1994) indicating that 
5'GC or 5'CG inter-strand crosslinks are more likely to result. However, since the 
alkylating groups of bis-mustard 1,4-disubstituted anthraquinones are far more widely 
spaced than either mechlorethamine or quinacrine, this new class of compound is not 
necessarily restricted to this paradigm. 
In summary, the sequence specific DNA studies have demonstrated that the 
chloroethylaminoanthraquinones alkylate DNA at guanine bases. They show selectivity for 
5'PyG and isolated 5'PyGPy sites and have considerably improved DNA targeting over 
mechlorethamine. This is thought to be directly related to the presence of a DNA affinic 
anthraquinone chromophore within their structure. Furthermore, the sequence preference of 
these agents inferred that they would be good candidates for inter-strand crosslink 
formation and this was confirmed by the low concentration of drug that was required to 
inhibit DNA strand separation. The two studies have identified that the 
chloroethylaminoanthraquinones are excellent DNA inter-strand crosslinking agents whose 
mechanism of action may take place by inital DNA intercalation followed by the alkylation 
of adjacent base pairs. 
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Chapter 5 TOPOISOMERASE II INHIBITION STUDIES 
5. 1 INTRODUCTION 
Topoisomerase II (topo In is essential for cell proliferation and cell viability, hence 
it is an attractive target for anti-cancer agent development. Unlike mammalian cells, yeast 
cells possess a single topo II enzyme which presumably performs the functions of both 
human isoforms (Nitiss et al., 1988). Recent studies have shown that the yeast topo II can 
successfully be replaced with either of the human topo II isoenzymes, a or p, which can 
then be expressed from full length cDNA in a drug permeable yeast strain such as 
Saccharomyces cereviciae (Sc.ce) (Hammonds et al., 1998). In view of this, each 
isoenzyme may be studied individually without the effects of the second isoform interfering 
with data. Moreover, the topo II selectivity and isoenzyme specificity of a drug can be 
assessed more accurately. 
As topo II is the cellular target for a number of intercalating agents including the 
drug mitoxantrone (section 1. 3. 2), compounds of an analogous structure would also be 
expected to target this enzyme. Three novel hydroxyethylaminoanthraquinones (ZP257, 
ZP265 and ZP275) and four chloroethylaminoanthraquinones (ZP28l, ZP282, ZP285 and 
ZP289) were assayed to determine their topo II inhibitory activity and isoform selectivity in 
relation to drug covalent and non-covalent binding. 
5.2. CHEMICALS AND REAGENTS 
Yeast Nitrogen Base (YNB) purchased from Gibco, UK. -Leucine (-LEU) drop out 
media was purchased from Bio 101, UK. Mineral Oil (nuclease free), biological grade 
DMSO and glucose were purchased from Sigma, Poole, UK. Agar was purchased from 
Biogene Ltd, UK. All materials, yeast strains and plasmids were kindly supplied by Dr J. 
Jenkins, MRC Toxicology Unit, Leicester, UK. All compounds were serially diluted into 
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DMSO and stored at -20°C prior to use. Following the addition of drug to media the final 
drug concentrations were 0.1 J.lM, 1J.lM, 5J.lM ,10J.lM, 50J.lM and 100J.lM. 
5.3. CHARACTERISATION OF TOPO II a AND B YEAST STRAIN 
The yeast used in this assay was the JJ700 strain expressing a promoter from the 
following plasmids: pYT0300 (wild-type Saccharomyces cerevisiae (Sc. ce) topo II gene); 
pHT300 (human topo IIcr gene [cDNA]); pHT400 (human topo lIP gene [cDNA]). Yeast 
cells were constructed and grown in synthetic media by Dr J. Jenkins, MRC Toxicology 
Unit, Leicester, UK. 
5.4. DETERMINATION OF THE EFFECT OF ANTHRA-QUINONES 
ON YEAST STRAINS CONTAINING HUMAN a, Band 
SC.CEREVISAE TOPOISOMERASE II 
The three yeast strains (deletion strains (.1top02)) containing either plasmid 
pHT300, pHT400 or pYT0300 were grown at 30°C on agar plates containing medium 
lacking leucine and 2% glucose. A small sample was taken from the growing colonies of 
each strain and diluted into the synthetic media (see appendix 2) to produce seeding 
cultures containing approximately lOs to 106 cells/ml which gave an OD630 reading (optical 
density at 630nm) of 0.05. To 96 microtitre plate wells was added the media (174J.ll), the 
drug (lJ.lI) in DMSO at six different concentrations, or DMSO (lJ.lI) (control), and finally 
the yeast seeding culture (25J.lI). Each well was overlayed with 2 drops (approximately 
50J.lI) of mineral oil and initial OD630 readings were taken before leaving the cultures to 
grow at 30°C. Following a twenty hour incubation period the well contents were carefully 
mixed with a multi-channel pipette, and the OD630 recalculated for each well. All 
experiments to determine the 50% inhibitory concentration (ICso) for each compound were 
performed in triplicate. 
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5.5 RESULTS 
5. 5. 1. EFFECT OF NOVEL ANTHRAQUINONES ON YEAST STRAIN GROWTH 
The growth inhibition of topo II isoform containing yeast cells was determined by 
the assay of (Hammonds et al., 1998). Values were obtained by calculating cell survival as 
a percentage of the control OD630 and plotted against six increasing drug concentrations for 
each topoisomerase II (a, p and Sc.ce) containing yeast strain. Furthermore, as the 
anthraquinone chromophore absorbs in the visible region at 630nm it was also necessary to 
subtract the OD630 of drug in media from the appropriate drug containing yeast cells to give 
the actual cell survival. 
Three chloroethylaminoanthraquinones ZP281, ZP285 and ZP289 inhibited the 
growth of yeast containing either: human topo II a, human topo II p or wild type Sc.ce topo 
II. The increasing order of activity was (least active) ZP289 < ZP281 < ZP285 (Table 5.1). 
ZP285, demonstrated the highest inhibitory activity at approximately (lC50 4JlM) for all 
three yeast strains, and similar to ZP281 in that both showed no isoenzyme specificity (Fig. 
5. 1 and Fig. 5. 2). In comparison, ZP289 showed a slight preference for the a isoenzyme. 
ZP282 was anomalous to the trend of topo II inhibition established by the 
chloroethylaminoanthraquinones, and was found to be inactive in all three yeast strains at 
the highest concentration. The reason for this is unknown. 
The hydroxyethylaminoanthraquinones ZP257, ZP265 and ZP275 had no effect on 
cell viability at low concentrations and precipitated from the media at 100JlM which 
prevented a conclusive assessment of their topo II activity from being made. 
All drugs were assayed in triplicate and the standard error at each concentration 
point was determined for the three active compounds (Fig. 5. 1-5. 3). By applying the 
Student's T-test (Carter et al., 1981) at the 5% single tail significance level it was 
established that the data did not conclusively state that ZP281, ZP285 or ZP289 target 
human topo II a or p selectively. The standard error for the three compounds was 1.25, 1.32 
and 0.94 respectively which is below the 5% confidence level of 2.16 at four degrees of 
freedom. 
114 













0.1 5 10 50 
Drug Concentration (uM) 
100 
-+-Topo IIa 
__ Topo lib 
-llt-Sc. Ce 
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Fig 5. 3 Effect of ZP289 on the survival of yeast cells transfected with human 
topo II ex , P or yeast topo II. All samples measured at OD63o 
and given as mean triplicate values with standard deviation at 
each concentration point. 
Table 5.1 The effect ofthe chlorethylaminoanthraquinones on the inhibition 
of yeast cell growth 
Topo ITa. Topo ITP Topo IT 
DRUG ICso(~M) ICso(~M) ICso (~M) 
ZP281 24.7 ± 2.S 2l.9 ± 1.9 2S.1 ± 2.1 
ZP282 nli nli nli 
ZP285 4.4 ± 0.1 4.3 ± 0.02 3.8 ± O.OS 
ZP289 36.4 ± 9.9 4S.9 ± 14.7 47.6 ± 8.1 
Topo IT a. and P represent plasmid DNA containing either human isofonn ex or P; topo IT 
represents plasmid DNA containing yeast topo IT from Saccharomyces Cereviciae. 
IC50(~M) = concentration of drug required to inhibit SO% of cell growth (± standard 
deviation, n = 3); n/i=no inhibition 
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5. 6. DISCUSSION 
Topo II is a DNA associated enzyme which introduces a double-strand break into a 
DNA segment allowing the passage of another duplex through the break before resealing 
the cleavage. Many Topo II inhibitors are thought to induce cytotoxicity by stabilizing the 
DNA-topo II cleavable complex and preventing strand religation, they are known as 'topo 
II poisons' (Fig. 1. 2B). 
Investigation into the effects of seven novel anthraquinones on the inhibition of 
yeast transfected with either human topo ITa, human topo Up or yeast topo II (Sc. ce) 
demonstrated that three chloroethylaminoanthraquinones ZP281, ZP285 and ZP289 (Fig. 4. 
3) may potentially inhibit this enzyme. Their increasing order of reactivity was (least 
potent) ZP289 < ZP281 < ZP285. Suprisingly, ZP282 was not cytotoxic towards any of the 
yeast strains. This is contrary to studies in Chapter 4 which suggested that the 
chloroethy1aminoanthraquinones including ZP282 selectively crosslinked DNA through a 
chromophore directed mechanism of alkylation. Furthermore, in mammalian cells ZP282 
was found to be extremely potent demonstrating growth inhibition and a cross-resistance 
profile similar to the most cytotoxic chloroethylaminoanthraquinones (see Chapter 6). 
Evidence therefore suggested that ZP282 would also inhibit yeast cell growth. The reason 
for this lack of cytotoxicity in yeast, even at high drug concentration, is unknown. 
Computer modelling has indicated that compounds that share the same relative 
space occupancy and electronic distribution, even if chemically unrelated, have the same 
topo II-DNA sequence specificity (Paoletti et al., 1993). Furthermore, it is recognised that 
nucIeotides immediately adjacent to the site of Topo IIIDNA cleavage are specific to this 
class of inhibitor. For example, in the presence of mitoxantrone, topo II cleaves DNA with 
a pyrimidine base 5' (Paoletti et al., 1993; Capranico et al., 1993) and this site shows 
consistency with the preferred DNA alkylation sequence identified for the 
chloroethylaminoanthraquinones, 5'PyG (see Chapter 4). By analogy, the cellular 
mechanism of topo IT inhibition by these agents is likely occur in a similar if not identical 
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manner to mitoxantrone, the difference being that the chloroethylaminoanthraquinones 
would bind covalently to their target. 
Topoll 
Fig. 5. 4 Shows the drug crosslinked with topo II and DNA to fonn a 
ternary complex 
Most topo II inhibitors associate with the cleavable-complex by non-covalent 
binding and so the drug is often readily displaced from the active site, particularly if cellular 
resistance mechanism are present (see section 1. 5). Conversely, drugs that have the 
capacity to intercalate into DNA (Fig. 5. 4) and fonn covalent DNA-protein crosslinks 
should remain permenantly trapped at the cleavge site. This would lead to an irreversible 
inhibition of strand religation and to increased DNA double strand break production which 
is vital to the onset of cell death. An investigation into the mechanism of topo II inhibition 
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has identified a model in which the drug forms a ternary complex with the DNA /enzyme 
and is placed at the interface between the DNA cleavage and enzyme active sites 
(Capranico et al., 1990). To substantiate this, a photoactivatable mAMSA analogue has 
demontrated covalent binding to DNA bases at the + 1 and -1 positions of the cleavage site 
(Freundreich et al., 1994). Moreover, camptothecin is proposed to interact at specific amino 
acid residues on topo I and with its GC specific base pair sequence at the topo V DNA 
active site (Reindbo et al., 1998). Collectively these studies support the idea that covalent 
inhibitors such as the chloroethylaminoanthraquinones which may target the topo IVDNA 
active site have the potential to alkylate specific nucleophilic sites on the enzyme and/or 
DNA following initial non-covalent association with DNA. 
Various groups have found that enzyme inhibition for a number of topo II targeted 
agents can be dependent on a particular isoform and can also influence the outcome of drug 
resistance (see section 1. 5. 1. 2). In the yeast assay of Hammonds et al., (1998) 
mitoxantrone inhibited topo ITa at half the concentration required to inhibit topo IIp. A 
similar conclusion was derived by Meczes et al., (1997) using temperature sensitive yeast 
strains. Of the drugs that showed inhibitory activity in this study only ZP289 demonstrated 
a slight preference for a particular enzyme isoform and this was topo IIa. By close 
inspection of the data the large standard deviation at the drug (ICso ) make this observation 
inconclusive (Table 5. 1). In contrast, ZP285 and ZP281 did not distinguish between either 
isoenzyme which was evident by the similarity in their cell growth inhibition curves (Fig. 
5.1 and Fig. 5.2). As a consequence it is not possible to state conclusively that they inhibit 
topo II and may indeed have a different cellular target. However, previous reports of 
indiscriminate isoform selection have been observed for doxorubicin (Hammonds et al., 
1998) and m-AMSA (Meczes et al., 1997) and can perhaps be reasoned by the high 
sequence homology of topo II a and p, even within the active site (Austin et al., 1993). It is 
possible that such an effect would be more pronounced with the mustard anthraquinones 
because of the potential for drug covalent binding of nucleophilic sites within the active 
region ofthe enzyme. 
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The hydroxyethylaminoanthraquinones ZP257, ZP265 and ZP275 (Fig 5. 5) 
precipitated at high concentration (lOOIlM) and at low concentrations had no effect on cell 
growth inhibition. DNA binding studies (see Chapter 3) demonstrate that these compounds 
have strong affinity for DNA in a manner which is consistent with intercalative binding. 







n = 2, RJ = -CH2CH20H; R2 = R3 = ~ = CH3 
n = 2, RJ = R3 = -CH2CH20H, R2 = ~ = CH3 
n = 2, RJ = R2 = -CH2CH20H, R3 = ~ = CH3 
Fig 5. 5 Structure ofZP257, ZP265 and ZP275 
carcinoma cell line expressing MDRI which confers resistance to natural products such as 
the anthraquinones (see Chapter 6). Furthermore, mitoxantrone an analogous drug (see Fig. 
1. 5) has demostrated both potency and enzyme isoform selectivity in an identical assay 
(Hammonds et al., 1998). Hence, it was expected that the 
hydroxyethylaminoanthraquinones would also target topo II. One explanation for poor drug 
activity in yeast is low cell permeability through the yeast cell wall. Mutations are required 
to be placed in specific yeast genes so that sufficient drug is absorbed and this is reflected 
by the higher concentration of drug required to kill yeast cells compared to mammalian 
cells (Nitiss, 1994). It has been suggested that to enhance drug uptake of these agents it may 
be necessary to use a different permeability mutation to the ISE2 (Inhibitor Sensitive 2) 
gene which is present in this yeast (personal comm. Dr J. R Jenkins). Alternatively, the 
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high cytotoxicity of the chloroethylaminoanthraquinones may result from a lack of DNA 
repair enzymes. Mutations in genes that abolish DNA repair such as RAD52 are necessary 
to promote yeast cell kill following the creation of double strand breaks resulting from topo 
II inhibition (Nitiss, 1994). These mutations may also serve to enhance the cytotoxicity of 
the nitogen mustards as such drugs have previously demonstrated increased sensitivity 
when cellular DNA repair mechanisms are absent (section I. 5. 1.4) 
In summary, this study demonstrated that three compounds ZP281, ZP285 and 
ZP289 inhibited yeast cell growth at low concentrations, possibly as a consequence of topo 
II enzyme inhibition. When specificity was investigated, ZP281 and ZP285 did not exhibit a 
preference for either isoform which may be explained by the high sequence homology 
between the active sites of the isoenzymes. In contrast, yeast containing ZP282 and the non-
mustard analogues resulted in no measurable loss of yeast viability. This may be due to 
poor drug penetration into the yeast or to efficient lesion repair. In conclusion, the data 
suggests that the DNA targeted nitrogen mustard anthraquinones have greatly enhanced 
cytotoxicity towards yeast when compared to their hydroxyethylaminoanthraquinone 
counterparts. 
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Chapter 6 CYTOTOXICITY STUDIES 
6. 1 INTRODUCTION 
The success of the quinone anti-cancer agents over the past 30 years has led to the 
synthesis of structurally related compounds in an attempt to enhance antitumour activity 
and potentially avoid the mechanisms of resitance that are associated with the prolonged 
use of these drugs in the clinic (section 1. 5.). A series of chloroethylamino- and 
hydroxyethylaminoanthraquinones have been synthesised on the principle that the 
alkylating anthraquinones may induce irreversible DNA damage by covalent stabilisation of 
the topo II-DNA cleavable complex. As the hydroxyethylaminoanthraquinones would 
principally act by non-covalent means, a difference in cytotoxicity and cellular resistance 
could be predicted. 
This study was performed in two wild type ovarian cancer cell lines A2780 and 
CHI and their cisplatin or adriamycin resistant mutants A2780CisR, CHIcisR, SKOV-3 
and 2780AD. Resistance was also determined in chromosome transfer modified cisplatin 
resistant cell line B 1. 
6. 2 METHODS 
6.2. 1. DETERMINATON OF CYTOTOXICITY OF ANTHRAQUINONES IN WILD 
TYPE AND CISPLATIN RESISTANT HUMAN OVARIAN CANCER CELL LINES 
The cytotoxicity (ICso) values of substituted anthraquinones in five human ovarian 
carcinoma cell lines: A2780, A2780cisR, CHI, CHIcisR and SKOV-3 were determined by 
Dr Lloyd R Kelland, CRC Centre for Cancer Therapeutics, Sutton. The compounds were 
dissolved into DMSO at a concentration of 20mM immediately before adding to the cell 
lines to give final drug concentrations of 25,5, 1,0.25 and 0.05J.lM. Cell growth inhibition 
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was determined after 24h drug exposure followed by a 3 day growth period and assessed by 
staining with sulphorhodamine B (SRB) and measuring the remaining cell numbers. Seven 
compounds ZP257, ZP265, ZP275, ZP281, ZP282, ZP285 and ZP289 were selected for re-
evaluation at lower concentrations at 4h drug exposure and 24 h drug exposure. 
6. 2. 2. COMP ARA TIVE STUDY OF CYTOTOXICITY IN WILD TYPE, CISPLATIN 
RESISTANT AND ANTHACYCLINE RESISTANT HUMAN OVARIAN CANCER 
CELL LINES 
Cytotoxicity (ICso) was further investigated with ovarian carcinoma cell lines A2780 
and 2780CP (also known as A2780CisR or CP70) both assayed in section 6. 2. 1, in 
addition to 2780AD and B 1 by the CRC Department of Medical Oncology, Beatson 
Laboratories, University of Glasgow. Drug sensitivity was determined by the MTT assay 
with a 24 hour drug exposure period and 3 day growth period. 
6.3 RESULTS 
6. 3. 1. EFFECT OF SUBSTITUTED ANTHRAQUINONES ON A2780, A2780cisR, 
CHI, CHIcisR and SKOV-3 CELL LINE VIABILITY 
The cytotoxicity of a series of hydroxyethyl- and chloroethylaminoanthraquinones 
was investigated in wild type ovarian carcinoma cell lines A2780 and CHI, their cisplatin 
resistant cell lines A2780cisR and CHIcisR and also in SKOV-3, an ovarian cell line that 
shows intrinsic resistance to cisplatin (Table 6. 1 and Table 6. 2). A range of in vitro drug 
potency was observed across all cell lines assayed in some cases at nM concentrations. 
Identification of a relationship between compound structure and cytotoxicity revealed that 
in most cases the I,4-disubstituted-5,8-dihydroxyanthraquinones were the most potent. The 
order of increasing cytotoxicity was found to be mono substituted anthraquinones < 5,8-
dihydroanthraquinones < 5,8-dihydroxyanthraquinones. This trend was observed within the 
hydroxyethyl and the chloroethylaminoanthraquinones classes of drug. 
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Alkylating anthraquinones generally exhibited greater potency over their 
hydroxyethyl equivalent compounds. The relative difference in cytotoxicity was dependent 
on the drug and the cell line used. For example in A2780, ZP289 was approximately 110 
fold more cytotoxic than ZP240. Monofunctional alkylating agents were also found to be 
less potent that their difunctional equivalents and this is exemplified by ZP288 which was 
approximately 5 fold less cytotoxic than ZP284. 
Resistance factors (RF = ICso resistant cell line/lCso parent cell line) were found to 
be below 3 for all compounds assayed demonstrating low cross-resistance against cisplatin. 
ZP281 was the least cross resistant agent (RF approx. 1) in all cell lines. 
After 24hr drug exposure seven compounds ZP257, ZP265, ZP275, ZP281, ZP282, 
ZP285, ZP289 inhibited cell growth below the concentration of O.05J.lM. This assay was 
subsequently repeated in the same cell lines at lower drug concentrations and an additional 
comparative assay was performed to determine the effects of cell growth after short term 
(4h) drug exposure. In tables (6. 3 and 6. 4.) the data from these assays is compared with 
historical values derived for mitoxantrone, cisplatin, chlorambucil and doxorubicin under 
the same conditions. By prolonging drug exposure in non resistant cell lines (4h to 24h) a 
2-5 fold increase in potency was observed. In the resistant cell line A2780cisR the 
cytotoxicity of ZP257 and ZP265 was increased by 200 fold after 24hrs. In contrast pnly a 
6-8 fold increase in cytotoxicity was observed for the alkylating anthraquinones in the same 
cell line. This effect was specific to A2780cisR as in CHlcisR all compounds produced a 
similar increase in cytotoxicity. Only ZP245 was inactive at the highest drug concentration 
(25J.lM). 
By comparison of historical data it can be shown that seven anthraquinone 
compounds were more potent cytotoxins than the anti tumour drugs mitoxantrone, cisplatin 
and chlorambucil in all the cell lines assayed. 
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Table 6. 1 The effect of 24h drug exposure on the growth of ovarian cancer cell line 
A2780 
A2780ICso A2780cisR ICso 
Compound (~M) (~M) RF 
ZP1 3.4 4.2 1.2 
ZP150 3.1 3.3 1.1 
ZP232 3.3 3.5 1.1 
ZP240 3.5 3.4 1.0 
ZP242 0.72 0.58 0.8 
ZP245 >25 >25 
ZP249 3.3 3.2 1.0 
ZP254 6.6 19.0 2.4 
ZP255 0.68 0.74 1.1 
ZP257 <0.05 <0.05 
ZP265 <0.05 <0.05 
ZP274 0.082 0.115 1.4 
ZP275 <0.05 <0.05 
ZP280(M) 0.12 0.17 1.4 
ZP281(M) <0.05 <0.05 
ZP282(M) <0.05 <0.05 
ZP284(M) 0.41 0.64 1.6 
ZP285(M) <0.05 <0.05 
ZP286(M) 0.135 0.355 2.6 
ZP288(M) 2.7 2.7 1.0 
ZP289(M) <0.05 <0.05 
ZP290(M) 0.051 0.096 1.9 
ZP293(M) 4.6 8.0 1.7 
A2780 is the wild type ovarian cell line; and A2780cisR is its cisplatin resistant cell line. 
RF=Resistance factor; ICso concentration of drug(~M) required to inhibit 50% of cell 
growth. M =chloroethylaminoanthraquinone 
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Table 6. 2 The effect of 24h drug exposure on the growth of ovarian cancer cell lines 
CHI and SKOV-3. 
CHI ICso CHlcisR ICso SKOV-3ICso 
Compound (J.lM) (J.lM) RF (J.lM) 
ZPl 2.9 2.8 1.0 13 
ZP150 2.6 2.6 1.0 11.5 
ZP232 3.9 3.3 0.8 18 
ZP240 2.2 2.4 1.1 6.7 
ZP242 0.68 0.8 1.2 3.3 
ZP245 >25 >25 >25 
ZP249 2.4 2.3 1.0 9.2 
ZP254 13 11.0 0.9 21.5 
ZP255 0.58 0.78 1.3 2.45 
ZP257 <0.05 <0.05 0.3 
ZP265 <0.05 <0.05 11 
ZP274 0.3 0.37 1.2 1.5 
ZP275 <0.05 <0.05 0.26 
ZP280(M) 0.054 0.11 2.0 1. 45 
ZP281(M) <0.05 <0.05 0.155 
ZP282(M) <0.05 <0.05 0.185 
ZP284(M) 0.185 0.55 2.9 1.9 
ZP285(M) <0.05 <0.05 0.1 
ZP286(M) 0.11 0.145 1.3 0.77 
ZP288(M) 1.44 1.3 10.8 
ZP289(M) <0.05 <0.05 0.19 
ZP290(M) 0.078 0.092 1.2 0.86 
ZP293(M) 2.5 3.1 1.2 13.5 
CHI is the wild type ovarian cell line; and CHlcisR is its cisplatin resistant cell line. 
SKOV -3 is intrinsically resistant ovarian cell line. RF=Resistance factor; ICso concentration 
of drug (J.lM) required to inhibit 50% of cell growth. M=chloroethylaminoanthraquinone 
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Table 6. 3 The cell growth inhibition concentration of the seven most potent 
anthraquinone compounds following 24h exposure to wild type A2780 and cisplatin 
resistant ovarian carcinoma cell line A2780CisR. 
A2780(ICso) A2780cisR(lCso) 
Compound (IlM) (IlM) RF 
ZP257 0.005 0.0058 1.0 
ZP265 0.0041 0.0039 1.0 
ZP275 0.0125 0.013 1.0 
ZP281(M) 0.016 0.019 1.2 
ZP282(M) 0.0275 0.0375 1.4 
ZP285(M) 0.009 0.024 2.7 
ZP289(M) 0.031 0.052 1.7 
Mitoxantrone 0.92 0.93 1.0 
Cisplatin 0.3 3.3 11 
Chlorambucil 9.0 52.5 5.8 
Doxorubicin 0.01 0.014 1.4 
ICso represents the concentration of drug required to inhibit cell growth by 50 %. RF = 
Resistance factor (ratio of inhibition in the resistant celliinel inhibition in parent cell line). 
(M)=chloroethylaminoanthraquinone 
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Table 6. 4 The cell growth inhibition concentration of the seven most potent 
anthraquinone compounds following 24h exposure to wild type CH 1 and cisplatin resistant 
CH 1 CisR and SKOV -3 ovarian carcinoma cell lines. 
CHI ICso CH 1 cisR ICso SKOV-3 
Compound (JlM) (JlM) RF (JlM) 
ZP257 0.0235 0.045 1.9 0.6 
ZP265 0.0082 0.0215 2.6 0.24 
ZP275 0.0295 0.046 1.6 0.85 
ZP281(M) 0.018 0.019 1.0 0.49 
ZP282(M) 0.025 0.035 1.4 0.76 
ZP285(M) 0.0069 0.0135 1.9 0.29 
ZP289(M) 0.03 0.11 3.7 0.82 
Mitoxantrone 0.54 >1.0 >1.0 
Cisplatin 0.1 0.65 6.5 4.4 
Chlorambucil 3.3 7.9 2.4 35 
Doxorubicin 0.0035 0.004 1.1 0.05 
ICso represents the concentration of drug (JlM) required to achieve 50% inhibition of cell 
growth. RF=resistance factor; ICso resistant cell linelICso parent cell line. 
M=chloroethylaminoanthraquinone 
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Table 6. 5 The effect of short term (4 hour) drug exposure on the growth of human 
ovarian carcinoma cell line A2780 and resistant cell line A2780cisR 
A2780 ICso A2780cisR ICso 
Compound (~M) (~M) 
ZP257 0.089 1.45 
ZP265 <0.05 0.78 
ZP275 0.06 0.15 
ZP281(M) <0.05 0.28 
ZP282(M) 0.195 0.22 
ZP285(M) 0.052 0.17 
ZP289(M) 0.165 0.4 
Mitoxantrone 12.5 12.5 








Table 6. 6 The effect of short term (4 hour) drug exposure on the growth of human 
ovarian carcinoma cell line CHI, cisElatin resistant cell lines CHlcisR and SKOV-3. 
CHI ICso CH1cisR ICso SKOV-3ICso 
Compound (~M) (~M) RF (~M) 
ZP257 0.063 0.35 5.5 2.6 
ZP265 <0.05 0.17 0.9 
ZP275 0.074 0.58 7.8 2.1 
ZP281(M) 0.058 0.41 7.1 0.66 
ZP282(M) 0.175 0.85 4.8 2.8 
ZP285(M) <0.05 0.16 0.64 
ZP289(M) 0.165 0.82 4.9 2.2 
Mitoxantrone 5.1 12.0 2.3 >25 
ICso is the concentration of drug required to inhibit cell growth by 50%. RF=resistance 
factor; ICso resistant celllinel ICso parent cell line. M=chloroethylaminoanthraquinone 
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6. 3. 2. THE EFFECT OF SUBSTITUTED ANTHRAQUINONES ON A2780, 2780AD, 
A2780CisR(CP70) AND B 1 CELL LINE VIABILITY 
The cytotoxicity of seven compounds ZP257, ZP265, ZP275, ZP28l, ZP282, ZP285 
and ZP289 were investigated in the following human ovarian carcinoma cell lines supplied 
by a different laboratory: Wild type A2780 and cisplatin resistant cell line 2780CP (also 
known as A2780CisRior CP70), both previously assayed in section 6. 2. 1. 1. Doxorubicin 
resistant cell line 2780AD and chromosome transfer modified cell line B 1 (Table 6. 7 and 
Table 6. 8). Included are the cytotoxicities of cisplatin and doxorubicin assayed in the same 
cell lines. 
The data highlighted mechanisms of resistance that distinguished the alkylating 
anthraquinones ZP281, ZP282, ZP285 and ZP289 from the three hydroxyethyl 
anthraquinones. All compounds, with the exception of ZP289, were found to be more 
potent than doxorubicin in the parent cell line A2780. ZP265 and ZP285 a 
hydroxyethylaminoanthraquinone and chloroethylaminoanthraquinone respectively, gave 
ICso values of less than 1 nM. All compounds showed varying degrees of cross-resistance in 
the anthracycline resistant cell line 2780AD. ZP285 was the most cross resistant (RF 616) 
whilst ZP281 exhibited only a 4-fold resistance. 
As expected, mechanisms that are responsible for cisplatin resistance such as those 
present In A2780CisR had little effect on the cytotoxicity of the 
hydroxyethylaminoanthraquinones. RF values for these compounds were similar to 
doxorubicin (RF 2.6) and in agreement with cell growth inhibition studies in the same cell 
lines demonstrated in section 6. 3. 1. In contrast, three chloroethylaminoanthraquinones 
ZP282, ZP285 and ZP289 all showed approximately 16-fold cross-resistance with cisplatin, 
whilst ZP281 again demonstrated weak cross- resistance (RF 2.9). 
In Bl, the re-introduction of the mismatch repair hMLHI gene (reviewed in section 
1. 5. 1. 4) resulted in only a 40-70% restoration of the original cytotoxicity of the 
chloroethylaminoanthraquinones suggesting that mismatch repair is potentially a 
mechanism which contributes to the cell sensitivity of these agents. 
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Table 6.7 Effect of 24hr drug exposure on the growth of human ovarian carcinoma cell 
line A2780 and doxorubicin resistant cell line 2780AD. 
A2780ICso 2780AD ICso 
Compound (nM) (nM) RF 
ZP257* 1.69 ± 0.14 40.4 ± 6.6 23.9 
1.57 ± 0.39 17.1±1.0 10.9 
ZP265 0.71 ± 0.32 2l.2 ± l.5 30 
ZP275* 1.12±0.14 144.5 ± 7.5 129 
1.42 ± 0.48 
ZP281(M) 4.01 ± 0.57 16.0 ± 1.72 4.0 
ZP282(M)* 3.04 ± 0.57 245.8 ± 11.8 81 
4.47 ± 0.46 308.7 ± 2.3 69 
ZP285(M) 0.93 ± 0.31 573.3 ± 132.6 616 
ZP289(M) 7.56 ± 0.88 2637 ± 154 348 
Cisplatin 340.0 ± 0.06 3.02 ± 0.22 9.0 
Doxorubicin 4.98 ± 1.07 4860 ± 510 976 
* compounds evaluated on two separate occasions to confirm the initial data. 
M=chloroethylaminoanthraquinone; ICso represents the concentration of drug (nM) required 
to inhibit 50% cell growth. ± = standard error of the mean triplicate estimations. 
RF=resistance factor. 
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Table 6. 8 Effect of24hr drug exposure on the growth of human ovarian carcinoma cell 
line 2780CP and chromosome transfer modified cell line B 1. 
2780CP IC50 B1 IC50 
Compound (nM) RF (nM) RF 
ZP257* 1.22 ± 0.45 1.0 0.93 ± 0.17 1.0 
1.68 ± 0.22 1.0 2.20 ± 0.12 1.4 
ZP265 1.55 ± 0.24 2.1 1.79 ± 0.24 2.5 
ZP275* 2.55 ± 0.44 2.2 2.19 ± 0.65 2.0 
3.98 ± 0.73 2.8 5.02 ± 0.42 3.5 
ZP281(M)* 11.8±1.4 2.9 7.02 ± 0.64 1.7 
50.2 ± 3.9 16.5 19.6 ± 2.6 6.4 
ZP282(M) 76.0 ± 12.8 25 42.9 ± 4.1 9.5 
ZP285(M) 14.3 ± 1.0 15.3 5.81 ± 1.53 6.2 
ZP289(M) 125.9 ± 20.8 16.6 66.0 ± 4.5 8.7 
Cisplatin 2.62 ± 0.73 7.7 1.83 ± 0.23 5.3 
Doxorubicin 13.3 ± 0.9 2.6 11.7± 1.0 2.3 
* compounds evaluated twice to confirm initial data. M=chloroethylaminoanthraquinone 
IC50 represents the concentration of drug (nM) required to inhibit 50% cell growth. 
± = standard error of the mean triplicate estimations; RF=resistance factor (ratio of ICso 
resistance celliinel parent cell line A2780) 
6.4. DISCUSSION 
The human ovarian carcinoma cell line was selected for this study as anthracyclines 
such as doxorubicin and the anthraquinone mitoxantrone are often used in combination 
with cis-diamminedichloroplatinum (II) (cisplatin) in the clinical treatment of ovarian 
cancer. Although treatment is initially successful, it can often fail due to acquired resistance 
to these agents. Cisplatin causes cytotoxicity by platinating DNA. It is generally classed 
alongside the alkylating agents as it is able to form both DNA inter and intra-strand 
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crosslink:s at the guanine N7 position (Eastman et al., 1983). Furthennore, the development 
of cross-resistance amongst anti-cancer agents generally indicates similar mechanisms of 
toxicity. 
All the drugs tested showed excellent activity in all cell lines (Table 6. 1 - 6. 8). The 
cytotoxicity of drug was found to increase in the order I-monosubstituted anthraquinone < 
1, 4-disubstituted-5,8-dihydroanthraquinone < 1, 4-disubstituted-5,8-
dihydroxyanthraquinone for both the chloroethylamino- and the 
hydroxyethylaminoanthraquinone classes of compound. A similar relationship was 
established from the DNA affinity studies of the hydroxyethylaminoanthraquinones 
(Chapter 3), and can be related to both sidechain and hydroxyl group substitution onto the 
chromophore. Early cytotoxicity studies of 1, 4-disubstituted anthraquinones demonstrated 
that mitoxantrone which contains 5 and 8 substituted chromophore hydroxyl groups is up to 
100 fold more potent than ametantrone which is unsubstituted (Nishio et al., 1983). 
Generally, the mustard anthraquinones were found to be the more potent 
compounds. This can be explained by their ability to bind covalently with their target (see 
Chapter 4) which is suggested to lead to the creation of pennanent cytotoxic lesions. In 
contrast, the non-covalent binding nature of the hydroxyethylaminoanthraquinones 
predisposes them to cellular efflux over time, paricularly if resistance mechanisms are 
present (Smith et al., 1990 and 1992). Previous reports have indicated that nitrogen 
mustards that have an ability to bis-alkylate DNA tend to be more cytotoxic than their 
monoalkylating counterparts. Kohn et al., (1994) observed that cytotoxicity increased 10 
fold when comparing mono to bifunctional alkylating 9-aminoacridines in human 
carcinoma HT -29 cells. The reduced potency of the monofunctional alkylating agents, 
including the mono alkylating chloroethylaminoanthraquinones, is related to their inability 
to fonn DNA crosslinks as they are instead thought to fonn mono adducts which are 
considered to be genotoxic rather than cytotoxic (Povirk et al., 1994). 
Seven compounds ZP257, ZP265, ZP275, ZP281, ZP282, ZP285, ZP289 were re-
assayed at nanomolar concentrations and demonstrated a comparable cytotoxicity to 
doxorubicin in all cell lines. Consistent with mitoxantrone, the hydroxyethylamino-
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anthraquinones were not affected by cisplatin resistance mechanisms. The initial evaluation 
of the four chloroethylaminoanthraquinones in A2780CisR (2780CP) and CHcisR cell lines 
(Table 6. 3. and 6. 4.) showed that ZP282, ZP285 and ZP289 exhibited a weak cross-
resistance to cisplatin, whilst ZP281 remained unaffected. These observations were 
confirmed when the compounds were re-investigated in a comparitive study with 
A2780cisR (2780CP) (Table 6. 8). However, in this assay three of the mustard 
anthraquinones demonstrated 16 fold resistance, twice that of cisplatin. Although both 
assays established similar trends amongst the compounds the large RF value difference for 
identical cell lines may reflect the conditions under which cell growth occured in the 
presence and following the removal of drug. 
A2780CisR (2780CP) is a cisplatin resistant variant in which resistance is due in 
part to the lack of expression of the hMLHI protein involved in mismatch repair 
(Drummond et a/., 1996) (section 1. 5. 1. 4). The effect ofre-introducing the hMLHl gene 
into cell line 81 (Table 6. 8) was to restore partial sensitivity to nearly all drugs. From this 
it can be assumed that a lack of mismatch repair can affect chloroethylaminoanthraquinone 
cellular resistance, however it is likely that other resistance mechanisms also exist in this 
cell line. These may include enhanced DNA repair through the induction of the ERCCl 
mRNA expression (Li et a/., 1999) and elevated levels of glutathione (GSH) (Parker et a/., 
1991). 
The investigation of all compounds in cell line SKOV -3 which shows intrinsic 
resistance to cisplatin both in vitro and in vivo (Kelland et a/., 1992) demonstrated a good 
response. Resistance in SKOV -3 has been linked to a deficient tumour suppressor gene p53 
which reduces the ability of a cell to undergo apoptosis (Ormerod et a/., 1996). 
The cell line 2780AD overexpresses the drug efflux pump (Pgp), and is consistent 
with the MDRI phenotype which confers resistance to natural products such as the 
anthraquinones (section 1. 5, 1. 1.). The compounds tested, with the exception of ZP281 
were found to be extremely cross-resistant in 2780AD. ZP281 is unsymmetrical with an 
alkylating function confined to one side arm, this feature distinguishes it from the other 
drugs in terms of structure and may be an important factor in its poor substrate specificity 
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for Pgp. The circumvention of the MDRI mechanism has been described previously for the 
morpholinoanthracyclines and was suggested to be attributed to their lipophilic nature as 
this promotes rapid drug uptake into cells (Johnston et ai., 1987; Coley et ai., 1993). A 
similar mechanism of drug uptake may exist for ZP281. Once the drug is bound covalently 
to DNA drug efflux from the cell nucleus would become ineffective. 
The seven compounds were further evaluated at short term (4h) drug exposure to 
compare the effects of covalent and non-covalent binding on the rate of cell growth 
inhibition. Because nitrogen mustards such as mechlorethamine are non-cell cycle specific 
(section 1. 4) a more immediate cytotoxic effect was predicted for the mustard 
anthraquinones. All compounds showed enhanced potency after 24 hours in both resistant 
and non-resistant cell lines consistent with cell cycle progression. However, no difference 
was found in the inhibitory effects of the two classes of compound after short term exposure 
to cells, perhaps suggesting that the chloroethylaminoanthraquinones and 
hydroxyethylaminoanthraquinones have similar cell cycle specificities. The closeness of the 
IC50 values obtained for the covalent and non-covalent binding drugs, particularly 
structurally similar ZP285 and ZP265 suggests that it is likely that some of the alkylating 
drug is lost to cellular nucleophiles before it goes on to bind with its target. Hence, the 
observed cytotoxicity of the chloroethylaminoanthraquinones may be an effect of a reduced 
concentration of drug. 
The cytotoxicity of mitoxantrone is related to its ability to persistently trap the 
'cleavable complex' by continually reforming with its nuclear target topo II (Smith et a/., 
1992; Feofanov et ai., 1997). Although in this thesis the studies of drug-topo II inhibition 
were inconclusive (Chapter 5) they do not discount the fact that the seven compounds tested 
may target this enzyme. If this is indeed the case, the lack of topo II isoform selectivity 
demonstrated by ZP285 and ZP281 may be recognised as advantageous because cell growth 
inhibition would not be dependent on the topo IIa status of the cell but would be effected 
by either isoenzyme. This is a positive response towards at-MDR where the loss of one topo 
II isoform has been linked to reduced drug sensitivity and resistance (Harker et ai., 1991; 
Mirski et ai., 1993). However in order to substantiate these suggestions it necessary to 
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investigate further the topo II inhibition of the seven novel anthraquinones (for discussion 
and future work, see Chapters 5 and 7). 
In summary, all the compounds assayed demonstrated excellent cytotoxicity in all 
cell lines tested. The seven most potent drugs were closely compared for their activity in in 
order to distinguish differences between covalent and non-covalent binding target 
interaction. This became apparent when only three chloroethylaminoanthraquinoncs 
showed cross-resistance with cisplatin in A2780CisR. ZP281 also a mustard remained 
active in all resistant cells tested at comparable concentrations to the parent wild type cells. 
The similarity in ICso values obtained from both classes of drug infers that some 
chloroethylaminoanthraquinone is lost to cellular nucleophiles before it reaches its target 
and so the true effect of these drugs is not reflected in this study. To conclude, the drug 
ZP281 showed good activity in all ovarian cell lines which corresponded with lack of cross-
resistance to cisplatin and doxorubicin. ZP281 is therefore an interesting candidate for 
further study as a drug that may possibly inhibit topo II and evade multi-drug resistance 
mechanisms. 
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CHAPTER 7 SUMMARY, FUTURE WORK AND 
CONCLUSION 
The nitrogen mustards are bifunctional anti-tumour agents that are cytotoxic through 
an ability to alkylate DNA via the formation of covalent inter and intra-strand crosslinks. 
Their high reactivity and lack of specificity leads to much drug being lost to cellular 
nucleophiles before it reaches its target (see section 1. 4). Previous groups have identified 
that by linking the mustard function to a DNA affinic chromophore an increase in DNA 
specificity and cytotoxicity can be achieved. The DNA intercalating drug mitoxantrone 
inhibits topo II by reversible association. By combining an aliphatic nitrogen mustard 
function with an anthraquinone chromophore such as that found in mitoxantrone it is 
envisaged that such drugs would have improved target specificity and the potential to 
covalently bind the 'cleavable complex' and cause a permanent inhibition of the topo II 
enzyme. 
In this study a number of hydroxyethylaminoanthraquinones were synthesised and 
reacted further to gIVe a senes of nitrogen mustard anthraquinones 
(chloroethylaminoanthraquinones) comprised of mono- or bis-alkylating 
chloroethylaminoalkylamino side chains substituted onto either the 1 position of the 
anthraquinone chromophore, or onto the 1, 4 position of either a 5,8-dihydroanthraquinone 
or 5,8-dihydroxyanthraquinone chromophore. The hydroxyethylaminoanthraquinones were 
isolated with relatively poor yield, between 20-50% depending on the purity of the side 
chains used. Conversion to the mustards was achieved by reacting with triphenylphosphine/ 
carbon tetrachloride as the halogen donor to give products in approximately 80% yield. 
Further to this, the potential for enhancing the selectivity of the 
chloroethylaminoanthraquinones for hypoxic conditions was explored. 
Bioreductive prodrugs are compounds that are non-toxic to normal cells but can be 
metabolically activated under reductive conditions to target hypoxic cancer cells 
(Workman, 1992). Hypoxic cells maintain viability despite existing at an oxygen 
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concentration that is suboptimal for cell growth and metabolism. They constitute only a 
minor subpopulation in mostly solid tumours but are found to be resistant to chemotherapy 
through poor drug accessibility (Workman et al., 1993). AQ4N is an anthraquinone 
prodrug (Patterson, 1989) that is soon to go into clinical trials. The electrically neutral side 
chains of this compound diminish its affinity for DNA and consequently drug cytotoxicity. 
Under aerobic conditions AQ4N is stable, however in the absence of oxygen it is reduced 
enzymatically to the potent metabolite AQ4 (Patterson, 1993). By analogy it can be 
rationalised that a chloroethylaminoanthraquinone N-oxide would also have the potential be 
effective in the selective treatment of hypoxic tumours. Although previous work has 
suggested that the alphatic bifunctional mustard moiety can be stabilised to hydrolysis by 
conversion to an N-oxide (Connors, 1988) the attempted synthesis of ZP293 N-oxide 
hydrochloride (section 2. 6.) resulted in the isolation of an unstable product. This proved to 
be consistent with previous reports of the synthesis of both aliphatic (Owari et al., 1953) 
and aryl nitrogen mustard N-oxides (Tercel et al., 1995) which were found to degrade to 
cyclic hydroxylamines. In order to prevent similar instabilities it is possible that the 
synthesis of future nitrogen mustard N-oxides may be achieved by designing substituted 
alkylating side chains that are constrained and so unable to cyclise to active metabolites. 
This approach is presently ongoing in this laboratory. 
The novel anthraquinones were investigated to determine their affinity for DNA 
through intercalative binding. Spectroscopic titration of the 
hydroxyethylaminoanthraquinones gave DNA association constants (K1) in the range 0.2-
1.2x 107M-I , consistent with mitoxantrone and its 5,8-dihydro derivative ametantrone 
(Kapuszcinski et al., 1985; Lown et al., 1985). In contrast, the 
chloroethylaminoanthraquinones did not show isosbestic behaviour and instead displayed a 
massive change in the visible region on addition to buffer and calf thymus DNA. In view of 
this, it is possible that high salt concentration, although discouraging surface binding, may 
encourage drug dimerisation. Previous reports have shown that the formation of the 
aziridinium ion is reversible in the presence of high chloride ion concentration (Chang et 
al., 1979). Indeed it is conceivable that high salt concentration may be the cause of the 
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spectral shifts and lack of an isosbestic point for these hydrophobic mustard 
anthraquinones. O'Connor et al., (1992) determined the DNA binding constants of aniline 
mustards linked to acridine under salt free conditions and so it is advisable that future work 
be conducted in the absence of sodium chloride. 
DNA thermal denaturation studies identified that drug-helix stability increases with 
substitution onto the anthraquinone chromophore, and is influenced by side chain type and 
the chromophore hydroxyl groups. A similar relationship was established when comparing 
increasing cytotoxicities within the chloroethylamino- and 
hydroxyethylaminoanthraquinone class of drug (see Chapter 6). The alkylating 
anthraquinones were found to apparently bind weakly to DNA and only ZP281 stabilised 
the helix to some extent. This did not reflect the DNA crosslinking studies performed in 
Chapter 4 which demonstrated that a one hundred fold lower concentration of drug could 
successfully inhibit DNA strand separation. The small 6T m values of the mustard 
anthraquinones may arise from the fact that significant binding would be associated with 
DNA crosslinking and the resultant abolition of DNA melting characteristics. ZP281 is 
distinguished by having only one alkylating side chain and so would provide fewer DNA 
cross-linked sites and so allowing DNA melting to take place. This can be substantiated to 
some extent as ZP281 was found to be the weakest DNA strand separation inhibitor assayed 
(see Chapter 4). 
The DNA alkylation sequence of four chloroethylaminoanthraquinones ZP281, 
ZP282, ZP285 and ZP289 produced an altered pattern of alkylation compared to that of the 
untargeted mustard mechlorethamine. This followed the principle that an intercalating 
chromophore dictates the site of alkylation. Furthermore, preferential selection for 5 'PyG 
bases could be identified with sites of mitoxantrone chromophore intercalation (5'CG) 
(Bailly et al., 1996) and potential sites of DNA inter-strand crosslink formation. Although it 
is recognised that untargeted nitrogen mustards such as mechlorethamine crosslink DNA at 
5'GNC complementary base pairs (Osbom-e et al., 1993) it is likely that an aliphatic 
nitrogen mustard moiety linked with a short side chain to an intercalated chromophore 
would restrict alkylation to nearby nucleophi1c centres. The 
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chloroethylaminoanthraquinones could therefore only effectively crosslink the base pairs at 
the intercalation site. This may be confinned by the use of molecular modelling which 
would establish if such a confonnation was possible at 5'PyG DNA sequences. 
Bidirectional footprinting may also be useful to identify inter-strand crosslinked sites on the 
complementary strand of DNA (Hartley et al., 1993). As 5'GNT inter-strand crosslinks 
have been identified for both mechlorethamine and L-phenylalanine mustards (Osborne et 
al., 1995) it would also be interesting to detennine if the chloroethylaminoanthraquinones 
are able to fonn crosslinks with thymine. 
Three chloroethylaminoanthraquinones: ZP281, ZP285 and ZP289 demonstrated 
growth inhibition of yeast strains transfected with either human a or p, or wild type Sc. ce 
topo II isofonns. However the observed lack of drug isofonn selectivity led to inconclusive 
evidence for topo II inhibition as a mechanism of cytotoxicity (see Chapter 5). In favour of 
topo II inhibition, the (S'PyG) sequences identified from chloroethylaminoanthraquinone-
DNA alkylation studies (see Chapter 4) coincide with those previously identified with 
mitoxantrone topo II inhibition (S'C/T) and this supports the postulation that drugs of the 
same class stimulate identical topo II-DNA cleavage sites (Capranico et al., 1993; Paoletti 
et al., 1993). Moreover, because a high sequence homology exists between the a and p 
active sites, drug-covalent binding of nucleophilc sites (amino acids) within this region 
could potentially afford almost unifonn levels of inhibition of both isoenzymes. 
Alternatively, extensive DNA-drug crosslinking (demonstrated at low concentrations in 
Chapter 4) may serve to distort the helix and prevent the enzyme from recognising DNA as 
a substrate. In this case the chloroethylaminoanthraquinone would act as 'DNA binding 
inhibitor' and not a 'topo II poison' (see Fig. 1. 2A and B). 
In contrast, the hydroxyethylaminoanthraquinones (ZP257, ZP265 and ZP275) 
precipitated from the media at high drug concentration (100JlM), and at low concentrations 
were found to be inactive possibly due to to poor drug penetration of the yeast cell wall. 
The use of other penneability mutations to ISE2 for example MDSI (Mixed Drug Selection 
1) may benefit the outcome of future inhibition studies that utilise this assay (personal 
comm. Dr J. Jenkins). 
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A more accurate assessment of to po II selectivity can be made by studies with either 
purified topo II enzyme (a or P), or by topo II mediated kDNA decatenation (Smith et al., 
1997). These are assays designed to determine the specific targeting of topo II by gel 
electrophoresis. Alternatively, the DNA footprinting assay may perhaps be utilised to reveal 
drug-DNA-topo II adducted binding sites (Panoussis et al., 1994). As lysine residues are 
highly nucleophilic and known to be important in DNA recognition by topo II (Li et al., 
1997), it may be possible to establish drug alkylation specificity of the topo II protein active 
site. 
All the anthraquinone compounds assayed showed excellent activity in the ovarian 
carcinoma cell lines. Seven compounds ZP257, ZP265, ZP275 (hydroxyethyl-
anthraquinones) ZP28I, ZP282, ZP285 and ZP289 (chloroethylaminoanthraquinones) 
demonstrated comparable cytotoxicity with doxorubicin. In cisplatin resistant cell line 
A2780cisR (CP70), the hydroxyethylanthraquinoes showed no cross-resistance confirming 
that they avoid the mechanisms of resistance usually associated with alkylating agents. In 
contrast, the chloroethylaminoanthraquinones with the exception of ZP281 (RF 2. 9), were 
16 fold resistant. Six compounds with the exception of ZP28I showed cross-resistance in 
the doxorubicin resistant cell line A2780AD. Furthermore, when the mismatch repair gene 
hMLHI was re-introduced into BI, cytotoxicity was partially restored to the 
chloroethylaminoanthraquinones suggesting that mismatch repaIr IS a mechanism of 
resistance that can directly affect the sensitivity of these drugs. 
The data derived from the cytotoxicity study of the novel-anthraquinones has 
uncovered that ZP281 may avoid the mechanisms of resistance associated with both 
anthraquinone and nitrogen mustard resistance. To further support this, it would be 
advantageous to determine the effects of ZP281 in cell lines displaying at-MDR such as the 
ovarian cell line ESR-2 which has demonstrated resistance to doxorubicin through reduced 
expression of topo II (Bielack et al., 1995), or in cell lines that overexpress either topo II 
isoform (Houlbrook et al., 1996). These assays may also serve to confirm drug selectivity 
for the enzyme. 
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Attempts at covalent drug-topo IT inhibition have been made previously. Koyama ct 
al., (1988 and 1989) synthesised a series of aliphatic mustards linked to chrysophanol and 
emodin as potential irreversible inhibitors of the DNA-topo II complex. Although some of 
these compounds showed good enzyme inhibition and enhanced anti-leukemic properties 
they were not carried forward for further study because they were not significantly potent 
(Watanabe et al., 1991). More recently, an azido derivative of the DNA intercalating agcnt 
ethidium (8-azidoethidium) has been developed to explore the effects of covalent binding 
on enzyme inhibition. Following chromophore intercalation into DNA the drug is 
photo activated to an irreversible binding agent that can increase the number of single and 
double strand breaks created by topo IT (Marx et al., 1997). However this method of 




Fie 7. 1 Structure of compound ZP281 
The work in this thesis has identified ZP281 (Fig. 7. 1) as a potential irreversible 
inhibitor of the DNA-topo II cleavable complex. ZP281 has demonstrated an ability to 
inhibit DNA strand separation at nanomolar concentrations and to alkylate DNA base pairs 
at 5'PyG sequences which are consistent with previously identified sites for topo II 
inhibition. The cytotoxicity data indicates that ZP281 is extremely potent with nanomolar 
ICso values in all cell lines tested. It is not cross resistant with doxorubicin and is therefore 
unaffected by the overexpression of P-glycoprotein, the drug efflux pump. Furthennore, its 
relative low cross-resistance in the cisplatin resistant cell line demonstrates that it is only 
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minimally affected by cisplatin resistance mechanisms and the mismatch DNA repaIr 
process. ZP281 differs from the other chloroethylaminoanthraquinones by comprising of 
two unsymmetrically substituted side chains. The alkylating function being confined to only 
one side arm. It is possible that this configuration is responsible for the evasion of these 
resistance mechanisms. ZP281 is therefore a good candidate for further study. 
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APPENDIX 1 : STANDARD EXPERIMENTAL PROCEDURES 
Chapter 3 
AI. I PREPARATION OF DNA SOLUTION 
Calf thymus DNA (200mg) was dissolved into a sterile flask containing low ionic 
strength buffer (lOOml) (see appendix 2) to give a concentration of 2mglml. This process 
was repeated using high ionic strength buffer (see appendix 2). The two flasks were then 
covered to exclude light and the DNA left to stir at 4°C for approximately 5 days. After this 
time each solution was filtered through glass wool into a series of sterile containers. A 
sample was taken from each flask and diluted (x50) into dH20 and its absorbance measured 
at 260nm. By taking into account that the molar extinction co-efficient of calf thymus DNA 
per nucleotide is 6600cm-1 at 260nm, Beer-Lamberts Law was applied to determine the 
nucleotide concentration of the DNA. 
Chapter 4 
AI.2 LINEARISATION OF PLASMID DNA pBR322 
A combination of the following was added to a sterile eppendorf and vortex mixed: 
Plasmid DNA pBR322 (15~g /60~1), react 3 buffer (10~1), and dH20 (27~l). To this 
reaction mixture was then added the restriction enzymes BamHII SaIl (3~l) to make up a 
total volume of 100~l. The sample was then incubated at 37°C for 60 min. To precipitate 
the DNA, sodium acetate (3M, pH 3.3, 30~1) and 95% ethanol (300~L) were added to the 
eppendorf, the sample vortex mixed and frozen in a dry ice/ ethanol bath for 20 min. 
Following centrifugation at I5,000xg ,4°C for 15 min, the supernatant was discarded and 
the pellet washed with 70% ethanol. After drying the pellet by lyophilisation, the DNA was 
resuspended in dH20 (33~l) and 1~1 removed to verify its linearity by electrophoresis. 
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AI. 3. DNA ALKYLATION STUDIES 
AI. 3. 1 DRUG TREATING THE DNA 
The DNA plasmid pBR322 was linearised according to the method in appendix AI. 
2. The following constituents were added to a sterile eppendorf: Linearised plasmid DNA 
pBR322 (O.5J-lglIOJ-lI per PCR reaction), TEoA buffer (5J.ll) and drug solution (lJ.ll) to give 
final assay drug concentrations of IOOnM, 50nM, 10nM, 5nM and a mechlorethamine 
(control drug) concentration of 2.5J.lM. Each sample was made up to 50J.ll with dH20, 
mixed and then incubated for 1 h at 37°C. To precipitate the DNA, aqueous sodium acetate 
solution (3M, pH 3.3, 30J.ll), dH20 (40J.ll) and ethanol (300J.ll) were added to the sample, 
which was vortex mixed and frozen on a dry ice/ethanol bath. Following centrifugation at 
1300rpm, 4°C for 15 min, the supernatant was removed and the pellet washed twice with 
75% ethanol (lOOJ.lI) and dried by Iyophilisation. The DNA was then resuspended in dH20 
(40J.lI /0.5J-lg per sample). 
AI. 3. 2. END LABELLING THE PRIMER WITH 32p_yATP 
The following constituents were added to a sterile eppendorf and mixed: Primer 
(5.5J.lI), forward buffer 5x (5J.ll), 32p-yATP soln (lJ.ll) and the volume made up to 24J.lI with 
dH20. To this was then added the enzyme T4 kinase (l J.ll) and after careful mixing the 
sample was incubated at 37°C for 1 h. The resulting incubate (25J.ll) was then passed 
through a BIO-SPIN column at 1100rpm, 20°C for 4 min and the eluent collected. The 
BIO-SPIN column was then re-washed with dH20 (25J.ll) and the eluents combined to give 
a total volume of 50J-l1. 
AI. 4 DNA CROSSLINKING ASSAY 
AI. 4.1. DEPHOSPHORYLATION OF LINEARISED PLASMID pBR322 
The following constituents were added to a sterile eppendorf and mixed: Linearised 
plasmid pBR322 DNA (79J.lI), BAP buffer 5x (20J.ll) and BAP (lJ.ll). The sample was then 
incubated at 65°C for 60 min. After the sample had cooled to room temperature the DNA 
was extracted twice with phenol:chloroform:isoamyl alcohol (l :24: 1) (1 OOJ.lI) and once with 
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chlorofonn:isoamyl alcohol (24: 1) (lOO)lI). The DNA precipitated and the pellet dried as 
described above and resuspended in dH20 (17)l1 per S).!g of DNA). 
AI. 4. 2 S' END LABELLING OF LINEARlSED, DEPHOSPHORYLATED DNA 
T4 polynucleotide kinase (l)ll) was added to a sterile eppendorf containing a 
mixture of linearised dephosphorylated DNA pBR322 (S)lg) in dH20 (17)l1), forward 
reaction buffer Sx (S)ll) and l2p-ATP so In (2)l1) and the reaction mixture incubated at 37°C 
for 30 min. The resulting incubate (2S )ll) was then centrifuged at 1100rpm for 4 min 
through a pre-prepared BIO-SPIN column and the sample collected. The BIO-SPIN column 
was then further washed with dH20 (2S).!I) by centrifugation for 4 min, and the resulting 
sample collected to give a total sample volume of SO)ll. The DNA was precipitated by 
adding to the sample 7.S M ammonium acetate (2S)lI) and 95% ethanol (ISO).!I), and the 
pellet recovered and dried as above. To further remove any undissolved protein, the pellet 
was resuspended in dH20 (SO)lI), precipitated in 9S% ethanol (lOO)lI), centrifuged, dried 
and re-suspended dH20 (20)l1). 
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APPENDIX 2: BUFFER SOLUTIONS AND MEDIA 
Chapter 2 
HPLC Mobile phase 
(a) Methanol (99gem3) 
Trifluoroaeetie acid (1.0 em3) 
(b) dH20 (99gem3) 
Trifluoroacetic acid (1.0 em3) 
Chapter 3 
High ionic strength buffer pH 7.2 (O.5M NaCll 
Sodium chloride (29.22g) 
Tris-Base (0.96g) 
dH20 (ldm3) 
pH 7.2 adjusted with HCI 
Low ionic strength buffer pH 7.2 (O.05M NaCI) 





pH 7.2 adjusted with HCI 
TEA (lOx) buffer 




Acetic acid (58g) 
dH20 (ldm3) 
pH 8.1 adjusted with HCI 
Strand separation buffer 
DMSO (30g) 
EDTA (O.OI92g) 
bromophenol blue (O.04g) 
xylene cyanol (O.04g) 





pH 7.2 adjusted with HCI 
Formamide dye 
Bromophenol blue (3mg) 
Cyanol (3mg) 
O.5M EDTA (O.4ml) 
Formamide (9.6ml) 
Yeast synthetic media 





Amino acid mixture (-LEU)(0.70g) 
dH20 (ldm3) 
A2.1 PREPARATION OF THE ELECTROPHORESIS RUNNING GEL 
TBE Buffer (lOx) (stock solution) 
Tris base (12l.1g) 
Boric Acid (5l.35g) 
EDTA (3.72g) 
dH20 (ldm3) 
pH 8.0 adjusted with HCI 
The following solutions were prepared: 
a) Polyacrylamide gel: 
Sequagel 6 (80.0g) 
Complete mix (20.0g) 




c) Gel casting solution: 
TEMED (70~1) 
10% APS (50JlI). 
TBE buffer (1/10) (0.0Idm3) 
The polyacrylamide gel (O.Oldm\ TEMED (40JlI), 10% APS (340Jll), TBE buffer (diluted 
1 inlO into dH20) (90ml) were mixed together to form a thin film coating in between two 
vertical glass plates (ImxO.4cm) which were held in place together with plastic holders and 
a gel caster (c). 
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Fig:A3.2 The HPLC profile of the reaction ofZPl with thionyl chloride 
after 24h at room temperature. Peak a) Starting compound ZPl. b) Required 
product ZP293; c), d), and e) Unknown impurities. 
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